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THESIS SUMMARY 
The usefulness of physiologically based pharmacokinetic (PBPK) modelling in 
antimalarial drug research is evolving. Antimalarial agents are subject to drug-drug 
interactions (DDIs) and the resultant pharmacokinetics in special population groups 
is not well understood. To optimise antimalarial dosing in special population groups, 
the application of PBPK modelling has significant advantages towards improving 
clinical efficacy. This thesis addresses some of the drug therapy issues associated 
with antimalarial treatment in special populations using PBPK modelling. Firstly, it 
addresses the problem of the impact of DDI interaction between artemether and 
lumefantrine and rifampicin based anti-tuberculosis agent in children, then the effect 
of DDI perpetrated by efavirenz and ritonavir on the pharmacokinetics of piperaquine 
during pregnancy was evaluated. Finally, PBPK modelling was used to optimise the 
dose of chloroquine for the treatment of ZIKV disease during pregnancy. 
The fixed dosed combination of artemether and lumefantrine (AL) is widely used for 
the treatment of malaria in adults and children in sub-Sahara Africa, with 
lumefantrine day 7 concentrations being widely used as a marker for clinical efficacy. 
Both are substrates for CYP3A4 and susceptible to drug-drug interactions (DDIs) 
but the knowledge of the impact of DDIs is currently sparse in paediatric population 
groups therefore complicating the treatment of malaria in patients co-infected 
with other infectious diseases like tuberculosis. The concomitant treatment of AL 
with tuberculosis chemotherapy, which includes the CYP3A4 inducer rifampicin, 
increases the risk of parasite recrudescence and malaria treatment failure. This study 
developed a population-based PBPK model for AL in adults capable of predicting 
the pharmacokinetics of AL under non-DDI and DDI conditions, as well as 
predicting AL pharmacokinetics in paediatrics of 2–12 years of age. The validated 
model was utilised to assess the concomitant treatment of rifampicin and 
lumefantrine under standard body-weight based treatment regimens for 2–5 year 
olds, and demonstrated that no subjects attained the target day 7 concentration (Cd7) 
of 280 ng/mL, highlighting the importance of this DDI and the potential risk of 
malaria-TB based DDIs. An adapted 7-day treatment regimen was simulated and 
resulted in 63% and 74.5% of subjects attaining the target Cd7 for 1-tablet and 2-tablet 
regimens respectively. 
Antimalarial therapy during pregnancy poses important safety concerns due to 
potential teratogenicity and the impact of maternal physiological and biochemical 
changes during gestation. Piperaquine (PQ) has gained interest for use in pregnancy 
in response to increasing resistance towards sulfadoxine–pyrimethamine in sub‐
Saharan Africa. Coinfection with HIV is common in many developing countries; 
however, little is known about the impact of antiretroviral (ARV) mediated drug–
drug interaction (DDI) on piperaquine pharmacokinetics during pregnancy. This 
study applied mechanistic pharmacokinetic modelling to predict pharmacokinetics in 
non‐pregnant and pregnant patients, which was validated in distinct customised 
population groups from Thailand, Sudan and Papua New Guinea. In each population 
group, no significant differences in day 7 concentrations were observed during 
different gestational weeks (GW) (weeks 10–40), supporting the notion that 
piperaquine is safe throughout pregnancy with consistent pharmacokinetics, although 
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possible teratogenicity may limit this. Antiretroviral‐mediated DDIs (efavirenz and 
ritonavir) had moderate effects on piperaquine during different gestational weeks 
with a predicted AUCratio in the range 0.56–0.8 and 1.64–1.79 for efavirenz and 
ritonavir, respectively, over GW 10–40, with a reduction in circulating human serum 
albumin significantly reducing the number of subjects attaining the day 7 (post‐dose) 
therapeutic efficacy concentrations under both efavirenz and ritonavir DDIs. This 
present model successfully mechanistically predicted the pharmacokinetics of 
piperaquine in pregnancy to be unchanged with respect to non‐pregnant women, in 
the light of factors such as malaria/HIV co‐infection. However, antiretroviral‐
mediated DDIs could significantly alter piperaquine pharmacokinetics. Further 
model refinement will include collation of relevant physiological and biochemical 
alterations common to HIV/malaria patients. 
The treatment of tropical diseases is often faced with the problem of appropriate drug 
therapy. While researchers work to isolate new molecules that might be used to treat 
them, the benefits of using PBPK modelling for repurposing molecules with 
potentially efficacious and safe profiles against these diseases is yet to be explored. 
The insidious nature of Zika virus (ZIKV) infections can have a devastating 
consequence for foetal development. Recent reports have highlighted 
that chloroquine (CQ) is capable of inhibiting ZIKV endocytosis in brain cells. We 
applied pharmacokinetic modelling to develop a predictive model for CQ exposure 
to identify an optimal maternal/foetal dosing regimen to prevent ZIKV endocytosis 
in brain cells. Model validation used 13 non-pregnancy and 3 pregnancy clinical 
studies, and a therapeutic CQ plasma window of 0.3-2 μM was derived. Dosing 
regimens used in rheumatoid arthritis, systemic lupus erythematosus, 
and malaria were assessed for their ability to target this window. Dosing regimen 
identified that weekly doses used in malaria were not sufficient to reach the 
lower therapeutic window, however daily doses of 150 mg achieved this therapeutic 
window. The impact of gestational age was further assessed and culminated in a final 
proposed regimen of 600 mg on day 1, 300 mg on day 2 and 3, and 150 mg thereafter 
until the end of trimester 2, which resulted in maintaining 65% and 94% of subjects 
with a trough plasma concentration above the lower therapeutic window on day 6 
and at term, respectively. 
This thesis demonstrates that PBPK modelling may be used to optimise drug 
treatment in special population groups and in the case of complex drug therapy 
problems.  
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1.1 Malaria and its prevalence 
Malaria is a deadly parasitic disease spread by the female anopheles 
mosquitoes infected with Plasmodium falciparum (1, 2). Derived from the Italian 
word “mal’ aria” meaning bad “air”, the disease might have been in existence as far 
back as 1550 B.C. The World Health Organisation’s (WHO) target to eliminate 
malaria in 35 countries by 2030 has led to several measures being taken over the past 
few decades directed towards malaria prevention and treatment in order to reduce its 
prevalence and mortality rate (2). The transmission of malaria is extensive, affecting 
over 219 million people across 90 countries in 2017 (2, 3). The sub-Saharan Africa 
region carries 80% of the global malaria burden as 90% of the malaria cases reported 
in this period were in this region, while in the South-East Asia and Eastern 
Mediterranean region, 7% and 2% of the overall cases respectively were reported. 
Between 2010 and 2017, the World Health Organisation (WHO) reported a 20% 
reduction in malaria cases in sub-Saharan Africa compared to South East Asia and 
the Americas, who recorded a 48% and 22% reduction in malaria related cases 
respectively. In 2017, 435,000 cases of malaria reported resulted in death, with 91% 
of the malaria deaths occurring in sub-Saharan Africa. Children younger than 5 years 
of age are one of the most vulnerable to the disease. In 2015, they accounted for about 
70% of all reported malaria deaths (2).  
1.1.1 Life cycle of the malaria parasite 
The life cycle of the malaria parasite is summarised in  Figure 1.1. An infected 
female anopheles mosquito injects the sporozoite of a P. falciparum parasite through 
a bite on its human host, the sporozoites migrates to the liver to undergo its 
exoerythrocytic part of its life cycle also known as the exoerythrocytic schizogony. 
There it matures into schizonts. A fully mature schizont then ruptures to release 
merozoites. While some parasites are asexually replicated, the others undergo sexual 
replication. The asexually replicated parasites become trophozoites while the 
sexually replicated parasites become the gametocytes. The trophozoites and 
gametocytes are taken up by the red blood cells to begin their erythrocytic stage of 
their lifecycle called erythrocytic schizogony. The trophozoites mature schizonts 
again, release merozoites and then become trophozoites to keep the cycle going while 
the gametocytes are ingested during a mosquito bite to continue their life cycle in the 
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mosquito host. The erythrocytic schizogony stage of the P. falciparum life cycle is 
said to be responsible for the clinical signs associated with malaria. In the mosquito 
host, the ingested gametocytes become macrogametocytes, then become 
exflagellated microgametocytes, they transform into ookinetes and rupture into 
oocysts which then release the sporozoites that may be injected again into human to 
continue the life cycle (4). 
 
 
Figure 1.1: Lifecycle of the malaria parasite.  
(Adapted from https://www.cdc.gov/malaria/about/biology/index.html) (4)  
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1.1.2 Malaria symptoms and development of immunity 
The incubation period of Plasmodium parasite, that is, the time from infection 
until the time of onset of symptoms, depends on species of plasmodium parasite, 
immunity status of individual, use of pharmacological preventive methods and the 
density of parasite innocula. Incubation can vary from about one week to a month, 
though P. falciparum has the shortest incubation period of about 10 days. Malaria 
infection can be uncomplicated or severe. Typically, symptoms of malaria vary from 
one individual to the other. Some symptoms include febrile events which may be 
associated with sweating, chills, and rigours. More generally, malaria infection 
presents as pyrexia, body ache, headache, joint ache and general weakness. 
Clinically, complicated malarial infection can result in severe anaemia and end-organ 
damage affecting the kidney, liver, brain and lung leading to life threatening 
conditions.  
Immunity against malaria may have both mortality and morbidity implications. 
Immunity may occur as a result of human exposure to the parasite after a few 
occasions and this is thought to decrease the likelihood of death resulting from an 
infection. Also, immunity may result from more frequent exposures to the parasite, 
which may lead to reduced susceptibility to the clinical manifestation of the disease 
(5-7). In acquired immunity, the human may be protected against the sporocytes and 
their maturation in the liver and, therefore, this protects the human from an infection 
in the first place. This type of immunity may result from prolonged exposure to the 
transmitted parasite but may not be noticed at the early or later stages of exposure to 
the parasite. Furthermore, a non-protective form of immunity occurs when an 
individual spontaneously produces antibodies after the expression of a gametocyte 
and becomes immune against the gametocytes, the form of the parasite that is 
ingested by the anopheles mosquito during a blood meal (8-10). The body requires 
immunity against the asexual form of parasite life cycle; that is, the trophozoites in 
order to stay protected from future infections. The process involved in the body’s 
development of immunity against this form is intricate as there is evidence to suggest 
that the body needs to defend itself against each strain of malarial parasite it is 
exposed to (7, 9). The consequences of not attaining sufficient immunity is more 
severe in the very young children due to underdeveloped processes involved in 
building their immunity, so children are more susceptible to the life-threatening 
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conditions of malaria, such as severe anaemia and cerebral malaria (7, 11, 12). 
Another important population to consider are the pregnant women. Although this 
cohort may have well developed immunity against malaria prior to pregnancy, 
gestation may suppress their immunity and therefore expose them and their unborn 
child to threatening conditions such as still births, miscarriages, low birth weight and  
infant mortality (7). 
1.1.3 Malaria parasites 
There are five species the Plasmodium parasite known to cause malaria 
infection in humans.  These are P. falciparum, P. vivax, P. ovale, P. malariae, P. 
knowlesi. Of these, P. falciparum is known to cause the highest incidence of malaria 
cases in sub-Saharan Africa accounting for 99% of all reported malaria cases in this 
region and results in the majority of deaths globally (2). P. vivax is prevalent in the 
Americas accounting for 64% of all malaria cases in that region while in South-East 
Asia, the malaria incidences resulting from P. vivax account for over 30% of cases 
and 40% of cases in the Eastern Mediterranean regions.  
1.1.4 Malaria prevention and management 
Interventions to curb the spread and consequences of malaria infections have 
been widely studied and may be preventive or curative. These range from non-
pharmacological methods such as the use of diagnostic testing, vector control 
measures such as insecticide treated nets (ITN) and indoor residual sprays (IRS) to 
pharmacological methods involving intermittent preventive treatments (IPT) and the 
use of effective antimalarial treatments (13-16). Both non-pharmacological and 
pharmacological approaches have drawn global attention in recent years as these 
have shown different degrees of effectiveness towards the overall goal to eradicate 
malaria (17). 
1.1.4.1 Non-pharmacological methods of combating malaria 
ITN is a vector control method of controlling malaria infection and a few 
studies have been carried out to ascertain the effectiveness of this approach in the 
fight against malaria. A study carried out among residents of a malaria endemic 
region in Senegal between 2010 and 2011, found that the use of long-lasting ITN 
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provided a significant level of protection against malaria infection (18). Another 
study conducted in Lake Victoria, Kenya found that there was reduced malaria 
burden in school children who used long-lasting ITN (19).  However, a study carried 
out among under five-year olds in Nigeria identified that despite having ITN in their 
possession, there was no significant decline the incidence of malaria parasite burden 
among them. They acknowledged that despite the known effectiveness of ITN, the 
majority of their study population did not utilise the ITN in their possession, this was 
attributed to poor public health education (20).  
Rapid diagnostic treatments (RDT) have the potential to reduce the use of 
antimalarial drug therapy. Yukich et al (2012) (21) showed that malaria management 
after implementation of RDT in Zambia was lower than before its implementation 
and suggested that RDT contributed toward justifying a need for antimalarial therapy 
in Zambia. Furthermore, Murray et al (2008) (22) reported the effectiveness of RDT 
across different healthcare facilities.  
Indoor residual sprays are another vector control method. They have been 
found to effectively reduce the incidence of mosquito bites. In one study, it was 
argued that their ability to reduce incidence of mosquito bites does not imply its 
effectiveness in reducing malaria prevalence (23). In other studies, IRS used in 
combinations of one or more preventive measures reduces the prevalence of malaria 
(24). 
1.1.4.2 Pharmacological methods of combatting malaria 
1.1.4.2.1 Intermittent preventive treatment 
Intermittent preventive treatment (IPT) is the recurrent use of pharmacological 
antimalarial agents to prevent malaria. The use of IPT has been suggested in certain 
populations such as pregnant women and children (25). Used in combination with 
ITN, sulphadoxine and pyrimethamine (SP) is the first choice IPT choice by the 
WHO to be used in pregnant women in the high transmission areas in sub-Saharan 
Africa (26).  
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Concerns have grown about the effectiveness of SP because of the issue of 
antimalarial resistance. Harrington et al (2016) (27) argued that resistant strains 
developed from SP use may put pregnant women and their infants at a risk of malaria 
infection and suggested a newer approach to malaria prevention, however, Gutman 
et al (2016) maintained that SP is efficacious for malaria prevention in pregnant 
women in most parts of Africa (28). A recent study suggests the use of 
dihydroarteminisin-piperaquine (DP) may be a suitable alternative to this in 
pregnancy (29). The beneficial effect of IPT in children has been studied and though 
the use of IPT may offer some preventive measure against malaria, there are concerns 
about the impact of the side effects that may result from its use (25).  
1.1.4.2.2 Quinine 
The treatment of malaria was discovered three centuries before there were 
scientific breakthroughs on the knowledge of its cause and its mode of transmission 
(30). The history of malaria treatment cannot be discussed without the mention of a 
tree native to the tropical Andes forests of South America – the cinchona tree. In the 
1600s, it was believed that the wife of a viceroy of Peru, the Countess of Chinchon 
had recovered from malaria after immersing herself in a pond underneath a cinchona 
tree, as a result cinchona tree was derived from her name. First found by the 
Quichuans, they used the bark of cinchona for the treatment of fevers and shivering 
and the Spanish Jesuit missionaries were the first Europeans to benefit from the 
healing power of the cinchona bark (30). In the early 1800s, Joseph Pelletier and Jean 
Binenaime Caventou successfully isolated a bitter alkaloid they called quinine from 
the cinchona bark to which the healing potential of the cinchona bark is attributed. 
(31). Quinine may be administered in oral or parenteral dosage forms and following 
oral administration, quinine exhibits fast absorption and an extensive distribution in 
the body. It is metabolised in the liver by mainly CYP3A4 and to a lesser extent by 
CYPs 1A2, 2C9 and 2D6. Approximately 20% of administered quinine is not 
metabolised but excreted unchanged kidney, bile and saliva (32). 
1.1.4.2.3 Chloroquine 
Chloroquine was an essential component of the WHO’s fight against malaria 
after World War II (33, 34). Unfortunately, sometime in the 1950s, resistance to 
chloroquine developed, first in the Thia-Cambodian border, and spread to some 
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regions in Colombia and Venezuela in the 1960s. Following this, more chloroquine 
resistance cases were reported in Papua New Guinea around 1975, in Kenya and 
Tanzania around 1978 and by the early 1980, in Sudan, Uganda, Zambia and Malawi 
(33, 34). The emergence of chloroquine resistance to falciparum malaria has led to a 
focus on its efficacy for other forms of malaria infection as chloroquine efficacy on 
P. vivax, P. ovale, P. malariae, P. knowlesi has been robustly reported though a 
recent study suggest P.malariae might be resistant to chloroquine (32, 35). 
Chloroquine undergoes quick and nearly complete absorption following an oral 
administration. It is about 55% bound to plasma protein and it is widely distributed 
into body tissues. It undergoes hepatic metabolism through cytochrome 2C8 and 3A4 
metabolic pathways which contributes to about half of its elimination from the body 
leaving the other half to the kidney elimination (32). 
1.1.4.2.4 Antifolates 
Antifolates undergo their antimalarial effect by competitively inhibiting the 
dihydrofolate reductase enzyme in the parasite while the sulpha antifolates 
competitively inhibits the effects of the dihydopteroate synthase enzyme. Proguanil 
was the first antifolate antimalarial agent to be discovered and the discovery of other 
antifolate antimalarial agents, such as pyrimethamine and clociguanil followed.  
However, many antifolates are faced with similar problems associated with 
antimalarial resistance.  
To reduce the potential for resistance, many antifolates are used in combination 
therapies with sulphone or sulphonamides to give an additive antimalarial effect. 
These agents are still in use in some parts of the world where malaria is endemic 
either as monotherapy or as combination treatment as atovaquone/proguanil and 
sulphadoxine/pyrimethamine (SP) but mainly as preventive therapies (36-38). The 
efficacy of atovaquone/proguanil (AP) in treatment of uncomplicated malaria has 
been demonstrated in a few studies. Krudsood et al (2007) showed that in Thailand-
Myanmar patients with uncomplicated malaria, 97.8% of patients administered 
atovaquone/proguanil were cleared of parasitaemia, however, there was a report of 
treatment failure in three patients which was attributed to antimalarial resistance (39). 
This finding was supported by Cottrell et al (2014) where they concluded that 
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resistance to atovaquone had resulted in poor AP eradication of the malaria parasite 
(40).  
The efficacy of SP was demonstrated in a 2003 Sudan study where SP was 
showed to proffer satisfactory clinical and parasitological responses following 
treatment of 102 Sudanese patients with 25mg/kg and 1.25mg/kg SP respectively 
(41). Conversely, Pitmang et al (2005) argued that SP is not as efficacious as its 
comparators in clearing malaria parasites. They showed that in Nigerian patients, by 
day 3 and day 7, parasite clearance rate was 52% and 67% respectively in patients 
with uncomplicated malaria treated with standard doses of SP (42). Similarly, Basco 
et al (2002) reported that the therapeutic failure of SP was highest (13.6%) compared 
to amodiaquine (10.2%) and SP+amodiaquine (0%) among the patients they studied 
in that trial (43).  
Atovaquone is lipophilic in nature and its oral absorption is poor with an oral 
bioavailability of 20% that varies widely from person to person but proguanil is 
quickly absorbed in the GIT. The absorption of atovaquone is enhanced with food 
hence AP should not be taken on an empty stomach  (32). Atovaquone is 99% bound 
to plasma proteins and slowly cleared from the body with a half-life of about three 
days and excreted mainly in the faeces chemically unaltered. Proguanil shows 75% 
protein binding and is metabolised in the liver by CYP2C19 and perhaps, 3A4 and 
about 50% of the drug is eliminated by the kidneys (44). Sulfadoxine and 
pyrimethamine share similar pharmacokinetic characteristics. They both undergo 
quick absorption following enteric administration and are both approximately 90% 
bound to plasma proteins and have half-lives ranging from two to nineteen days, 
however, pyrimethamine has a volume of distribution that is larger than 
sulphadoxine. Both are metabolised by the liver and undergo kidney excretion (32, 
45).  
1.1.4.2.5 Artemisinins 
In 2006, artemisinin derivatives used as a combination with other antimalarial 
agents were recommended by the WHO for the first line treatment of malaria in 
endemic areas (3). Though there are concerns about resistance to these agents, they 
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have emerged as antimalarial agents with a relatively satisfactory efficacy and less 
worrisome resistance profile when used as a combination therapy with other 
antimalarial agents (3).  
Artemisinin was first identified in China in 1972 from a plant Artemisia annua, 
locally called Qinghao, several centuries after the same had been discovered by 
Chinese natives to have medicinal properties (31, 46). Around this time, the extracts 
from the plant were tested on malaria infected mice and found to be efficacious and 
were later tested by Mao Tse Tung in humans and also found be efficacious. This 
finding was published in 1979 (31, 46). Though potent, artemisinin was found to be 
unstable in vitro and this led to discovery of more stable forms of artemisinin namely 
artemether and artesunate. The process of synthesising these derivative requires the 
formation of dihydro-artemisinin (DHA) which is in itself a potent antimalarial agent 
but is less stable. It has been found that in the body, both artemether and artesunate 
are converted to DHA (31, 46). 
 These drug compounds are not recommended for use in uncomplicated malaria 
as lone oral treatments, though  intravenous or intramuscular AST or intravenous 
ART when AST is not available is recommended in the treatment of severe malaria 
in adults, children and pregnant women for at least 24 hours depending on response 
to the treatment (32). In 2012, Sinclair et al published a systematic review of eight 
randomised controlled trials that compared parentally administered artesunate (AST) 
to quinine in subjects from different Asian and African countries who were treated 
for malaria between 1989 and 2010 (47). This research demonstrated that malaria 
related death among these subjects was significantly reduced by 40% in adults and 
25% in children with administration of intravenous AST when compared to 
intravenous quinine (48).  
 The lipophilicity of artemether (ART) is higher than other artemisinin 
derivatives and it has a fast onset of action with a good oral absorption profile. Time 
to reach maximum plasma concentration after an oral administration is about two 
hours. Studies show that following the consumption of a fat rich meal, the 
bioavailability of artemether is more than doubled (49). ART undergoes rapid and 
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significant hepatic metabolism by the CYP3A4/5, and to a lesser extent by CYP2B6, 
CYP2C9/19. Dihydroartemisinin (DHA) is an active metabolite formed after a 
CYP3A4 metabolism of ART or AST. This active metabolite has been said to 
potentiate its antimalarial effects. Artesunate is rapidly absorbed through oral 
intramuscular or rectal routes of administration. When administered orally, it is 
metabolised into active DHA by CYP2A6. DHA, when administered orally is 
quickly absorbed from the GIT. It exhibits up to 93% plasma protein binding 
following absorption after oral administration or as a product of artemether or 
artesunate metabolism and it is rapidly eliminated with half-life of about one hour 
(32). Some artemisinin based combination treatment available for uncomplicated 
malaria include (32): 
• Artemether/lumefantrine (AL) 
• Dihyrdoartemisinin (DHA)-piperaquine (DP) 
• Artesunate-amodiaquine (AA) 
• Artesunate-mefloquine (AM) 
• Artesunate-sulphadoxine/pyrimethamine (ASP) 
1.1.4.2.6 Lumefantrine 
Developed by Chinese scientists in 1967 (46) lumefantrine is a racemic product 
of fluorine with its chemical structure related to the arylaminoalcohol group of 
antimalarials such as quinine, halofantrine and mefloquine. During the haemoglobin 
break down by P. falciparum, heme, a toxic product of haemoglobin is changed to a 
non-toxic form called hemozoin. It has been proposed that P.falciparum death occurs 
when there is a build-up of heme as a result of a lumefantrine mediated disruption of 
the transformation of heme to hemozoin (50, 51). Lumefantrine is also well absorbed 
orally and with fat rich food, its bioavailability has been shown to increase by 
approximately 16-fold (49). A study which compared the impact of meal and milk 
consumption on the absorption profile of lumefantrine found that children who 
consumed a meal and were administered a crushed tablet of a lumefantrine based 
antimalarial agent had a 100% rise in plasma lumefantrine levels while those 
administered dispersible tablets had a 55% rise in plasma lumefantrine 
concentrations (49). Consumption of milk also increased the plasma lumefantrine 
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concentrations by 57% and 65% for crushed and dispersible tablets respectively (49). 
Lumefantrine has a relatively slow onset of action of around 6-8 hours after oral 
administration and is also slowly cleared from the body having a terminal half-life of 
about 4 to five days (49, 52).  
1.1.4.2.7 Piperaquine 
First synthesised by the Shanghai Research Institute of Pharmaceutical 
Industry in 1966, the use of piperaquine a 4-aminoquinoline for malaria dates to the 
late 1970s. It effectiveness against falciparum malaria resistant and non-resistant to 
chloroquine has been demonstrated in several studies (53). A number of studies have 
demonstrated the high cure rates for PQ combination with dihydroartemisinin 
(DHA). In 2007, Janssens et al in a randomized open-label study in Cambodia 
showed that a 97.5% cure rate on day 63 post treatment was observed following a 
standard 3-day regimen with about 62% parasite clearance on day one of treatment 
(54). In a more recent study in 2016, Kakar et al reported a 100% cure rate for DHA-
PQ in Pakistani patients with mutant falciparum infection after 42 days from the first 
treatment dose (55). However, another recent report in 2016 has raised concern about 
a DHA-PQ treatment failure observed in Europe following infections with 
falciparum strains from Ethiopia. In the report, a failed DHA-PQ treatment case was 
reported at 32 days post treatment in an elderly Italian woman. Also, there are 
indications that DHA-PQ might be insensitive to falciparum strains in Cambodia due 
to resistance (56, 57). Used as a monotherapy, Pasay et al (2016), demonstrated that 
piperaquine is not as effective for malaria treatment as its use was associated with 
gametocytemia in subjects treated with it even at high doses (58). Piperaquine is 
rapidly absorbed in the GIT when administered orally with time to achieve peak 
concentrations at about 3 to 6 hours. It is widely distributed in the body and has a 
high protein binding of about 99%. It has a long elimination half-life of about two to 
four weeks (32). 
1.1.4.2.8 Mefloquine 
In the early 1970s, mefloquine was discovered to help combat the threat of 
malaria. In 1974, mefloquine, which was a joint discovery of the US Army medical 
and research command and the Hoffman La Roche, Inc. was shown to be effective 
as a preventive antimalarial agent ; it was later shown to be also useful to treat malaria 
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as well (38). However, in 1985 after the drug became available to the public, 
resistance to mefloquine was reported in Asia (38). In order to combat the challenge 
of resistance, around the mid-90s, it was combined with ACTs and found effective 
in some parts of Asia as well as Southern parts of America. The neuropsychiatric and 
gastrointestinal adverse effects of mefloquine may have impeded its use as a choice 
antimalarial in regions where malaria is prevalent though these side effects are 
thought to be related to dosing amount (59, 60). Mefloquine monotherapy is now 
commonly used as a chemoprophylactic measure to foreigners travelling to malaria 
endemic regions (61). Due to its ineffectiveness, the WHO discourages its use as 
monotherapy for treating both acute and severe forms of malaria. Mefloquine in 
combination with artesunate (an ACT) is recommended as one of the choices for 
treatment of uncomplicated malaria in malaria-endemic regions, but it is 
contraindicated in subjects with neuropsychiatric problems. The pharmacokinetics of 
mefloquine are thought to be altered in patients with malaria compared to patients 
without malaria as it has been shown that its concentration in the plasma is higher 
and it has higher elimination rates in patients with malaria compared with those 
without the disease. It exhibits wide inter-individual variation in absorption rates, it 
is widely distributed in the body and has a plasma protein binding of about 98%. It 
is primarily metabolised by hepatic CYP3A4 and has an elimination half-life of about 
3 weeks. It is mainly excreted in the faeces as metabolites and unaltered drug and a 
small amount is excreted in the urine (32). 
1.1.4.2.9 Amodiaquine 
Amodiaquine is a 4-amino quinoline and its use for both malaria treatment and 
prophylaxis has been hit by several ups and downs in history. In 1977, it was first 
included the WHO essential drug list but due to its comparativeness with 
chloroquine, it was removed in 1979 but this decision was reversed that year. Since 
then, there have been modifications to its indications,  and deletions from several 
national malaria control guidelines, mainly due to the adverse drug events associated 
with its use (62). However, based on evidence from several studies, amodiaquine as 
a combination therapy is used for treatment and prevention of malaria but due to drug 
resistance, monotherapy is not encouraged (32, 63). A 2017 study showed that 
artesunate-amodiaquine was well tolerated among Cote d’Ivoire subjects with 
uncomplicated malaria who were treated with this combination (64).  Amodiaquine 
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is quickly absorbed from the GIT and undergoes biotransformation to it active 
metabolite, desethylamodiaquine which is mainly responsible for its antimalarial 
activity. Desethylamodiaquine is slowly cleared from the body compared to 
amodiaquine, having an elimination half-life up to 10 days (32). 
1.1.5 Challenges with AMT therapy and the role of pharmacokinetics 
research 
Malaria parasite resistance to antimalarial therapy is perhaps one of the most 
significant concerns of antimalarial (AMT) treatment currently (65). The main cause 
of this has been linked to the mutation of the parasite strains following exposure to 
antimalarial treatment (65). It has been showed that there is a link between malaria 
parasite mutation and subtherapeutic antimalarial concentrations and many studies 
have shown that subtherapeutic concentrations of antimalaria treatment has led to 
treatment failures and recrudescence of malaria infection (66). The attainment of 
subtherapeutic systemic concentrations of AMTs may be due to a poor understanding 
of the pharmacokinetics of many AMTs in subjects especially special populations 
like children and pregnant women as these are not routinely recruited into clinical 
trials.  This may further be confounded by drug to drug interaction (DDIs) as many 
of AMT are likely to be administered with other medicinal agents capable of reducing 
their systemic concentration. 
In a review by White et al (2004) on antimalarial drug resistance, the authors 
provided an explanation on how the pharmacokinetics of an antimalarial may be 
linked to antimalarial drug resistance (ADR) (67). In the review, the author explained 
that pharmacokinetic properties such as the oral bioavailability, volume of 
distribution and elimination half-life are important in ADR and explained that most 
antimalarials are highly lipophilic, hence their absorption is prone to high variability 
leading to erratic peak plasma concentrations which may favour ADR. They also 
explained that due to very long half-life of some slowly eliminated antimalarials, 
these antimalarials offer sufficient time for selection of resistance among sensitive 
parasites but selection for resistance may not occur at the terminal elimination phase 
when resistance might have occurred due to sub-inhibitory concentration of 
antimalarial agent towards the resistance strains (67). 
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Despite the fact there are many pharmacokinetic studies involving the 
antimalarials, these studies depend hugely on the availability of clinical data in the 
subjects involved, which in most cases do to not entirely represent the real therapeutic 
challenges that may be found in practice. Clearly, ethical constraints may hinder the 
ability to obtain data involving such “real” therapeutic situations, therefore, there is 
a need to find alternative methods of mechanistically analysing the pharmacokinetics 
of antimalarial concentration data, especially in population groups wherein ethical 
policies might hinder the collection of useful clinical data. 
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1.2 Basic principles of pharmacokinetics  
Pharmacokinetics is the field of pharmacology which studies the “kinetics” or 
movement of drugs in the body. This involves the study of the processes of drug 
absorption, distribution, metabolism and excretion (68, 69).  
1.2.1 Pharmacokinetic parameters 
These are parameters derived during plasma drug concentration versus time 
analysis. They are used to quantify the manner in which the body alters the 
concentration of drugs following administration and may be classified as primary or 
secondary pharmacokinetic parameters (70). 
1.2.1.1 Primary pharmacokinetic parameters 
Primary pharmacokinetic parameters are those parameters that depend on the 
physiology of the species and may not be derived from other parameters. These are 
clearance and volume of distribution (70). 
1.2.1.1.1 Clearance 
The clearance of a drug describes the process of elimination from the body as 
it is defined as the ‘volume of body fluid from which the drug is eliminated per unit 
time’ (70, 71). Typically, clearance is measured in either plasma or blood, giving rise 
to the plasma clearance (CLp) or blood clearance (CLb). 
The main sites of drug clearance are the liver and the kidney; however, drugs 
may be eliminated from other sites in the body, e.g. from the sweat or from the saliva 
(71) . The total body clearance (CLT) of a drug is the sum of the clearances from all 
organs where drug elimination occurs, and may be expressed as (70):  
𝐶𝐿𝑝 +  𝐶𝐿𝑏 +  𝐶𝐿𝑜𝑡ℎ𝑒𝑟 =  𝐶𝐿𝑇    ( 1 ) 
The ratio between the amount of drug being excreted from an organ to the 
amount of drug entering is called the extraction ratio (ER) (70). The product of the 
blood flow to an organ and the extraction ratio of a drug is defined as the clearance 
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from that organ (Equation 2) (70). The clearance of a low extraction drug is 
restrictive, that is, only unbound drug is cleared while the clearance of a high 
extraction drug is non-restrictive whether or not the drug is highly bound to protein 
(70, 71). 
               𝑄𝑜𝑟𝑔𝑎𝑛 . 𝐸𝑅 =  𝐶𝐿𝑜𝑟𝑔𝑎𝑛    ( 2 ) 
The clearance of drug in a particular organ is dependent on the organ blood flow and 
the eliminating capacity of the organ – the intrinsic clearance (CLint), that is the ability 
of the organ to eliminate drug without any influence of blood flow (Q) or protein 
binding (fu). The CLint is obtained from in vitro studies that involve primary 
hepatocytes, subcellular liver fractions or transfected cell lines. Furthermore, as 
drugs are often bound to plasma proteins or partitioned into the blood, only the free 
fraction (unbound) drug is available for elimination and therefore the plasma protein 
binding capacity of a drug may also affect its clearance (70). 
In the 1970s, Pang and Rowland (72-74) described a model that may be used 
for the prediction of human in vivo drug clearance from in vitro intrinsic clearance. 
This model was called the well-stirred model and it assumes that the eliminating 
organ, for instance the liver, is a one compartment and well-stirred system and there 
is equilibrium between unbound drug concentration in the exiting blood and unbound 
drug concentration in the organ (75). The well-stirred model for estimating hepatic 
clearance CLh, is represented in equation 3:  
                                                 𝑪𝑳𝒉 =  
𝑸𝒉 × 𝒇𝒖 × 𝑪𝑳𝒊𝒏𝒕
𝑸𝒉+ 𝒇𝒖 × 𝑪𝑳𝒊𝒏𝒕
               ( 3 ) 
 
1.2.1.1.2 Volume of distribution 
The volume of distribution of a drug is the volume of body fluid in which a 
drug must be present to reflect a particular body concentration. It is a proportionality 
factor that relates the amount of drug in the body to the concentration of drug present 
in the blood, and therefore it is not a ‘real’ volume but an ‘apparent volume’. Drugs 
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that are lipophilic in nature will tend to distribute to adipose tissues, with hydrophilic 
drugs distributing into more of the water fractions of tissue and organs (70, 71). 
The volume of distribution depends upon the drug’s binding capacity to the 
blood (erythrocytes), plasma proteins and tissue (non-specific) binding, as only the 
unbound drug is available to be distributed to different parts of the body such that 
drugs with high binding capacity are likely to exhibit low volumes of distribution and 
vice versa (70, 71). Assuming a non-exponential decline in drug concentration in the 
body, the volume of distribution may therefore be expressed with respect to the 
administered dose and expected plasma/blood concentration (C) using equation 4 
(70, 71). 
𝑉 =   
𝐷𝑜𝑠𝑒
𝐶
      ( 4 ) 
1.2.1.2 Secondary pharmacokinetic parameters 
Secondary PK parameters are those PK parameters derived from the primary 
PK parameters, they do not directly depend on changes in physiological parameters 
in the organism but are directly dependent on the changes in the primary PK 
parameter. There are several of them but half-life, AUC and bioavailability will be 
discussed. (70, 71). 
1.2.1.2.1 Half-life 
The time taken for the plasma concentration of a drug to be reduced by 50% is 
called its half-life (t1/2). This parameter is important for making drug dosage 
decisions as it gives an indication of drug disposition, but it is not the sole measure 
of drug disposition because it depends on the clearance and the volume of 
distribution. Alterations in protein binding can impact both the clearance and the 
volume of distribution of a drug and these may erratically affect the half-life of the 
drug. The relationship between these parameters can be represented equation 5 (70). 
𝑡1 2⁄ = (0.693) .
𝑉
𝐶𝐿
     ( 5 ) 
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1.2.1.2.2 Area under the concentration versus time curve (AUC) 
The measure of systemic (plasma/blood) drug exposure following drug 
administration through any route of administration is called the AUC (70, 71). It is 
determined by calculation of the area under the concentration-time curve using the 
trapezoidal rule (70) (Figure 1.2). Assuming a drug undergoes complete oral 
absorption and is completely eliminated, the AUC may be estimated with respected 
to the oral dose (Doseoral) and the clearance (CLT) as (70): 
𝐴𝑈𝐶𝑜𝑟𝑎𝑙,𝑚𝑎𝑥 =
𝐷𝑜𝑠𝑒𝑜𝑟𝑎𝑙
𝐶𝐿𝑇
                                             ( 6 ) 
1.2.1.2.3 Bioavailability (F) 
The is the fraction of the dose administered that enters the systemic circulation 
intact (70). For drug administered intravenously, F = 1 since all the drug is 
immediately available for systemic circulation. However, drugs that are administered 
through other routes of administration typically have a F < 1 (70, 71). The oral route 
of administration is the most common route of drug administration, however drug 
given through this route may be subject to chemical degradation due to pH changes 
along the GIT; secretion due to the effect of efflux proteins or enterocyctic 
metabolism due to the impact of drug metabolism enzymes (70, 71). Drugs may also 
be metabolised in the liver before they reach the systemic circulation. The 
metabolism of drugs either in the enterocyte or the liver the first time they come into 
contact with these organs is known as the “first pass effect” (70, 71). The oral 
bioavailability after the first pass effect can be determined using the equation 7 or 8 
(70, 71): 
              𝐹 =  
𝐴𝑈𝐶𝑜𝑟𝑎𝑙
𝐴𝑈𝐶𝑖𝑣
                              ( 7 ) 
or 
𝐹 =  
𝐴𝑈𝐶𝑜𝑟𝑎𝑙 
𝐴𝑈𝐶𝐼𝑉
 𝑋  
𝐷𝑜𝑠𝑒 𝐼𝑉
𝐷𝑜𝑠𝑒 𝑂𝑟𝑎𝑙
      ( 8 ) 
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However, if the oral absorption of drug is complete, the maximum F(Fmax) if the drug 
is metabolised by the liver may be calculated  using equation (9) (70, 71): 
𝐹𝑚𝑎𝑥 = 1 −  𝐸𝑅ℎ𝑒𝑝𝑎𝑡𝑖𝑐     ( 9 ) 
1.2.2 Pharmacokinetic processes 
1.2.2.1 Absorption 
The therapeutic effects of drug are only expected if an administered drug can 
move from its site of administration to the systemic circulation where it will be 
circulated to the site of action  (76). The process involved in drug molecules 
transferring from the site of administration into the blood is called absorption. 
Absorption does not occur for drugs administered intravenously (IV) since all the 
drug reaches the bloodstream immediately after administration.  For drug absorption 
to take place after oral administration of a solid drug formulation, the release of active 
ingredient in the dosage form must be preceded by disintegration and dissolution 
processes in the gastrointestinal fluid  (76).  
Disintegration is the process whereby solid dosage forms disintegrate to release 
the active pharmaceutical ingredients (APIs). In order to ensure that the highest 
possible amount of API is absorbed from the solid dosage form, the disintegrating 
capability of the dosage form need to be carefully considered (76).                               
Dissolution is the process whereby the API is dissolved in the dissolution medium of 
the gastrointestinal tract for absorption to take place. The dissolution rate is affected 
by manufacturing processes, water solubility, particle size and the excipients added 
to the formulation. Arthur Noyes and Willis Rodney Whitney (77) described the 
formulation and drug-specific properties which influence the rate of in vitro 
dissolution in equation 10: 
𝑑𝐶
𝑑𝑡
= 𝑘. (𝐶𝑠 − 𝐶)                             ( 10 ) 
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where Cs is solubility concentration of the drug, C is the concentration of the 
drug in bulk media and k is the dissolution rate constant of the drug. 
Following dissolution, the released drug will then permeate through the cell 
lining of the gastrointestinal tract, to be absorbed. As illustrated in Figure 1.2, 
absorption through this physiological barrier typically occurs either by through 
passive diffusion or active transport in the small intestine.  
 
Figure 1.2: Processes of molecular drug transport across a cell membrane 
 
Molecules with low molecular weight are usually absorbed by passive 
diffusion.  Passive transport involves diffusion of drug molecules from a region of 
higher concentration to a region of lower concentration across the epithelial cells 
membrane until equilibrium is reached. Most drugs are absorbed passively from the 
enterocytes present in the duodenum or the jejunum of the GIT. The main routes of 
passive absorption in the GIT is transcelluar routes for lipophilic drugs and 
paracellular routes for hydrophilic drugs. In drug transport involving the paracellular 
route, the drug molecules move across the cell through aqueous membrane pores 
while drug transport through the transcellular route involve drug permeating through 
the cell membrane as shown in Figure 1.2 (78).   
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The ideal absorption site are the enterocytes located at the villi of the duodenum 
or jejunum, however the epithelial cells that form an anatomical barrier to the GI 
lumen may possess certain metabolising enzymes capable of oxidative, conjugative 
or hydrolytic metabolic reactions. This implies that drug which pass through the 
luminal plasma membrane will be exposed to metabolising enzymes and this might 
result in some form of extra-hepatic metabolism of the drugs even before the drug 
reaches the hepatic system. The portion of drug that escapes the intestinal enterocytes 
intact is typically expressed as Fg (78). 
Passive diffusion exhibits direct proportionality to concentration gradient 
across the membrane, lipid to water partitioning coefficient of the drug and the 
surface area of the cell. Un-ionised drug forms have higher lipid solubility compared 
to the ionised forms; hence these diffuse with ease across the cell membrane.  Hence 
the extent of drug ionisation (pKa) and gastric pH will also affect drug absorption 
through passive diffusion across the cell membrane. The Lipinski Rule-of-5 
describes the properties of drug that makes it likely absorbable through transcellular 
route in the gastrointestinal tract (GIT). The properties include: presence of at most 
5 hydrogen bond donors, that is oxygen or nitrogen atoms with at least one hydrogen 
atom; drug molecule should have not more than 10 hydrogen bond acceptors, that is 
nitrogen or oxygen atoms; drug molecular weight should be not more than 500g/mol 
and octanol-water partition coefficient (log Pow) should be less than 5 (79-81).  
In active transport, also known as the carrier-mediated transport, drug moves 
through the barrier against a concentration gradient with the aid of membrane 
localised drug transporter proteins, in a process which requires energy.  Key 
transporter categories include those belonging to the adenosine triphosphate (ATP) 
binding cassette (ABC) and the solute carrier (SLC) group of transporters, which are 
present at the apical and basolateral membranes. Active transport through ABC 
transporters depend on energy released from the hydrolysis of ATP, whereas drug 
transport through SLC occurs through H+, Na+ and Ca2+ gradients by Na+/K+-
ATPase, Na+/H+- ATPase.  
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1.2.2.2 Drug Distribution 
Distribution of the drug molecule to different parts of the body starts after 
absorption has taken place. During distribution, drug molecules which are unbound 
to the plasma proteins distribute into the tissues and organs, some of which might 
possess high tissue binding capacity.  For drugs to reach the site of action from the 
blood, organ perfusion, organ permeability, drug-to-plasma and drug-to-tissue 
binding, and the lipid nature of drug are all important factors to consider (82, 83). 
1.2.2.2.1 Tissue perfusion 
The extent of blood flow to different body organs may determine the extent to 
which a drug is capable of being distributed into that tissue. Rapidly perfused organs 
such as the liver, brain and kidney receive the rich supply of drugs carried in the 
blood or plasma while slowly perfused tissues such as the skeleto-muscular system 
and the adipose tissues have limits to the rate and extent to which a drug distributes 
into them and may lead to a delayed clinical effect (82, 83). 
1.2.2.2.2 Tissue partitioning 
Tissue partitioning is dependent on tissue composition. Lipophilic drugs are 
partitioned into high fat organs/tissues such as adipose, liver, brain, and kidney, while 
hydrophilic drugs are preferentially partitioned into water rich organs such as muscle 
(82, 83).  
1.2.2.2.3 Plasma and tissue drug binding 
In addition to tissue perfusion and tissue partitioning, distribution of drug to its 
site of action also depends on drug binding to plasma protein. Drugs will not produce 
a therapeutic response in a bound state as it is the unbound drug that distributes into 
circulation to elicit a clinical effect at target sites. The plasma proteins to which most 
drugs are bound are human serum albumin (HSA) and alpha-1 acidic glycoprotein 
(AAG) (82, 83). 
1.2.2.3 Metabolism 
Occurring primarily in the liver, drug metabolism is the process in which the 
chemical structure of a drug is altered to enhance its eventual elimination and this 
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process is mediated by enzymatic processes.  Drug metabolism in the liver occurs in 
two phases – phase I and phase II and may be mediated by cytochrome P450 (CYP) 
enzymes or through non-CYP enzyme pathways. Metabolism may also occur outside 
the liver (84-87). 
1.2.2.4 Phase I 
CYP enzymes are typically located within the mitochondria or the endoplasmic 
reticulum and at least 57 functional CYPs genes and 58 pseudogenes have been 
identified and classified into 18 families and 43 subfamilies (88). Of these, CYP1, 
CYP2, CYP3 subfamilies are largely responsible for the metabolism of about 75% 
of drugs and xenobiotics (88). Of all the human CYP which have been characterised, 
the CYP3A4 is most abundant and has relatively greater number of drug substrates, 
inhibitors and inducers compared to the other human CYP enzymes (88). Table 1.1 
summaries the abundance of some CYP enzyme expressed and their typical 
substrates, inducers and inhibitors.
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Table 1.1 Human Cytochrome P450 enzymes, abundance, relevance in metabolism, substrates, inhibitors and inducers. 
Data obtained from Zanger et al (2013)  (88).
Family Isozyme 
Hepatic 
abundance 
(pmol/mg) 
Amount of 
liver P450 
pool (%) 
Involvement in 
drug metabolism 
(%) 
Example of substrate Example of inhibitor Example of inducer 
CYP1 1A2 17.7 – 65 4.4 - 16.3 8.9 
Caffeine, Naproxen, 
Acetaminophen 
Cimetidine, Ciprofloxacin,  
Carbamazepine, 
Omeprazole, Phenytoin 
CYP2 
2A6 14 – 56 3.5 – 14 3.4 Efavirenz 
Selegiline, 
Tranylcypromine 
Rifampicin, Phenobarbital, 
Artemisinin 
2B6 6.9 – 21 1.7 - 5.3 7.2 
Artemether,  
Bupropion, Efavirenz 
Clopidrogrel, 
Clotrimazole, 
Carbamazepine, Artemisinins, 
2C8 29.3 – 30 ̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴ 7.5 4.7 
Amodiaquine, 
Rosiglitazone 
Montelukast, 
Gemfibrozil 
Dexamethasone, 
Phenytoin 
2C9 18 – 116 4.5 – 29 12.8 
Diclofenac, Warfarin, 
Irbesartan, Ibuprofen 
Fluconazole, 
Amiodarone 
Rifampicin, 
Prednisolone, Ritonavir 
2C19 3.6 – 15 0.9 - 3.8 6.8 Omeprazole, Clopidrogrel, 
Clopidogrel, Fluoxetine, 
Ticlopidine 
Artemisinins derivatives, 
Carbamazepine, Efavirenz 
2D6 5 – 17 1.3 - 4.3 20 
Amitriptyline, Codeine, 
Carvedilol 
Quinidine 
Induction by prototypical 
P450 inducers not significant 
2E1 22 – 66 5.5 - 16.5 3 Chlorzoxazone Disulfiram, Orphenadrine Isoniazid, Ethanol 
2J2 1 – 2 < 1 3 
Albendazole, Amiodarone, 
Cyclosporin 
Danazol  
CYP3 
3A4 58 – 146 14.5 -37 30.2* 
Clindamycin, Artemether, 
Lumefantrine, Midazolam, 
Tramadol, etc. 
Ketoconazole, Isoniazid, 
Clarithromycin, Ritonavir, 
Diltiazem 
Rifampicin, Ritonavir, 
Statins, Phenytoin, 
Valproic acid 
3A5 3.5 – 4 ̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴̴1     
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1.2.2.5 Phase II 
Phase II metabolism is typically mediated by non-CYP enzymatic degradation, wherein 
the products of phase I metabolism are conjugated through glucuronidation, sulphation, 
acetylation, glutathione, Acyl Co-enzyme A conjugation and methylation to form inactive 
metabolites (85).  
Uridine 5’-diphospho-glucuronosyltransferase (UGT) is a common phase II 
enzyme which mediates glucuronidation with hydroxyl, carboxylic acid and amine 
groups. Products of glucuronidation are generally nontoxic, though some carcinogenic 
glucuronides has been described in some studies. Sulphotransferases (SULTS) are 
responsible for sulphation metabolic reactions that lead to inactivation of some drugs. 
However, some studies have shown that this reaction could produce metabolites that are 
toxic to the genes (89, 90).  
Acetylation reactions involve the catalytic effect of N-Acetyl transferases (NATs) 
present within the cytosol whereby amino groups take up the acetyl released from acetyl-
coenzyme A to form inert metabolites.  NAT exhibits polymorphs characterised as NAT1 
found throughout the body and NAT2 is mainly located in the liver and gut.  Glutathione 
conjugation is another metabolism pathway in the phase II metabolism involved in the 
biotransformation of many drugs. This pathway involves a glutathione S-transferase 
(GST) mediated catalysing reaction between nucleophilic glutathione and the 
electrophilic epoxide, ester, ketone, sulfoxide, peroxide and hydrocarbon groups on drugs 
undergoing metabolism (85, 87).  
Further conjugation steps occur for some drug that have carboxylic acid groups 
after their glucuronide formation to produce acyl CoA thioesters. These conjugates may 
form taurine, glycine and carnitine conjugates following a reaction with amino acids. 
Finally, methylation occurring in phase II metabolism is not a common drug metabolism 
pathway and involves methyl substitution catalysed by methyl transferase (85, 87).  
1.2.2.6 Non-CYP metabolism 
Non-CYP oxidative reactions may involve the flavin-containing monoxygenases 
(FMOs); alcohol and aldehyde dehydrogenase (ADH and ALDH); peroxidases; 
monoamine, xanthine and aldehyde oxidases (MAOs, XO and AOs) (91-95). Non-CYP 
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reduction reactions involve nitro-, aldehyde, ketone and nitro reduction of drug entities; 
these reactions may involve NAD(P)H-quinone reductase (DT-diaphorases); NADPH-
cytochrome P450 reductases; isoxazole reduction and aldo-keto reductase (AKR) (85, 
96). Hydrolysis mainly involves non-CYP enzyme reactions where esters and amides and 
non-polar components of alkyl groups are subject to catalytic reactions of amidases and 
esterases (85). 
1.2.2.7 Extra hepatic metabolism 
Though the liver is the main site of metabolism in the body, metabolism may also 
occur in other organs or systems in the body. This is because metabolising enzymes may 
be expressed in varying degrees in any one organ. In 1994, Krishna et al reported different 
CYP P450 expressions in different parts of the brain, where the brain stem and cerebellum 
had the greatest CYP enzyme expression. Table 1.2 summarises the expression of CYP 
enzymes in different body systems (86, 87). 
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Table 1.2: Extrahepatic Cytochrome P450 enzyme expression  
 
 
 
 
Data adapted from Jhajra et al (2012) and Krishna et al   (1994) (86, 87)
Body Systems Cytochrome P450 enzyme genes 
Gastrointestinal 2A6 2C8 2C19 2D6 2E1 2J2 3A4   
Pulmonary 1A2 2A6 2B6 2C8 2C19 2D6 2E1 2J2 3A4/5 
Urinary 2D6 2J2 3A4/5       
Central 
nervous 
1A2 2A6 2C8 2D6 2E1 2J2 3A4/5    
Cardiovascular 1A2 2A6 2B6 2C9 2C19 2D6 2E1 2J2 3A4/5  
Skin 1A2 2B6 2C9 2C19 2D6 2E1 2J2 3A4/5   
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1.2.2.8 Excretion 
Excretion is the process whereby products of metabolism are irreversibly removed 
typically through the kidneys or through biliary excretion into the faeces. The kidney is 
the primary route of drug excretion and the process of excretion involves filtration, 
secretion and reabsorption. Blood flow to the kidney undergoes glomerular filtration 
driven by hydrostatic pressure in the glomerular capillaries.  The rate at which filtration 
occurs per time is expressed as glomerular filtration rate (GFR). The GFR is an indicator 
of renal function and it describes the elimination of drug which does not undergo secretion 
or reabsorption. Creatinine is the marker used for measuring the GFR in humans and the 
normal GFR is 100 – 125 ml/min. The size and charge of the molecule determines 
whether they will be excreted through filtration. Molecules with size less than 500 g/mol 
are easily filtered by the kidney while molecules with negative charges are not readily 
filtered in the kidney (75). 
Tubular secretion is an active process that occurs mainly at the proximal tubules 
where organic acids are transported against a negative membrane potential in the 
basolateral and luminal membranes through protein transporters. This process is  
saturable and it may have the potential to cause drug to drug interactions (75). Factors 
such as plasma binding, renal blood flow and intrinsic clearance can affect the secretion 
of drug compounds in the proximal tubules.  
Tubular reabsorption in the kidney opposes the action of filtration and secretion, in 
that it involves transporting drugs from the kidney back into the blood. This process 
occurs at the proximal tubules; and is largely thought to be a passive process though some 
research has shown that some renal transport proteins are involved in tubular 
reabsorption. Rate of urine flow may influence reabsorption processes, a high urine flow 
rate reducing reabsorption by reducing contact time, and concentration gradient. The 
reverse happens with a low flow rate. Molecules that are large or ionised or hydrophilic 
in nature are not likely to be reabsorbed (75).  
Equation 11 describes the estimation of renal clearance incorporating all three processes 
involved: 
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𝐶𝐿𝑟𝑒𝑛𝑎𝑙 =  𝐶𝐿𝑓𝑖𝑙𝑡𝑟𝑎𝑡𝑖𝑜𝑛 + 𝐶𝐿𝑠𝑒𝑐𝑟𝑒𝑡𝑖𝑜𝑛 −  𝐶𝐿𝑟𝑒𝑎𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛   ( 11 ) 
where CLrenal: Overall renal excretion, CLfiltration: filtration clearance, CLsecretion: secretion 
clearance, CLreabsorption: reabsorption clearance.  
However, renal CLreabsorption is more accurately expressed in relation to fraction of filtered 
and secreted drug that is reabsorbed indicated by R. The Equation 12 is generally used to 
estimate renal excretion: 
𝐶𝐿𝑟𝑒𝑛𝑎𝑙 =  [ 𝑓𝑢  ×  𝐺𝐹𝑅 +  (𝐶𝐿𝑠𝑒𝑐)]  × (1 − 𝑅)    ( 12 ) 
where CLsec is the secretion clearance  
Protein transporters involved with tubular secretion are the organic anionic 
transporters (OAT) 1, 3, 4. There is an overlap between substrates transported by OAT1 
and OAT3. OAT3 also transports sulphate and glucuronide conjugates. OAT4 participates 
in digoxin elimination. Those responsible for transport of basic compounds are the 
organic cationic transporters and these include OCT1, OCTN1 and OCTN2.  Other 
transporters are the multi-drug resistance-associated proteins (MRPs). MRP1, MPR3 and 
MRP5 are found in the basolateral membrane and MRP2 is thought to be involved in renal 
secretion. Also, the multidrug resistance (MDR) proteins, P-glycoproteins (P-gp) interact 
with many drug compounds and are found in the brush border membrane and are involved 
in drug efflux from the cells into the lumen  (97).  
  
 54 
  
1.3 Pharmacokinetic modelling analysis in antimalarial drug research. 
In order to appropriately quantify the pharmacokinetic (PK) parameters described 
above, proper analysis of drug concentration data is required. In practice, non-
compartmental analysis (NCA), compartmental modelling, population pharmacokinetic 
modelling (popPK) and physiologically based pharmacokinetic modelling are the 
common PK analysis methods and these will now be discussed. 
PK modelling studies involving compartmental, non-compartmental analysis 
(NCA) and population PK have been previously conducted to understand the PK of 
antimalarials in different population groups. For instance, Moore et al (2014), used 
compartmental PK modelling to determine the impact of fatty meal on the 
pharmacokinetic properties of DHA and PQ among children in Papua New Guinea (PNG) 
with uncomplicated malaria. In their model development, the researchers sought to 
determine how food intake affects the PK of PQ and DHA and they found that there were 
no significant impacts from the intake of food on the systemic exposure of PQ and DHA 
in children (98).Tarning et al (2008) using pop-PK modelling found that the clearance; 
volume of distribution and therefore the day 7 concentration of PQ was significantly 
affected by body weight (99). Salman et al (2015), used pop-PK to show that number of 
doses was a significant covariate that impacted on the PK of ART. They demonstrated 
that a subsequent dose of ART resulted in almost 70% increase in ART clearance in 
children. This was the only covariate they found that impacted on the PK of ART in 
children (100).  
1.3.1 Non-compartmental analysis (NCA) 
In NCA, statistical moment analysis is conducted such that the area under the drug 
concentration time profile (AUC0-inf) and the mean residence time (MRT) are indicative 
of the overall drug exposure after drug is administered via the intravenous or 
extravascular routes (68, 101).  
 55 
  
 
 
Figure 1.3 Linear trapezoidal method of estimating pharmacokinetic parameters 
The AUC is often estimated using the linear trapezoidal or log trapezoidal methods 
whereby the concentration of the drug is multiplied by time. If AUC over two adjacent 
time points t1 and t2 are to be estimated (Figure 1.3), the AUCt1-t2 may be estimated using 
the linear trapezoidal method in equation 13 or the log trapezoidal method in equation 14 
(68, 101). 
𝐴𝑈𝐶𝑡1−𝑡2 =
(𝑡2 − 𝑡1)  ×  (𝐶2 − 𝐶1)
2
    
    ( 13 ) 
𝐴𝑈𝐶𝑡1−𝑡2 =
(𝑡2 − 𝑡1)  ×  (𝐶2 − 𝐶1)
𝐼𝑛 (
𝐶2
𝐶1
)
    
    ( 14 ) 
When the concentration time profile curve is either slowly ascending or descending, 
the linear trapezoidal equation can be expected to give an accurate estimation of the AUC, 
however, when the curve is exponentially descending, the log trapezoidal equation gives 
a more accurate estimation of the AUC (101). The overall AUC for from time zero (t0) to 
last sampling time (tlast) may be estimated by summing up the AUCs from all the 
trapezoids in the concentration time profile. The AUC from the last time of sampling (tlast) 
to infinity, when it is assumed that the concentration at that time (Clast) is not null may be 
calculated using the equation below (68, 101). 
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𝐴𝑈𝐶𝑡𝑙𝑎𝑠𝑡−∞ =
𝐶𝑡𝑙𝑎𝑠𝑡
𝜆𝑍
        ( 15 ) 
where λZ is the terminal rate constant derived by non-linear regression analysis of 
concentration time profile plotted on a semi-logarithmic scale using time points that are 
not farther than the last sampling time. Where it is impossible to measure the Ctlast, as in 
the case when this concentration is below the quantifiable limit, the linear regression line 
fitted to the last three data points on the concentration time profile may be used to estimate 
the terminal rate constant (68, 101). 
The MRT describes the mean (arithmetic) time taken for the drug compound to 
reside in the body before it is eliminated. It is estimated by dividing the AUC0-∞ by the 
area under the first moment curve (AUMC0-∞). The AUMC 0-∞ is AUC obtained when 
each AUCt1-t2 point is plotted against the corresponding time and may also obtained using 
the trapezoidal method. The unit of AUMC is concentration x time2 and AUMCtlast from 
tlast to infinity is calculated using the equation 16 (68, 101):  
𝐴𝑈𝑀𝐶𝑡𝑙𝑎𝑠𝑡−∞ =
𝐶𝑡𝑙𝑎𝑠𝑡 .𝑡
𝜆𝑍
+
𝐶𝑡𝑙𝑎𝑠𝑡  
𝜆𝑍
2      ( 16 ) 
In NCA, the total body clearance (CLT) which may also be referred to as the 
systemic clearance following intravenous drug administration, the steady state volume of 
distribution (Vss) and oral bioavailability (F) of a drug may be estimated using equations 
17, 18 and 19 respectively  (68, 101): 
𝐶𝐿𝑇 =
𝐷𝑜𝑠𝑒𝑖𝑣
𝐴𝑈𝐶0−∞
𝑖𝑣
  
     ( 17 ) 
𝑉𝑠𝑠 = 𝑀𝑅𝑇
𝑖𝑣  ×  𝐶𝐿𝑠   
    ( 18 ) 
𝐹𝑝𝑜 =
𝐴𝑈𝐶0−∞
𝑝𝑜  
𝐴𝑈𝐶0−∞
𝑖𝑣  
×
 𝐷𝑜𝑠𝑒𝑖𝑣
𝐷𝑜𝑠𝑒𝑝𝑜
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   ( 19 ) 
During NCA, fewer assumptions are made compared to a compartmental analysis. 
But the disadvantage of NCA compared to compartmental analysis is that with NCA, PK 
profiles cannot be predicted when a dosing regimen is changed because it cannot predict 
compound concentration at any time (68, 101).  
1.3.2 Compartmental pharmacokinetic analysis  
Unlike NCA, in compartmental analysis the body is represented by one or more 
compartments that possess no real anatomical or physiological meaning and the 
movement of drugs in and out of the compartments is described by rate constants (68). 
Each compartment is a discrete pharmacokinetic compartment and is symbolic of a 
combination of tissues or organs in the body. Drug distribution between compartments 
are assumed to be rapid and at equilibrium with each other in one compartmental model 
but not so in multi-compartmental models (68). Multi-compartmental models are used to 
describe the shape of the concentration time profile. When plotted on a semi-log scale, if 
the concentration time profile produces a straight line, the drug is said to distributed into 
one compartment and follows a mono-exponential decay, but if lines on the semi-log scale 
appears to be in more than one phase, the drug is said to be distributed into multiple 
compartments depending on the number of phases observed in the semi-log profile (68). 
1.3.2.1 One compartmental pharmacokinetic model 
In one compartmental PK analysis, the body is assumed a homogenous 
compartment whereby the distribution of the drug in the body is instantaneous and in a 
single compartment (Figure 1.4) (68).  
 
Figure 1.4: A one-compartment model 
k: elimination rate constant  
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In a one compartmental model, the decline of a drug compound from the body is mono-
exponential and the concentration of the drug in the plasma or in the blood (C(t)) at a 
given time t, is calculated using equation 20 (68): 
   
𝐶(𝑡) =
𝐷𝑜𝑠𝑒𝑖𝑣
𝑉
 .  𝑒 −𝑘𝑡 
    ( 20 ) 
where V is the volume of distribution, k is the first order elimination rate constant and t is 
time.  
The one compartmental model for a drug administered through the extravascular 
routes will require incorporation of the absorption component into the model as depicted 
in Figure 1.5.  
 
Figure 1.5: A one-compartment model including extravascular absorption component 
ka: absorption rate constant 
This will involve the estimation of an absorption rate constant ka, using the curve fitting 
or residual method and concentration at any time  t, may be calculated using the equation 
21 (68): 
𝐶(𝑡) =
𝐾𝑎 .𝐹.  𝐷𝑜𝑠𝑒
𝑝𝑜
𝑉 .  (𝑘𝑎−𝑘)
 .  (𝑒 −𝑘𝑡 −  𝑒 −𝑘𝑎𝑡)     ( 21 ) 
1.3.2.2 Multi-compartmental pharmacokinetic modelling 
Multi-compartmental models are used to analyse the PK of drugs undergoing bi- or 
tri- exponential decay, in that their concentration time profile following will show a bi- 
or triphasic declines respectively. The body is assumed to be comprised of a central and 
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one or more peripheral compartments (Figure 1.6) whereby the central compartment is a 
lumped up compartment making up the highly perfused tissues such as the lungs, heart 
and kidneys while the peripheral compartment comprises the poorly perfused tissues like 
the fat, skin or muscles (68).  
 
Figure 1.6: Two-compartment model.  
k12, k21 and k are first-order rate constants: k12: rate of transfer from central to peripheral 
compartment; k21: rate of transfer from peripheral to central compartment; k: rate of 
elimination from central compartment. 
The assumption in a multi-compartmental model is that, after drug administration 
into the central compartment, drug is transferred between the central and peripheral 
compartments but the distribution of drug between the central compartment and the 
peripheral compartments is not instantaneous. The two compartmental model can be 
described as follows (68):  
𝐶(𝑡) = 𝐴 . 𝑒−∝.𝑡 + 𝐵 . 𝑒−𝛽.𝑡     ( 22 ) 
where A, B, are Y-intercepts while α and β are slopes (rate constant) following curve 
fitting of the plasma concentration time curve using the residual or nonlinear regression 
analysis methods such that A and α are the Y-intercepts and slopes of the distribution 
phases while B and β are the Y-intercept and slope of the elimination phase.  
The concentration at time zero C0 equal the sum of A and B while the volume of central 
compartment the Vc is the Doseiv/C0 (68). A steeper distribution phase occurring after 
administration depicts a rapid distribution and elimination of drugs from plasma to the 
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well perfused organs while a less steep phase depicts the elimination of the drug from the 
body (68). A three compartmental model comprising of a tri-phasic concentration time 
response may be expressed as equation 23 (68):  
𝐶(𝑡) = 𝐴 . 𝑒−∝.𝑡 + 𝐵 . 𝑒−𝛽.𝑡 +  𝐶 . 𝑒−𝛾.𝑡    ( 23 ) 
where the C and γ are the Y intercept and slope of the extra phase which may be an 
additional distribution phase or an additional elimination phase. 
1.3.3 Population pharmacokinetic modelling  
Under the same dosage scheduling conditions, the concentrations of a drug may 
vary from person to person within a similar population group due to different manners in 
which individuals handle the drug (102). Population PK (popPK) studies the inter-
individual variabilities (or between subject variability (BSV)) and intra-individual 
variabilities (or between occasion variability (BOV)) in PK of drugs and the 
demographic, pathophysiological or therapeutic factors (or covariates) that are 
responsible for the variations within a given population (102, 103).  Population PK 
modelling requires a thorough assessment of many models with varied amount of 
compartments, elimination methods and variabilities. In popPK analysis, drug 
concentration samples from representatives of the target population are collected and the 
variabilities in PK of the drug between the subjects or within the subjects are identified, 
explained and quantified (102). This process informs the optimisation of dosing strategies 
for the drug in the population of interest (102, 103). Population PK analysis may be 
carried out using the traditional “two-stage” approach or the non-linear mixed effect 
(NLME) method, the latter being more reliable and now more commonly used (102, 103).  
The two-stage method requires first, the estimation of the PK using the non-linear 
regression analysis of the individual patient concentration time profiles when there is rich 
concentration time data (102, 103). The individual PK parameters estimated from the non-
linear analysis are then used as input parameters in the second stage which involves a 
statistical analysis of individual PK parameters. During the second stage, linear stepwise 
regression, covariance analysis and cluster analysis may then be used to analyse whether 
parameters depend on covariates and the magnitude of the dependency (102, 103). The 
two-stage approach may yield accurate and unbiased estimation of population 
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characteristic but it requires large data sets of concentration-time points and may 
overestimate the random effects (that is, effects due to sampling times or methods) (102, 
103). The NLME approach does not require strict or restrictive sample collection designs, 
hence may be used to analyse sparse, fragmented and unbalanced data (102, 103). It uses 
the available drug concentration time data for assessing the  distribution of parameters 
and combines these with PK data from rigid and well-sampled PK studies to analyse the 
distribution of PK parameters across the population and estimate how these relate with 
covariates (102, 103).    
Population PK is widely used to determine the covariates that influence the 
systemic exposure of antimalarial agents across different population groups. One of such 
studies showed that body size and age were the main covariates which influenced the 
clearance of amodiaquine in 261 patients which included children younger than 5 years 
old and pregnant women (104).  Another study showed that body weight and malaria 
infection are significant covariates that affect the systemic disposition of mefloquine in 
43 patients who were being treated for malaria infection (105). Also, population PK has 
been used in dosage optimisation studies especially for the optimisation of antimalarial 
dosage strategies in children. For example, Hoglund et al  (2017) constructed an 
optimised dosing strategy of piperaquine across age groups as age was found a significant 
covariate which affected the systemic exposure of piperaquine in children (106). 
1.3.4 Mechanistic pharmacokinetic modelling  
In mechanistic PK modelling, the body is divided into organs which are represented 
by physiologically important compartments with precise blood flows rates and organ size 
such that changes in drug concentrations in these organs can be estimated using 
mathematical equations (107-110).  Physiologically based-pharmacokinetic (PBPK) 
modelling is a modelling approach whereby the PK of drugs can be studied 
mechanistically. One of such studies used a PBPK modelling technique to describe the 
pharmacokinetics of artemether in adults and paediatric patients (111). More recently 
Johnson et al (2019) developed a PBPK model for mefloquine in children and used their 
model for a dose selection study in Caucasian patients weighing between 5 and 10 kg 
(112).  
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1.4 Physiologically based pharmacokinetic modelling 
Initially developed as a predictive safety tool to address toxicity associated with 
environmental pollutant exposure to humans, physiologically based pharmacokinetic 
(PBPK) modelling has emerged as a promising technique to circumvent many challenges 
faced within drug development (113, 114). In 1937, Teorell first introduced the concept 
of simulating pharmacokinetic parameters in different types of compartmental models 
using physiological and biological mechanisms of species (109). Physiologically based 
pharmacokinetics (PBPK) is a branch of systems biology which utilises a mechanistic or 
“bottom up” method to make pharmacokinetic estimations. Mathematical  models are 
used alongside drug specific properties such as the physicochemical, metabolic and 
pharmacogenomic data obtained from preclinical or in vitro biochemical, chemical or 
pharmaceutical experiments and species specific anatomical, physiological and 
pathophysiological parameters to describe the best pharmacokinetic (PK) estimates of 
drugs in the body (109).  
In PBPK modelling, different organs of the body are represented by smaller 
compartments and different processes affecting drug concentrations in the body are 
modelled in mathematical expressions to quantify the drug concentrations in a particular 
tissue or organ (113, 114) (109).  In a typical PBPK model, the physiology of the main 
organs or tissues impacting upon the pharmacokinetics of the drug needs to be properly 
modelled, for instance, for a drug administered orally, factors influencing the release of 
drug molecule from its delivery system into the systemic circulation need to be accounted 
for in the model(109). These factors can include gastric emptying and intestinal transit 
time; intestinal pH and geometry; regional variations of drug; metabolising enzymes and 
transporter protein along the small intestine. Other pharmacokinetic processes such as 
absorption, drug permeability, tissue partitioning, metabolism and clearance of the drug 
are modelled as well to describe how each of these affect drug concentrations in 
plasma/blood or tissue (109, 113, 114). Figure 1.7 shows the structure of a minimal model 
and a generic whole body PBPK model. 
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Figure 1.7: Minimal PBPK models (a) and generic whole body PBPK model (b) 
adapted from (109, 115) 
 
1.4.1 Input parameters 
In PBPK models, input parameters required for simulations may be classified as 
either system-related parameters or compound-related parameters.  
1.4.1.1 System dependent parameters  
These are the species physiological or biochemical characteristics that affect the 
disposition of drug and these vary across species. The mechanistic nature of PBPK allows 
for characteristics such as organ blood flows, CYP450 enzymes, transporter protein 
expression, haematocrit, liver and kidney functions to be incorporated into the model 
(109). Other system-related parameters used in PBPK simulations are organ volume, 
glomerular filtration rates, body weight and adipose content (107).   
1.4.1.2 Drug-related parameters  
These parameters depend on drug molecule characteristics. These parameters are 
determined from prior in vivo or in vitro experiments or may be predicted and have an 
effect on the absorption and disposition of the drug in the body. They generally include 
the physicochemical properties of the drug such as pKa, molecular weight, tissue partition 
coefficients, permeability properties such as in vivo or in vitro permeability values 
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(effective permeability Peff and apparent permeability Papp), active transport, or metabolic 
properties such as the intrinsic clearance or the in vitro enzymatic clearance, which may 
be based on the Michaelis-Menten kinetics. 
1.4.2 Developing a model 
A whole body PBPK model incorporates the kinetic processes occurring in different 
tissues to determine the changes in drug concentrations over time in the body. The drug 
distribution processes are influenced by perfusion or permeability of the tissue. Most 
tissues in the human body exhibit mainly perfusion limited distribution. Conversely, some 
tissues have significant drug permeability problems making them permeability limited. 
In such tissues, permeability limited models will best describe the changes in drug 
concentration over time (107). 
In the perfusion-limited and permeability-limited models, tissue compartments are 
defined by the volume (VT) which are actual tissue volumes. These tissue compartments 
may be vascular or extravascular with volumes and composition characteristics readily 
available from published literature (116-119). In Figure 1.8 and 1.9, perfusion and 
permeability limited models for a one compartment tissue models are illustrated. Also, 
the rate of change of drug concentration in a perfusion limited organ can be determined 
using equation 24 while in a permeability limited organ, the rate of change of drug can 
be determined using the equations 25 and 26 (110, 120).  
 
Figure 1.8: A one-compartment perfusion limited model 
𝑉𝑇
𝑑𝐶𝑇(𝑡)
𝑑𝑡
=  𝑄𝑇 . 𝐶𝐴𝑅𝑇(𝑡) +  
(𝑄𝑇 .  𝐶𝑇)
𝐾𝑝
      ( 24 ) 
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Figure 1.9: A two-compartment vascular membrane permeability limited model 
𝑉𝑇
𝑑𝐶𝑉(𝑡)
𝑑𝑡
=  𝑄𝑇 . 𝐶𝐴𝑅𝑇(𝑡) +  
𝑃𝑆𝑇.  𝐶𝐸𝑉
𝐾𝑝
− (𝑄𝑇 +  𝑃𝑆𝑇) . 𝐶𝑉(𝑡)  ( 25 ) 
𝑉𝐸𝑉
𝑑𝐶𝐸𝑉(𝑡)
𝑑𝑡
=  𝑃𝑆𝑇 . 𝐶𝑣(𝑡) −  
𝑃𝑆𝑇.  𝐶𝐸𝑉(𝑡)
𝐾𝑝
      ( 26 ) 
where Q: blood flow; C: concentration; V: volume; Kp: tissue: plasma partition 
coefficient; PS: permeability surface area coefficient; Subscripts T, ART, VEN, V, and EV 
present tissue, arterial, venous, vascular compartment, and extravascular compartment, 
respectively. 
1.4.3 Mechanistic prediction of pharmacokinetic parameters 
Prediction of the pharmacokinetic parameters of drugs can be conducted 
mechanistically even without prior knowledge of the drug is in vivo pharmacokinetics in 
the species of interest (109). This is possible because drug specific parameters obtained 
from in vitro studies can be scaled to predict their pharmacokinetic parameters through a 
process termed ‘in vitro-in vivo extrapolation’ (IVIVE) (109). This technique provides a 
mechanistic framework which relies heavily of the availability of in vitro drug data that 
are used to extrapolate the in vivo PK characteristics of the drug (109). Pharmacokinetic 
processes of drug disposition and elimination have been mechanistically described with 
several mathematical models to enable adequate prediction of pharmacokinetic 
parameters, some of which are now discussed. 
1.4.3.1 Dissolution 
Mathematical models for dissolution was first proposed by Noyes and Whitney in 
1897 (77) following an in vitro dissolution experiment. Brunner and Nernst in 1904 (121, 
122) expanded Noyes and Whitney’s equation by including the surface area (A) of the 
drug particle available for dissolution in the equation 27: 
𝑑𝐶
𝑑𝑡
= 𝑘. 𝐴. (𝐶𝑠 − 𝐶)            ( 27 )                                
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Brunner and Nernst considered the impact of diffusion coefficient (D) of drug 
through diffusion and volume of the media (Vm) wherein the drug is to be dissolved and 
the thickness (h) of the diffusion layer may be incorporated into the equations by relating 
these variables to k using  Fick’s second law as shown in equation 28 and 29 (121, 122): 
𝐷
𝑉𝑚ℎ
= 𝑘           ( 28 ) 
therefore, they expanded the dissolution model equation as follows 
𝑑𝐶
𝑑𝑡
=
𝐷.𝐴
𝑉𝑚ℎ
. (𝐶𝑠 − 𝐶)      ( 29 ) 
Other in vitro dissolution models have been described apart from the Brunner and 
Nerst equations. These include the widely known Weibull model and other models like 
the Higuchi model, Korsmeyer–Peppas model and the Baker–Lonsdale models have been 
proposed (123).    
1.4.3.2 Drug permeability 
The flux (J) of drug molecules passively moving across a membrane can be 
expressed by equation 30 to incorporate the in vitro permeability (Peff), intestinal surface 
area S, and the change in concentration across the membrane, ∆𝐶 (107): 
𝐽 =  𝑃𝑒𝑓𝑓  ×  𝑆 ×  ∆𝐶              ( 30 ) 
For preclinical studies, however, the 𝑃𝑒𝑓𝑓, may not be obtained easily, therefore an 
apparent permeability (Papp) obtained by in vitro methods using cell culture based 
permeability studies with either human epithelial colorectal adenocarcinoma cells (Caco-
2) or Madin-Darby canine kidney (MDCK-II) cells, with Caco-2 being the method more 
predominantly used. A regression relationship has been determined to correlate Peff values 
for some drugs to their Papp values and the resultant correlation relationship (equation 31) 
can be used to estimate the Peff value from Papp values for other drug compounds (107). 
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𝐿𝑜𝑔(𝑃𝑒𝑓𝑓) = 0.6532 𝐿𝑜𝑔 (𝑃𝑎𝑝𝑝) − 0.3036    ( 31 ) 
Where there is active transportation of drugs due to membrane bound proteins, the 
flux of drug across the intestinal mucosa is affected. Caco-2 studies are able to detect this 
and such compounds will be subject to further studies to determine the kind of transporter 
proteins that influences their transport (107).  The determination of drug-transporter 
interactions using the Michaelis-Menten equation may appropriately express the 
relationship between drug and transporter; this is due to saturation of enzyme binding 
sites, however, when protein transporter abundance is known, the determination of 
specific transporter pathways has been developed using insect-derived membrane 
fractions which allow for more specificity. The flux of active transporter substrates can 
be determined by the equation 32 (107).  
𝐽𝑡𝑟𝑎𝑛𝑠𝑝𝑜𝑟𝑡𝑒𝑟 = 
𝐽𝑚𝑎𝑥 .  𝐶𝑙𝑢𝑚𝑒𝑛  
𝐾𝑚+ .𝐶𝑙𝑢𝑚𝑒𝑛 
     ( 32 ) 
where  𝐽𝑡𝑟𝑎𝑛𝑠𝑝𝑜𝑟𝑡𝑒𝑟 is flux of transporter; Jmax is maximum velocity of flux, Clumen is the 
concentration at the lumen and Km is the Michaelis-Menten constant. Since Jmax and Km 
are obtained from in vitro cell lines, in vivo scaling is accomplished by accounting for the 
segmental protein abundances along the small intestine (107). 
1.4.3.3 Drug metabolism and renal excretion 
Modelling of drug metabolism involves estimation of in vivo human clearances 
from clearance determined from in vitro experiments. Experimental in vitro hepatic 
intrinsic clearance CLint, are converted to in vitro unbound intrinsic clearance (CLint,u) by 
accounting for CYP enzyme or UGT protein concentrations and non-specific binding. 
The CLint,u is then converted to human unbound in vivo  intrinsic clearance (CLint invivo) by 
accounting for microsomal recovery, hepatocellularity and liver weight (equation 33). In 
equation 34, the fraction of unbound drug in the plasma and the blood to plasma ratio are 
incorporated in an equation together with the CLint invivo to determine the hepatic clearance, 
assuming a well stirred mechanistic liver model.  
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𝐶𝐿𝑖𝑛𝑡 𝑖𝑛 𝑣𝑖𝑣𝑜 = 𝐶𝐿𝑖𝑛𝑡 𝑖𝑛 𝑣𝑖𝑡𝑟𝑜 .
𝑚𝑖𝑙𝑙𝑖𝑔𝑟𝑎𝑚 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 (𝑚𝑔)
𝑔𝑟𝑎𝑚 𝑜𝑓 𝑙𝑖𝑣𝑒𝑟 (𝑔)
 .
𝐿𝑖𝑣𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔)
𝐵𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)
  
            ( 33 ) 
𝐶𝐿𝐻 = 𝑄𝐻 . [
(𝑓𝑢𝑝/𝐵:𝑃). 𝐶𝐿𝑖𝑛𝑡 𝑖𝑛 𝑣𝑖𝑣𝑜
𝑄𝐻+(𝑓𝑢𝑝/𝐵:𝑃) .   𝐶𝐿𝑖𝑛𝑡 𝐼𝑛 𝑣𝑖𝑣𝑜
]                           ( 34 ) 
Modelling the renal clearance has not been extensively explored. Presently, animal 
in vivo renal clearances are extrapolated to determine human adult clearance or estimation 
of clearance by calculation of glomerular filtration rates may be used to estimate human 
in vivo clearance. Only a few studies describe the processes of glomerular filtration, 
passive and active secretion/re-absorption occurring in the kidney from the mechanistic 
viewpoint, one of such is by Neuhoff et al (2013) where they developed a mechanistic 
kidney model (Mech KiM) that was able to account for the effect of both active and 
passive transport processes occurring in the kidney during the excretion of drugs (124) 
(107). 
1.4.3.4 Drug-tissue partitioning 
For drugs to elicit the desired therapeutic outcome, they need to be distributed to 
the primary site of action. The factors affecting drug tissue partitioning (drug distribution 
into the tissues) are the rate and extent of drug partitioning into a tissue. This may be 
affected by tissue composition, and the lipophilic property of drug molecule (107). 
Modelling partitioning of drug into the tissue involves determining the ratio of the 
concentration of drug in the tissue to its concentration in the plasma at steady state through 
in vitro or in vivo methods. This ratio is termed the partition coefficient Kp and calculated 
using equation 35 (107). 
𝐾𝑝 =
𝐶𝑡𝑖𝑠𝑠𝑢𝑒
𝐶𝑝𝑙𝑎𝑠𝑚𝑎
           ( 35 ) 
where Ctissue is the concentration of drug in the tissue; Cplasma is the concentration of drug 
in the plasma. When the fraction of unbound drug in the tissue and plasma is determined 
through in vitro equilibrium dialysis methods, the Kp can be is calculated by dividing the 
fraction of unbound drug in the tissue fut by the fraction of unbound drug in the plasma 
fup as shown in equation below (107): 
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𝐾𝑝 =  
𝑓𝑢𝑡
𝑓𝑢𝑝 
                           ( 36 ) 
In practise however, unbound tissue-to-plasma concentration ratio (𝐾𝑝𝑢) which accounts 
for the fraction unbound in the plasma 𝑓𝑢𝑝 is employed rather than the 𝐾𝑝. Therefore, 
the equation can be expanded to:      
𝐾𝑝 = 𝑓𝑢𝑡 . 𝐾𝑝𝑢                                                ( 37 ) 
therefore, 
𝐾𝑝 =
𝐶𝑡𝑖𝑠𝑠𝑢𝑒
𝐶𝑝𝑙𝑎𝑠𝑚𝑎
= 𝑓𝑢𝑡. 𝐾𝑝𝑢                              ( 38 ) 
It is normally difficult and costly to experimentally determine these values, so 
Poulin and Theil first developed a model to predict the Kp. Their model was later 
expanded in 2005 by Rodgers and Rowland (125, 126) to account for the ionisation 
properties of the drugs as well as the composition of the tissue the drug is partitioning 
into. Based on the Rodgers and Rowland tissue partitioning model, the Kp of moderate-
to-strong basic drugs: 
𝐾𝑝𝑢 =  [
(
1+𝑋.𝑓𝐼𝑊
1+𝑌
) +  𝐹𝐸𝑊 +  ( 
𝐾𝑎𝐴𝑃 .  [𝐴𝑃]𝑇 .  𝑋
1+𝑌
    ) + 
(
𝑃.𝑓𝑁𝐿+ (0.3𝑃+0.7).𝐹𝑁𝑃
1+𝑌
) 
]                          ( 39 ) 
An equivalent model was developed for Kpu drugs which are not moderate-to-strong 
basic as shown below: 
𝐾𝑝𝑢 =  [
(
1+𝑋.𝑓𝐼𝑊
1+𝑌
) +  𝐹𝐸𝑊 +  ( 𝐾𝑎𝑃𝑅 . [𝑃𝑅]𝑇   ) +
 (
𝑃.𝑓𝑁𝐿+ (0.3𝑃+0.7).𝐹𝑁𝑃
1+𝑌
) 
]                          ( 40 ) 
where P: n-octanol:water partition coefficient for unionised compound for all tissues 
besides the adipose, F: fractional tissue volume, IW: intra-cellular tissue water, EW: extra-
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cellular tissue water NL:  tissue neutral lipids, NP: tissue neutral phospholipids, [AP]T: 
tissue concentrations of acidic phospholipids and extra-cellular albumin (for acids and 
weak bases), [PR]T: tissue concentrations of lipoprotein (for neutrals),  KaAP: the affinity 
constant of the drug for acidic phospholipids which can be derived by  equation 41, KaPR: 
either extra-cellular albumin or lipoprotein, respectively which can be derived by 
equation 42,  X, Y and Z: drug ionisation as shown in Table 1.3 below: 
𝐾𝑎𝐴𝑃 =  [
𝐾𝑝𝑢𝐵𝐶 − (
1+𝑍
1+𝑌
 . 𝑓𝐼𝑊,𝐵𝐶) − 
(
𝑃.𝑓𝑁𝐿,𝐵𝐶+ (0.3𝑃+0.7).𝐹𝑁𝑃,𝐵𝐶
1+𝑌
) 
] . (
1+𝑌
[𝐴𝑃]𝐵𝐶.  𝑍
)   ( 41 ) 
𝐾𝑎𝑃𝑅 =  [
1
𝑓𝑢
− 1 −
 (
𝑃.𝑓𝑁𝐿,𝑃 + (0.3𝑃+0.7).𝐹𝑁𝑃,𝑃
1+𝑌
) 
] .
1
[𝑃𝑅]𝑃
                  ( 42 ) 
 
Table 1.3: Drug Ionisation   
 X Y Z 
Monoprotic 
base 
10𝑝𝐾𝑎−𝑝𝐻𝑖𝑤 10𝑝𝐾𝑎−𝑝𝐻𝑝 10𝑝𝐾𝑎−𝑝𝐻𝐵𝐶 
Diprotic 
base 
10𝑝𝐾𝑎2−𝑝𝐻𝑖𝑤
+  10𝑝𝐾𝑎1+𝑝𝐾𝑎2−2𝑝𝐻𝑖𝑤 
10𝑝𝐾𝑎2−𝑝𝐻𝑝
+  10𝑝𝐾𝑎1+𝑝𝐾𝑎2−2𝑝𝐻𝑝 
10𝑝𝐾𝑎2−𝑝𝐻𝐵𝐶
+  10𝑝𝐾𝑎1+𝑝𝐾𝑎2−2𝑝𝐻𝐵𝐶 
Monoprotic 
acid 
10𝑝𝐻𝑖𝑤−𝑝𝐾𝑎 10𝑝𝐻𝑝−𝑝𝐾𝑎 NA 
Diprotic 
acid 
10𝑝𝐻𝑖𝑤−𝑝𝐾𝑎
+  102𝑝𝐻𝑖𝑤−𝑝𝐾𝑎1−𝑝𝐾𝑎2 
10𝑝𝐻𝑝−𝑝𝐾𝑎1
+  102𝑝𝐻𝑝−𝑝𝐾𝑎1−𝑝𝐾𝑎2 
NA 
Zwitterion 
10𝑝𝐾𝑎𝐵𝐴𝑆𝐸−𝑝𝐻𝐼𝑊
+  10𝑝𝐻𝑖𝑤−𝑝𝐾𝑎𝐴𝐶𝐼𝐷 
10𝑝𝐾𝑎𝐵𝐴𝑆𝐸−𝑝𝐻𝑝
+  10𝑝𝐻𝑝−𝑝𝐾𝑎𝐴𝐶𝐼𝐷 
10𝑝𝐾𝑎𝐵𝐴𝑆𝐸−𝑝𝐻𝐵𝐶
+  10𝑝𝐻𝐵𝐶−𝑝𝐾𝑎𝐴𝐶𝐼𝐷 
Neutral 0 0 NA 
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1.4.4 Software based PBPK modelling approaches 
As a result of computational advancement in PK modelling, PBPK models are now 
being built into computer software programs to enhance the predictability capacity of the 
models. The use of computer software programs to predict PK parameters using PBPK 
modelling is known as in silico PBPK modelling. In silico PBPK modelling particularly 
addresses challenges such as cost at preclinical drug development stages when no clinical 
drug data exist so that potentially harmful drugs can be excluded at early stages of drug 
development. Some software programs have as a result emerged on a commercial scale 
such as GastroPlus (Simulation Plus: www.simulations-plus.com); Simcyp® (Simcyp® 
Ltd: www.simcyp.com); PK-Sim (Bayer: www.systems-biology.org). Some 
mathematical and statistical software are available like Simbiology (MATLAB, 
MathWorks, Inc., Natick, Mass., USA) and R (R Development Core Team) where desired 
models can be inputted to run PK simulations.  
Thus, PBPK may not only be useful for predicting PK parameters in single adult 
but can be employed for population PK simulation even prior to availability of clinical 
data in contrast to conventional population PK analysis where prior clinical data is 
analysed to describe PK of drugs. 
1.4.5 Modelling population variabilities in PBPK modelling  
The significance of population variability of pharmacokinetic parameters and the 
cause of this in a given population group cannot be overemphasised as the understanding 
of this guides researchers on dosing  recommendations especially in special 
populations(127). As the PBPK modelling technique is mechanistic in nature, covariate 
models which are based on the extrapolation of clinical pharmacokinetic parameters of 
the drug are therefore important. The  clinical pharmacokinetic parameters are obtained 
from well explained interindividual variabilities in parameters that are influenced by 
variation in physiological or anatomical characteristics within a population group (128). 
Huisinga et al (2012) demonstrated how mechanistic covariate models may be used to 
determine the population variabilities of different pharmacokinetic parameters (128). 
They showed that variation in tissue partition coefficients significantly influenced the 
variabilities of the predicted blood concentration time profile of a drug. They further 
explained that the influence of variable tissue/plasma partitioning coefficients on 
predicted blood drug concentrations was possibly more significant than might be 
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expected in the case of inter-individual variations in tissue volumes and blood flows 
(128). They also proposed a mechanistic covariate model which agreed with the principles 
of PBPK modelling that was able to mechanistically predict the expected inter-individual 
variabilities in pharmacokinetic parameters from variations in anatomical and 
physiological characteristics relevant to drug disposition. Their model was able to predict 
the inter-individual variation in plasma concentration of several drugs in a paediatric 
population group aged 5 years old and older using  the allometric scaling technique and 
the PBPK modelling technique. They found that in this population group there is no 
significant difference in the predicted volume of distribution and blood clearance using 
both methods (128). Also, prediction of factors influencing variability of drug disposition 
within a specific population can be performed using covariate models from multiple 
species, and this may be done through virtual population simulations (114). 
1.5 PBPK modelling in special populations  
Clinical studies are often conducted in individuals with normal physiological, and 
biochemical body compositions. The recruitment of special populations, such as 
paediatrics, pregnant women, geriatrics and patients with renal/liver impairment into 
clinical trials still remains challenging. Unfortunately, the lack of adequate clinical PK 
studies in these population group results in poorly made clinical decisions relating to 
doses of drugs. The uniqueness of PBPK modelling in incorporating physiological and 
biochemical variations across populations makes it a powerful tool in describing 
population specific PK parameters of drugs where there is sparse clinical data (129).  
Over the past decade, several studies have been used to reiterate the importance of 
PBPK modelling in improving drug treatments in special populations. In 2014, Khalil et 
al (130) used PBPK modelling to predict drug exposure of sotalol following oral 
administration in children from neonatal age till adolescence. Following a validation of 
model predictions with adult sotalol plasma concentration data, they scaled down 
simulations in paediatrics and their model-predicted PK parameters of sotalol were 
acceptable across all paediatric age groups except in neonates. They concluded that PBPK 
modelling was useful to guide the paediatric clinical data and help with clinical decisions 
with respect to sotalol therapy. Walsh et al (2016)(131) also discussed the usefulness of 
PBPK simulations in guiding actinomycin D dosing in young patients as they found that 
their model gave good actinomycin D predictions in this age group. Also Batchelor et al 
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(2015) (132) used PBPK modelling to show that there may be a marginally higher risk 
for supra-therapeutic phenytoin systemic exposure in children receiving 20 mg/kg IV 
loading dose, necessitating therapeutic drug monitoring when phenytoin is used in this 
group. 
 In pregnancy PBPK studies, Mendes et al (2015) (133) showed that PBPK models 
can be used to predict systemic drug exposure of antiretroviral (ARV) drugs excreted 
through the kidney. They proposed their models for optimizing ARVs in pregnant 
women. Again, Alqahtani et al (2015) (134) developed a PBPK model which adequately 
predicted the PK of indomethacin in women in their second trimester. PBPK also has 
been successfully applied to predict clinically observed plasma concentrations of 151 
compounds in patients with chronic kidney disease and another study showed its 
usefulness in predicting the altered plasma profiles of 7 drugs in patients with diabetes 
(135, 136).  
Finally, Polasek et al (2013) (137), showed that in the elderly, PBPK models 
predicted reduced metabolic clearance as they showed good model predictability with the 
four drugs used in their research. There is more room to explore the potential of PBPK 
modelling in special populations as there are several drugs whose PK parameters are not 
well described in special populations. 
1.6 Best practice in the use of PBPK modelling 
The increase in popularity in the use of PBPK modelling techniques during early 
and late drug development stages has prompted the requirement to follow a 
“standardised” approach during the development and application of PBPK models to 
ensure model validity, hence there has been a consensus among regulatory bodies, 
industries and the academia on the best ways to carry out and report PK analysis using 
PBPK modelling (138). Depending on the purpose of the PBPK study, there are stages 
that should be followed during modelling in order to increase reliability on the resultant 
PK predictions (139-141). PBPK modelling techniques follow a ‘predict-learn-confirm’ 
approach (Figure 1.10) whereby initial model development is followed by a validation 
process to identify possible faults in the initial model prediction and subsequent 
optimisation of the model which will then be followed by a validation of final model to 
ensure reproducibility across different dosing conditions (142).  
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Figure 1.10: Predict-learn-confirm procedures in PBPK modelling 
 
1.6.1 Predict 
This stage involves parameterising PBPK models by gathering relevant drug related 
data from in vitro or in vivo studies such as physiochemical drug data and 
pharmacokinetic data to create an initial model to simulate the concentration profile 
and/or predict the PK of the drug. At preclinical stages of drug development, there may 
be sparse PK drug data and more physicochemical data available for use during initial 
model development. These physicochemical data might be used to predict the necessary 
PK data that are required during simulations that guide first in human (FIH) clinical trials 
(109, 142, 143).  
1.6.2 Learn 
At this stage, validation and optimisation of the initial model is done using 
retrospective clinical data. Where the initial model is not able to recover the clinically 
observed concentration time profiles or adequately predict the PK of the drug, the sources 
of these inconsistencies are identified and refined. This may require sensitivity analysis 
of parameters to determine what impact changes in these parameters might have on the 
predicted output. In preclinical studies, this stage involves refining preclinical models 
with clinical ADME data (109, 142, 143) 
1.6.3 Confirm 
 This stage requires the application of the optimised model under different scenarios 
in other to further affirm the predictability of the model. During latter phases of drug 
development, this stage may guide drug dosage design in special populations or in 
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different disease states. It may also involve designing DDI studies or drug-food 
interaction studies (109, 142, 143). 
1.7 Opportunities for PBPK modelling in antimalarial drug research  
The pharmacokinetics of the pharmacological agents has a direct impact on their 
efficacy. There is sparse data available to describe the pharmacokinetics of antimalarials 
in children and pregnant women; this affects the quality of clinical decisions made during 
antimalarial treatment in these populations. In previous sections, the use of PBPK 
modelling has been elaborated and the fact that clinical data is not a prerequisite for 
developing models to describe the PK of a drug makes it an excellent tool for better 
understanding of uncertainties in the PK of antimalarial treatment in paediatrics and 
pregnant women. So far, there are only a few studies that used PBPK modelling to 
identify, explain or solve challenges that have PK implications in paediatric and 
pregnancy antimalarial drug treatment. Due to several physiological changes occurring in 
these such as the ontogeny of metabolising enzymes in children and changes in CYP 
enzyme activity in pregnancy, it may be erroneous to assume that healthy adults will 
handle drugs in the same manner, and bearing in mind  that they are at a higher risk for 
malaria induced mortality, there is a need to find alternative ways to optimise current 
treatments for them. Some areas wherein PBPK modelling can be used to improve 
antimalarial therapy in these populations are in assessing drug-drug interaction (DDIs) 
and dose optimisation of currently existing adult based dosing regimens (144-146). 
In children for example, an understanding of the metabolic pathways responsible 
for the biotransformation of drugs coupled with knowledge of the ontogenesis of the 
enzymes involved in these pathways are important (147), to determine the nature of DDI 
expected in children using antimalarials. As DDIs are mainly related to drug metabolism, 
in adults, the DDI between victim drug and interacting drug may be known, but the 
difference in pattern of expression of CYP enzymes in children may alter the way drugs 
are metabolised in them especially from birth till about 3 years of age (148). Therefore, 
the ontogeny of CYP needs to be considered when predicting DDI in children as this may 
affect the amount of drug metabolised in children compared to adults. An interacting drug 
that is a competitive inhibitor of the CYP (say 3A4 for instance) may increase the 
expected DDI between the drug and the victim drug in children about a month old since 
there is not sufficient 3A4 for binding to the substrate in the first place (148, 149). 
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Conversely, the induction effect of an inducer may not be sufficient to result in a DDI 
between and inducer and victim drug in child below one month old as there may not be 
sufficient enzymes to induce in the first place (148, 149).  
The DDI interactions between antimalarials and other drugs in paediatrics and 
during pregnancy are not well studied and this may impact on the clinical efficacy, and 
safety of the antimalarial drug therapy. PBPK modelling has been used in adult DDI 
studies (150, 151) and therefore its seems promising to study the DDI of antimalarials in 
children and pregnancy as well since it captures the dynamic nature of paediatric and 
pregnancy physiology and helps better understanding how drug metabolism is changed 
in these. Table 1.4 illustrates the main metabolic pathways of antimalarials used in these 
populations as well as possible inhibitors and inducers of their metabolic pathways and 
the drugs may inhibit or induce them. 
Table 1.4: Some antimalarials, enzymes involved in their metabolism, inhibitors and 
inducers of their metabolism pathway 
 
  
Antimalarials 
Main metabolising 
enzyme(152) 
Inhibitor(88) Inducer(88) 
Artemether, 
lumefantrine, 
mefloquine, 
piperaquine 
CYP34A 
Ritonavir, 
clarithromycin, 
itraconazole, 
ketoconazole 
rifampicin, efavirenz, 
nevirapine, carbamazepine 
Artesunate CYP2B6 Clotrimazole 
Rifampicin, nevirapine, 
ritonavir, efavirenz, 
carbamazepine 
Amodiaquine CYP2C8 
Trimethoprim, 
montelukast 
Rifampicin, ritonavir 
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1.8 Aims and Objectives 
The general aim of the thesis is to demonstrate the application of PBPK modelling in the 
assessment of the pharmacokinetics and the optimisation of antimalarial agents in special 
population groups, precisely in children and pregnant women. 
The thesis addresses three specific applications of PBPK modelling: 
1. Prediction of artemether and lumefantrine pharmacokinetics in absence and 
presence of DDIs with rifampicin in children using PBPK modelling 
This section of the thesis focusses on assessing the pharmacokinetic impact of 
DDIs in the treatment of malaria in children co-infected with tuberculosis. 
Artemether and lumefantrine (AL) are the first line treatment options for the 
treatment of malaria in malaria endemic regions but the challenge of using this 
medication to treat malaria in children who are also being treated with rifampicin 
based anti-tuberculosis (anti-TB) medication is yet to be addressed. This was 
addressed by developing a PBPK model for AL and validating it in adult and in 
children. The model was then validated in the presence of potential drug-drug 
interactions (DDIs) in adults and scaled down to children. The developed models 
were used to optimise the already existing dosing schedule of AL for the treatment 
of malaria in children who are co-administered rifampicin-based anti-TB 
medications.  
2. Assessment of the pharmacokinetics of piperaquine in the presence of drug-drug 
interaction with efavirenz and ritonavir during pregnancy. 
This section of the thesis aimed to assess the impact of DDIs on the 
pharmacokinetics of piperaquine during pregnancy. Though the pharmacokinetics 
of piperaquine is widely studied in the absence of DDIs during pregnancy, the 
effect of potential DDIs when it is administered with antiretroviral agents like 
ritonavir or efavirenz on its pharmacokinetics is not well known. This knowledge 
is important because pregnancy is known to alter certain physiological and 
biochemical properties in women, and this may have implications on the 
pharmacokinetics of AL. It is also known that there may be ethnic variation in 
physiological and biochemical parameters relevant to the understanding of the PK 
of piperaquine. DDIs between piperaquine, an antimalaria agent used during 
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pregnancy to prevent and treat malaria, and drugs that may be used to treat 
HIV/AIDs, e.g. ritonavir and efavirenz is highly likely since these co-morbidities 
are prevalent within the same ethnicity. In this study, a PBPK model for 
piperaquine was developed and robustly validated in non-pregnant population 
groups across different ethnic groups and then in pregnant population. Then the 
effect of changes in human serum albumin and gestational age was simulated in 
the presence of DDI interactions with ritonavir and efavirenz.  
3. Optimisation of chloroquine dosing for repurposing in the treatment of Zika Virus 
disease during pregnancy using PBPK modelling 
This section of the thesis aimed to optimise the dosing of chloroquine (CQ) for 
the treatment of Zika virus disease (ZIKV). The prevalence of ZIKV is becoming 
worrying and while scientists are racing against time to develop new drugs or 
vaccines to combat this infection, the potential for chloroquine to be repurposed 
for the prevention and/or treatment ZIKV has been reported. With well-defined 
effective dosing strategies for its use in the treatment of malaria and management 
of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) in pregnant 
women, a clinically viable dosing regimen of CQ for the inhibition of ZIKV is yet 
to be determined. In this study, PBPK modelling techniques were used to optimise 
the dosing of CQ for treatment of ZIKV during pregnancy. A PBPK model was 
developed for CQ and robustly validated in non-pregnant and pregnant subjects. 
This was followed by the determination of safe and effective dosing strategies of 
CQ in pregnant subjects.  
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CHAPTER 2            
PBPK prediction of artemether and 
lumefantrine pharmacokinetics in 
the absence and presence of DDIs 
with rifampicin in children 
 
 
Disclaimer 
Elements of this chapter have been published as follows:  
Olusola Olafuyi, Michael Coleman, Raj K.S. Badhan. Development of a paediatric 
physiologically based pharmacokinetic model to assess the impact of drug-drug interactions 
in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and 
the CYP3A4-inducer rifampicin. European Journal of Pharmaceutical Sciences. 2017 
Aug;106:20-33. 
DOI: 10.1016/j.ejps.2017.05.043   
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2.1 Introduction 
2.1.1 Malaria in paediatrics 
A new born baby living in a malaria endemic region has a high risk of contracting 
malaria infections before they are five years old. The WHO reported that in 2015, 
approximately 70% of malaria death occurred in children under 5 years of age (153). 
Contrary to adults who possess naturally acquired immunity, children lack this acquired 
immunity and this puts them at risk of succumbing to the infection (154). In addition to the 
transmission mode discussed in section 1.1.1, malaria may also be transferred through 
transplacental transmission, where an unborn child may develop congenital malaria from its 
mother. In this case the mother may be asymptomatic and possess malaria parasites in her 
placenta or other peripheral locations. Foetal infection may lead to anaemia in the child or 
even death. Uncomplicated malaria may be treated successfully, however, poor recovery may 
result in life-threatening severe malaria. Poorly managed malaria infection in children can 
results in complications such as seizures, acidosis, cerebral malaria, renal impairment, severe 
anaemia, hypoglycaemia, respiratory distress and jaundice (155, 156). Also, frequent malaria 
infection in children may result in malnourishment, poor growth and development as well as 
chronic anaemia.  
The risk of malaria infection and its complications is higher in children between the 
ages of 6 months and 5 years (32). It is thought that in malaria endemic regions, new-born 
babies possess non-specific temporary immunity conferred on them through the transfer of 
maternal immunoglobulin G (IgG) antibodies in the uterus around the third trimester of 
gestation and the levels of IgG decrease gradually after birth until around the first year of life 
(154). Though a study argues otherwise suggesting that humoral response to P. falciparum 
was implicated in age-related prevalence of malaria in its study subjects (157).  Another study 
explained that malaria immunity in infants may be due to parasite growth inhibitory factors 
like lactoferrin and secretory IgA which are present in the breast milk, maternal sera and 
infant sera (158). 
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2.1.1.1 Drugs used for the treatment of malaria in children 
Quinine is the oldest antimalarial agent known, and it has been modified structurally 
to produce newer antimalarials. Quinine may be used for complicated malaria especially 
when other agents recommended for uncomplicated malaria have failed. A major setback to 
malaria chemotherapy is with transmission of malaria resistance strains. Resistance to 
antimalarials like chloroquine and SP dated as far back as the 1970s. Unfortunately, drugs 
like mefloquine and atovaquone, developed with the purpose of defeating resistance, seem 
to have succumbed to it. New discoveries have led to the use of artemisinin based 
combination therapies to improve malaria treatment outcomes and possibly prevent 
antimalarial drug resistance. Though there are concerns resistant strains to this treatment 
approach has also emerged, they remain the least likely to be ineffective due to drug 
resistance (159). Commonly used antimalarial drugs in children will now be discussed. 
2.1.1.1.1 Dihyrdoartemisinin (DHA)-piperaquine (DP) 
Dihydroartemisinin (DHA)-piperaquine (DP) is an artemisinin based combination 
therapy (ACT) used to treat malaria in paediatrics. DHA is also available as a suppository 
but for the reasons discussed in section 1.1.4.2.5, it is used in combination with piperaquine. 
(160). The possibility of resistance to DP has been reported in Cambodia. Though in March 
2016, Amaratunga et al reported that the use of DP in treatment of malaria in their subjects 
some of which were children was associated with failed therapy (161), in another study, Adjei 
et al (2016) showed that in four sub-Saharan African countries, DP was efficacious for the 
treatment of uncomplicated malaria (162). 
2.1.1.1.2 Artemether/lumefantrine (AL) 
In children, AL is given as an oral dose of 2 mg/kg of artemether and 12 mg/kg of 
lumefantrine for managing uncomplicated malaria, though artemether alone is available as 
intramuscular and sublingual dosage forms (160). An AL efficacy study in children published 
by Sowunmi et al (2016) showed that in Nigeria children with anaemia associated malaria, 
AL was an efficacious treatment for malaria. A similar study carried out in Togo in children 
between 2 -3 years by Dorkenoo et al (2016) showed that AL and artesunate-amodiaquine 
(AA) were both efficacious, however, AL gave better parasite clearance rates than AA (163, 
164). 
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A key recommendation from the WHO for uncomplicated malaria treatment in children 
is artemether and lumefantrine (AL) (165) administered as a fixed dose combination (FDC) 
of 20mg/120mg respectively, in six doses usually over three days (commonly at 0, 8, 24, 26, 
48 and 60 hours). Typical treatment regimens for children include a similar 3 day six-dose 
regimen stratified based on body weight: 5-15 kg 1 tablet per dose; 15-25 kg 2 tablets per 
dose; 25-35 kg 3 tablets per dose and >35 kg 4 tablets per dose (26), with the latter dose 
primarily being the default adult dose.  
The safety and efficacy of AL in children has been demonstrated in a number of studies 
which have reported greater than 90% cure rates after a 4-week period without deleterious 
side effects. Falade et al  (2005) reported a 28 days 97% malaria cure rate following an AL 
treatment in Nigerian children, the same study reported that when given in a six-dose 
regimen, the cure rate was higher than a four-dose regimen (166, 167). Another AL study in 
Uganda showed that when compared to the cure rate from quinine treatment, the efficacy of 
AL was better than quinine in children between six and 59 months of age as the 28 day cure 
rate of quinine and AL were reported to be 64% and 96% respectively (168).  More recently, 
a study comparing sulfadoxine-pyrimethamine (SP), AL and artesunate-amodiaquine (AM) 
cure rates in children between 6 and 60 months revealed that AL gave the best efficacy profile 
compared to AS and SP with cure rates of 94%, 93% and 28% cure rates respectively (169).  
Despite the efficacy profile of AL for uncomplicated malaria, the WHO contraindicates 
AL for complicated malaria and cerebral malaria (165). AL has been shown to increase the 
QTc interval and is therefore not recommended in subjects with congenital QTc prolongation, 
or where there is a family history of cardiac arrhythmias or sudden death. Adverse effects 
associated with AL use may include vomiting, fever, headache and cough. Since ART and 
lumefantrine are both substrates of CYP3A4 enzyme, AL should be used with caution when 
used in combination with drugs that also interact with the CYP3A4 enzyme pathway (170).  
2.1.2 Therapeutic endpoint of AL 
One of the key therapeutic endpoints of AL treatment is the 28-day corrected parasite 
clearance rate (PCR)(171).  Several studies have been conducted to determine the correlation 
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between response to parasite clearance rates and systemic concentrations of lumefantrine. 
Ezzet et al (1998) showed that a day 7 lumefantrine concentration greater than 280 ng/ml 
was linked to a higher observation of 28-day PCR (172). Another study found recrudescence 
of malaria infection in patients with lumefantrine day 7 concentrations less than 175 ng/ml 
(173). Also, a meta-analysis of day 7 concentrations obtained from 21 studies with 2,782 
subjects concluded that day 7 lumefantrine concentrations less than 200 ng/ml were effective 
to prevent recrudescence. They highlighted that certain sub-populations groups may fail to 
achieve this level due to unsupervised treatments or may still experience recrudescence of 
malaria despite achieving this level, for example in patients with high level of parasitaemia 
(174).  
2.1.3 Drug-drug interactions (DDIs) associated with AMTs  
It was reported in 2015 that there were an estimated 10 million new tuberculosis (TB) 
cases worldwide of which 26 % of all TB cases were reported in Africa  and 10 % were in 
children (175). Worryingly, the mainstay treatments for tuberculosis, namely a FDC of 
rifampicin (10-20 mg/kg), isoniazid (10-15 mg/kg), pyrazinamide (30-40 mg/kg) and 
ethambutol (15-25 mg/kg), can directly affect CYP3A4 activity through rifampicin (inducer) 
(176, 177) or isoniazid (inhibitor) (177, 178). Thus, DDIs are commonplace in patients who 
present with both malaria and tuberculosis making dosing strategies in paediatrics complex. 
Although data is sparse and the connection between malaria and tuberculosis co-infection 
has not been widely investigated (in contrast to HIV and tuberculosis coinfection), one study 
in Angola reported that the presence of malaria in patients admitted with tuberculosis as 37.5 
% (179).  Furthermore, the risk of rifampicin-mediated induction in CYP3A4 
expression/activity would have the potential to significantly increase the clearance of AL, as 
has been demonstrated in adult populations (180) and has been contraindicated when used 
with rifampicin (181).   However, the magnitude of this induction effect on AL 
pharmacokinetics in children has not been investigated. DDIs between antimalarials and 
other drugs in paediatrics are not well studied and this may impact on the clinical efficacy, 
and safety of antimalarial drug therapy.  
A 2016 study demonstrated that in Ugandan children when the antiretroviral drug 
efavirenz was co-administered with AL, there was an overall reduction in exposure of AL by 
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2.1 to 3.4-fold when compared with the administration of AL alone. In the same study when 
lopinavir/ritonavir (LPV/r) was administered with the antimalarial concomitantly, the 
systemic exposure of lumefantrine increased by 2.1-fold, while a DDI between AL and 
nevirapine was only seen in artemether. There was also a 10-fold reduction of lumefantrine 
day 7 concentration in children co-administered efavirenz compared to those co-administered 
with  LPV/r. This reduction led to a fourfold higher likelihood of recurrent malaria 28 days 
after the start of therapy (182).This finding was supported by another Ugandan study that 
revealed that more than 80% of children who received efavirenz had target lumefantrine day 
7 concentrations below the therapeutic level (183). Another Ugandan study showed that in 
children who received amodiaquine for malaria infection and who were co-administered with 
the recommended antiretroviral (ARV) drug, there was an incidence of prolonged 
neutropenia, but did not clarify the degree to which the prolonged neutropenia was caused 
by the ARV (184).  
2.1.4 PBPK modelling in children  
Ethical procedures, study size, study length, invasiveness and recruitment procedures 
have historically impeded paediatric drug development (113, 185). Safe drug administration 
in children is crucial because there are weak evidence based paediatric clinical trials to 
support to use of many drugs in this population  (185). In practice, unapproved means of drug 
administration known as “off-label” methods are often employed during administration of 
many paediatric drugs. When drugs are used off-label, it implies that its dosage regimen are 
not as agreed and documented in the drug labelling and this method has potential for adverse 
drug reactions (114, 186).  
2.1.5 Developmental physiology and pharmacokinetic processes in children 
Between birth and adolescence, physiological and anatomical changes occur in the 
human body. The physiological changes may impact on the pharmacokinetics of drugs in this 
group making drug effect vary across these paediatric subpopulations. The paediatric 
populations have been classified into smaller groups to capture major physiological changes 
and according to the international conference on harmonisation (ICH)  E11 classification 
(187), paediatrics are classified as: 
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• Preterm newborn 
• Newborn   (0-28 days) 
o Infant and toddler (>28 days – 23months) 
o Infant   (>28 days – 12 months) 
• Toddlers   (>12 months -23 months) 
• Child    (2- 11 years) 
• Preschool child  (2-5 years) 
• School age child  (6-11 years) 
• Adolescents   (12 -18 years) 
2.1.5.1 Body size and composition in paediatrics  
Most body composition changes occur during the period between birth and three years 
of age. The body maturation process occurring within this period impacts on drug response, 
its safety profile and pattern of dosing (147, 188-190). Paediatric height doubles from the 
birth height by the time they are four years old (Figure 2.1). At six months, birth weight 
estimates are doubled and by one-year-old, their weight is three times the birth weight (Figure 
2.2). Body surface area (BSA) increases two fold by one year of age and by their fourth year, 
BSA triples the birth BSA (Figure 2.3) (190).  
 
Figure 2.1: Growth chart median height in centimetres in males and females 0-20 years 
of age  
Graph was adapted from Jong et al (190). 
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Figure 2.2: Growth chart median weight in centimetres in males and females 0-20 years 
of age 
Graph was adapted from Jong et al (190) 
 
Figure 2.3: Body Surface Area (BSA) curve for males and females 0–20 years of age. 
Calculation of BSA was based on the Mosteller formula (BSA = ( W × H /3600) 1/2 . Graph 
was adapted from Jong et al (190). 
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Paediatric body proteins, intracellular water and fat undergo remarkable changes within 
the early years of life as highlighted in Table 2.1 (191-193). In preterm neonates, 85% of 
body weight comprises total body water while in term neonates; it reduces to about 75% of 
body weight. At four months, these estimates further reduce to about 60% and remains 
virtually unchanged from that age onwards, though there is a decline in extracellular water 
throughout childhood. By about nine months, children begin to loss their baby fat and there 
is a steady increase in the protein portion of their body composition (190).  
Table 2.1: Percentage contribution of body composition to body weight in children  
 
 
 
 
 
 
 
 
 
 
ECW: Extracellular water; ICW: Intracellular water. Data obtained from Jong et al (2014) 
(189)  
Age Fat ECW ICW Minerals Carbohydrates Protein 
 % 
Birth 13.7 42.5 27 3.2 0.5 12.9 
1 month 15.1 41.1 27.3 3.2 0.5 12.9 
2 months 19.9 38 26.3 3 0.5 12.3 
3 months 23.2 35.7 25.8 2.9 0.5 12 
4 months 24.7 34.5 25.7 2.8 0.4 11.9 
5 months 25.3 33.8 25.8 2.8 0.4 11.9 
6 months 25.4 33.4 26 2.8 0.4 12 
9 months 24 33 27.2 2.9 0.5 12.4 
12 months 22.5 32.9 28.3 2.9 0.5 12.9 
18 months 20.8 32.3 29.9 3.1 0.5 13.5 
24 months 19.5 31.9 31 3.2 0.5 14 
3 years 17.5 31.1 32.8 3.4 0.5 14.7 
4 years 15.9 30.5 34.2 3.5 0.5 15.3 
5 years 14.6 30 35.4 3.7 0.5 15.8 
6 years 13.5 29.6 36.4 3.8 0.5 16.2 
7 years 12.8 29.1 37.1 3.9 0.5 16.5 
8 years 13 28.3 37.5 4 0.5 16.6 
9 years 13.2 27.6 37.8 4.1 0.5 16.8 
10 years 13.7 26.7 38 4.1 0.5 16.8 
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2.1.5.2 Absorption in paediatrics 
In children, drug absorption is influenced by the same factors as it in adults (190). The 
physicochemical properties of the drugs such as molecular weight, pKa and lipophilicity have 
some influence on absorption of drugs (189, 190).  However physiological changes resulting 
in differences in rate and extent of absorption, pH and emptying time of the stomach, surface 
area and transit time of the intestine, activities of bile and pancreas, bacterial flora, transporter 
systems and enzymatic activities occurring throughout childhood often account for 
differences in rate and/or extent of absorption of drugs at different stages of growth in this 
population (194). Table 2.2 summarises the physiological factors that may cause variations 
in absorption rate and extent from birth till early childhood as compared with the adult 
population in Alcorn et al’s review of drug delivery in the new-born.   
Table 2.2: Factors affecting gastrointestinal absorption and their influence on 
pharmacokinetic effects compared to adults 
Data obtained from Alcorn et al (2003) (195) 
 
  Newborn  
Neonate                            
(one day to one 
month) 
Infant                                  
(one month to 2 
years) 
Physiological factors    
Gastric pH Neutral → 1 > 5 Adult 
Gastric emptying 
Reduced 
(variable) 
Reduced (variable) Increased 
Intestinal surface area Reduced Reduced Adult 
Intestinal transit time Reduced Reduced Increased 
Pancreatic and biliary 
function 
Very immature Immature Adult 
Bacterial flora Very immature Immature Adult 
Enzyme/transporter 
activity 
Very immature Immature Adult 
Pharmacokinetic 
outcomes 
   
Rate and extension of 
absorption 
Variable Variable ≥ Adult 
Gastrointestinal first-
pass effect 
Very reduced Reduced Approaching adult 
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Gastric pH is neutral in newborns and gradually lowers to adult levels as they grow 
older. The implication of gastric acid pH changes is in the use of drugs that are sensitive to 
acidic environments like penicillin. Such medication has been shown to have a higher 
bioavailability in new-born infants compared with older children and adults. Drugs that are 
weak acids in nature are present majorly in easily absorbed non-ionic forms at the adult low 
stomach pH, such drugs will be poorly absorbed in new-borns (147, 196, 197).  
Intestinal motor activity is generally thought to be reduced at birth and improves to 
adult patterns towards childhood and adulthood (189, 196). There is a reduced intestinal 
surface area in newborns which is gradually increased to adult levels as they mature (147, 
189). It is therefore expected that orally administered drugs may achieve therapeutic plasma 
levels at a reduced rate compared to an adult population. Though absent at birth, biliary and 
pancreatic activities gradually approach adult patterns throughout infancy and childhood.  
2.1.5.3 Drug distribution in paediatrics 
From birth onwards, the apparent volume of drug distribution (V) is influenced by 
tissue composition, extent of plasma/tissue binding and carrier transporter maturation. (195, 
196). Compared to adults, the V of hydrophilic drugs in neonates is higher but for 
hydrophobic drugs, V is lower owing to the high total body water and low-fat levels from 
birth through childhood compared with adults. Studies have shown that total plasma protein 
is lower in neonates and infants compared to adults. This results in an increased level of free 
drug concentration and consequently the bioavailability of the drug (198, 199).  
2.1.5.4 Metabolism in paediatrics 
The liver blood flow, protein binding and the maturation of enzymatic capacity of the 
liver of new-borns, infants and children influence their drug metabolism capacity (195). The 
change in CYP expression in children from birth to approximately 3 years of age is dynamic 
and CYP expression exhibits inter-individual variations in children. Generally, in vivo and in 
vitro data show that at birth most CYP enzymes are either not present or are at relatively low 
levels compared to adult levels. CYPs 2C19, 2D6, 2E1 and 3A4 are present are birth in low 
levels, while 2D6 and 3A4 steadily increase in their expression till about 3 years of age, there 
is a markedly high expression of 2C19 and 2E1 compared to the other enzymes within the 
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first 24 hours followed by an increase in their expression until they align with adult levels. 
CYPs 1A2 and 2B6 are not initially present at birth while 2C8 and 2C9 are at very minimal 
levels compared to adults. Studies show that 1A2 is expressed within the first day of birth, 
and 2B6 is not detectable at birth but may be expressed at one tenth of adult levels within 
one year of life while 2C8 and 2C9 increase within the first few weeks of birth and may be 
30% of adult levels when they are about a year old. Conversely, high proportions of 3A7 are 
found in the foetus at birth reaching peak levels at about 7 days old then steadily reduces to 
adult levels. Of clinical therapeutic significance are 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 
since these are implicated in the metabolism of many drugs (149, 200).  
2.1.5.5 Elimination in paediatrics 
Primarily estimated in terms of the renal clearance, the elimination of substances at 
birth is noticeably reduced due to immaturity of the mechanisms involved in renal excretion 
(195), however, renal clearance appreciably improves to adult levels by their first birthday 
though the efficiency of renal elimination varies from child to child owing to differences in 
patterns and rates of development of both the kidney tubular functions and glomerular 
filtration (195).   
2.1.6 The role of PBPK modelling in paediatric antimalarial drug therapy  
There are few PBPK studies of antimalarials in children despite the significant potential 
in using this technique to address antimalarial therapy problems such as DDI studies in this 
population group. As many antimalarials are highly lipophilic in nature, the distribution of 
many antimalarials is expected to be significantly altered in children at different levels of 
their development due to changes in fat distribution and body water (201). Similarly, as 
metabolic mechanism in children is premature, the clearance of antimalarials that depend on 
such metabolic mechanisms will be altered. Salem et al (2013) reported that DDI trends in 
children younger than two years of age were likely to be different from those in adults due 
to several developmental changes occurring at this age and elaborated how PBPK modelling 
techniques can be used to address DDI is paediatric populations (202-204).    
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2.2 Aim and Objectives 
2.2.1 Aim 
The aim of this chapter was to demonstrate the application of PBPK modelling in the 
prediction of DDI risks in malaria-tuberculosis co-infection paediatric population groups.  
Specifically, the potential for a DDI between the CYP3A4 inducer rifampicin and AL was 
assessed among 2-5 year old population groups and a subsequent dosing optimisation 
strategy of AL in the presence of rifampicin was proposed in this population group.   
2.2.2 Objectives   
1. To develop and validate a PBPK model to predict the pharmacokinetic parameters 
of AL in adults and children 
2. To simulate and validate the impact of DDIs with rifampicin on the 
pharmacokinetic parameters of AL in adults  
3. To predict the impact of DDIs with rifampicin on the pharmacokinetic parameters 
of AL in children 
4. To optimise the dosing regimen of AL in the presence of DDIs with rifampicin in 
children 
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2.3 Methods 
All population based PBPK modelling was conducted using the virtual clinical trials 
simulator Simcyp® (Simcyp® Ltd, a Certara company, Sheffield, UK, Version 16) using 
either the pre-validated in-built ‘Healthy Volunteer’ or ‘Paediatric’ population groups.  The 
latter population group accounts for age-related changes in systems-parameters such as organ 
volumes, organ perfusion and ontogeny of drug metabolising enzymes (205-207) and allows 
for the prediction of drug behaviour in paediatric population groups.  In the case of both 
models, population variability was accounted for by the inclusion of a variability metric (% 
coefficient variability) which were retrieved from public health data bases such as the US 
National health and Nutrition Examination Survey (https://www.cdc.gov/nchs/nhanes/). 
 
   
9
3
 
 
2.3.1 Study design 
 A four-stage strategy was employed for model development and validation.  
 
Figure 2.4: Work flow process of model development for the simulation of AL pharmacokinetics in adults and children in the 
presence and absence of DDIs . 
The workflow was implemented for the prediction of the pharmacokinetics of artemether and lumefantrine in adults and paediatrics. 
The workflow also showed process involved in DDI prediction in adults and children, followed by dosage optimisation of 
artemether and lumefantrine in the presence of DDI with a rifampicin-based anti-tuberculosis regimen.
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2.3.1.1 Step 1: Base model development and validation 
This step focussed on the development of a base model on Simcyp®. The compound 
physicochemical properties of artemether and lumefantrine obtained from literature were 
used to develop a model that recovered the absorption, distribution and the elimination phases 
of the concentration time profiles observed from clinical studies and to simulate the key 
pharmacokinetic properties of artemether and lumefantrine such as the maximum 
concentration (Cmax), areas under the curve (AUCs) and the lumefantrine day 7 concentration 
where required at different dose regimens as reported in the clinical studies.  
When required, model parameters were optimised to produce parameters with better 
certainty, and which best recovered published clinical drug profiles. Parameter optimisation 
was done with the Weighted Least Square (WLS) approach and the Nelder-Mead 
minimisation method on Simcyp®. For artemether, literature- reported isozyme specific 
hepatic intrinsic clearances were utilised for the description of drug metabolism (Table 2.3).  
For lumefantrine, the isozyme specific hepatic intrinsic clearance (CLint) was back-calculated 
using the Simcyp® retrograde calculator  from the oral clearance and assuming CYP3A4 was 
the predominant isozyme for lumefantrine metabolism (208). The Simcyp® retrograde 
calculator is a feature on Simcyp® which permits the reverse calculation of intrinsic 
clearance of drug from either oral or intravenous clearance data. In certain cases, in vitro 
hepatic intrinsic clearance (CLint) of a drug molecule is not available, since PBPK modelling 
is dependent on this parameter to mechanistically predict the elimination of the drug, this 
parameter may be calculated using the data from adult human in vivo intravenous (CLiv) or 
oral (CLpo) clearance as long as the elimination pathway and hepatic uptake factor for the 
drug is known. The accuracy of such prediction is dependent on the accuracy of the in vivo 
intravenous (CLiv) or oral (CLpo) clearance reported for the drug. The reverse calculation 
method back-calculates the CLint values from the oral or IV clearance using information on 
additional clearance (for example, the biliary clearance), ideal renal clearance for a 20-30 
year old healthy male subject, hepatocyte uptake, unbound fraction of drug in plasma and 
blood to plasma ratio. This model also factors in the impact of fraction of drug absorbed (fa), 
fraction escaping gut metabolism (fgut) and contribution to clearance from other routes like 
the renal or biliary clearance (115). In this case, the CLint of lumefantrine (mechanistic 
parameter) was calculated from its CLoral (non-mechanistic parameter).  
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Table 2.3: Input base model parameter values and predicted PBPK values for use in the 
simulation of artemether, lumefantrine. 
 
 
 
 
 
 
 
 
a Simcyp® mechanistic prediction; b Default values in Simcyp®; c Parameter estimated;  d 
Simcyp® retrograde calculation from population estimates of CLpo followed by parameter 
estimation (final optimised value: 0.85 µL/min/pmol for CYP3A4);  MW: Molecular weight; 
Peff: human effective permeability; B/P: blood-to-plasma ratio; CLint: in vitro intrinsic 
clearance; Vss: Steady state volume of distribution; ISEF: Intersystem extrapolation factor 
for scaling CYP in vitro kinetic data; Ki: concentration of inhibitor supporting half-maximal 
inhibition; Kinact: inactivation rate of the enzyme; Kapp: concentration of mechanism based 
inhibitor associated with half-maximal inactivation rate. 
  
Parameters Artemether Lumefantrine 
Compound type Monoprotic base Diprotic base 
Molecular weight (g/mol) 298.4(209) 528.94(209) 
Log P  3.53(210) 8.70(211) 
Fu 0.05(212) 0.003 (212) 
pKa 1 3.9(209) 14.1(209) 
pKa 2 - 9.80(209) 
B/P 1.09a 0.80(213) 
Vss (L/kg) 1.77a 0.70a 
Peff (10-4 cm/s)  2.74a 8.3a 
Kp scalar 1b 1b 
Solubility (mg/mL) 0.012(214) 0.002(215) 
CLpo (L/min) - 0.25(172) 
CLint3A4 (µL/min/pmol) 1.47
(216) 2.61c,d 
CLint2B6 (µL/min/pmol) 9.31
(216) - 
ISEF CYP3A4 1b - 
ISEF CYP2B6 1b - 
Absorption model  ADAM ADAM 
Distribution model Full Full 
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Due to unavailability of published data for the human jejunal effective permeability 
(Peff), the molecular descriptors (PSA and HBD) of AL, were predicted and optimised for 
artemether and lumefantrine respectively. The Peff  was predicted using the equation below 
(217):  
𝑙𝑜𝑔𝑃𝑒𝑓𝑓 = 4 − 2.546 − 0.011 ×  𝑃𝑆𝐴 − 0.278 × 𝐻𝐵𝐷               ( 43 ) 
The  Kp scalar, which is a scaling factor used to scale the tissue to plasma partitioning 
coefficient (Kp) of the drug to the expected steady state volume of distribution (Vss) (218) 
of the drug were further optimised for AL using a parameter estimate method within 
Simcyp® to yield optimal estimates of tissue distribution and Vss prediction.   
Furthermore, for artemether, where necessary, the in vitro metabolic clearance was 
optimised through the parameter estimation of the Inter System Extrapolation Factor (ISEF) 
(Table 2.3). The ISEF is a scaling factor used for prediction of the human drug clearance 
(CLint) from in vitro CLint obtained from recombinantly expressed human cytochrome P450s 
(rhCYP). This is important because the intrinsic activity per unit CYP between rhCYP and 
human hepatic enzymes differs, therefore, the ISEF allows for IVIVE of human drug 
clearance from rhCYPs (219).  
The published clinical studies used for the validation of artemether and lumefantrine 
included a study conducted in 120 adult subjects who were orally dosed the branded AL 
combination called Coartem®, and studies conducted in 16 subjects who were orally dosed 
the branded AL combination called Riamet® (220).  For lumefantrine an additional study 
included a 6-dose study conducted in 17 subjects (221).  
2.3.1.2 Step 2: Simulation and validation of drug-drug (DDI) interactions in adults 
This step focussed on the validation of the adult DDI predictions. CYP3A4 inhibition 
and induction mechanisms were simulated using ketoconazole and rifampicin respectively. 
Following the successful development of and validation of the AL base model, all adult DDI 
simulations were, where possible, run identically to the reported clinical study with which 
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the validation was conducted against, and primarily included matching age ranges, male-to-
female ratios and identical dose/dosing intervals. In order to validate the capability of the 
model to predict a broad range of DDIs, the pre-validated Simcyp® in-built compounds 
ketoconazole and rifampicin were directly utilised in simulations as candidates to simulate 
CYP3A4 inhibition DDIs (ketoconazole) and CYP3A4 induction DDIs (rifampicin). 
Rifampicin and ketoconazole compounds were used in simulations without modification 
from the library of pre-validated drug molecules within the Simcyp® simulator, using a 1st-
order absorption model and assuming dosing in solution form.   
Where the Simcyp® ADAM (Advanced Dissolution Absorption Model) was used, an 
immediate release formulation with an applied diffusion layer model was utilised for 
modelling with literature-reported solubility parameters included.  Where simulations were 
performed in paediatrics, all APIs were assumed to be dosed in solution form, mimicking the 
dispersible/crushed application of AL in paediatric subjects (26). 
A previously validated isoniazid compound file (222) was used for all rifampicin DDI 
simulations to account for the impact of isoniazid mediated CYP3A4-inhibition associated 
with TB chemotherapy.  All simulations included both rifampicin (as the primary perpetrator) 
and isoniazid (as the secondary perpetrators), however results are presented for the key 
interactions between AL and rifampicin only, and reflects the clinical net effect of CYP3A4 
induction with the clinical use of the combination of rifampicin and isoniazid in DDI-
focussed studies (223-225). 
Clinical studies demonstrating such a DDI were obtained from Lefèvre et al (2002) 
who studied AL with ketoconazole (220) (single dose of 80/480 mg of AL and 5 day 
treatment with ketoconazole) and Lamorde et al (2013) (226), who studied AL DDI with 
rifampicin where rifampicin was dosed at 10 mg/kg for the duration of the study with AL 
dosed as six 80/480 mg doses (12 hourly) on days 8, 9 and 10.  
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2.3.1.3 Step 3: Simulation and validation of base model in paediatric population 
In this step the previously validated adult base model of artemether and lumefantrine 
were scaled to paediatric groups reported in clinical trials. This step focussed on the 
validation of artemether and lumefantrine model predictions in paediatrics. In these studies, 
weight bandings were simulated based on dosing strategies for AL if the clinical study did 
not use a weight normalised dosing method.  Dosing boundaries were set at 1 tablet for 5-
14.9 kg, 2 tablets for 15-24.9 kg and 3 tablets for 25-34.9 kg and trials were run to ensure, 
where possible, an equal proportion of subjects were included into each distribution banding 
based on the total number of subjects recruited within each reported trial.  Simulated profiles 
were body weight stratified according to the corresponding clinical trial and analysed 
consequently.   
2.3.1.4 Step 4: Prediction of drug-drug interaction between AL and rifampicin-based 
drug in the paediatric population 
This step focussed on simulations to predict the impact of rifampicin-mediated DDIs 
on artemether and lumefantrine pharmacokinetics in children of 2-5 years of age over a 
weight boundary of 5-14.9 kg or 15-24.9 kg.  In these simulations, trials of 100 subjects were 
simulated and analysed with appropriate weight-based dosing (see above) and under 
treatment of rifampicin with AL.  A 100-subject simulation was run in a 10x10 trial (10 
subjects per trial with 10 trials) to ensure that reasonable inter-/intra individual variability 
was captured within the model simulations.  However, as simulations are not possible with 
defined age and weight ranges, pooling and post-processing of output data was conducted to 
match individuals to the required age-weight boundary conditions for the study.  
For all validation steps, unless otherwise stated, all observed data sets were obtained 
from ‘supervised’ administration groups in reported clinical studies and simulated under 
‘fed’ conditions.  Furthermore, unless otherwise stated all simulations included subjects of ≥ 
5 years.
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2.3.2 Predictive performance 
Whilst no agreed criterion has been suggested for an ‘optimal’ predictive performance 
range, it is generally considered that a prediction to within 2-fold of the observed data is 
acceptable (227).  Given the wide inter-subject variability in artemether pharmacokinetics, 
this 2-fold range (0.5-2.0) was selected as the criterion for comparing Cmax and AUC 
parameters between model predictions and those clinically reported.  Where a DDI was 
simulated, the model performance was primarily dictated by a comparison of the AUC ratio 
(ratio of AUC in the absence and presence of the perpetrator agent) (AUCr). A prediction of 
AUCr within 2-fold of the reported AUCr was considered as acceptable, an AUCr greater than 
1.25 was indicative of an inhibition reaction whereas an AUCr less than 0.8 was indicative 
of an induction reaction whilst an AUC ratio of between 0.8 – 1.25 indicated no interaction.  
2.3.3 Visual Predictive Checks 
Model predictions were compared to existing clinical studies using visual predictive 
checking (VPC), an approach described at the 2012 FDA Paediatric Advisory Committee 
(US Food and Drug Administration, 2012) (228). In brief, the predictability of the 
simulations was confirmed by comparing the predicted 5th and 95th percentiles of predicted 
concentration–time profiles with the observed data for any validation data sets.  When the 
predicted data points overlapped with those from the observed data sets, which should 
(normally) contain a measure of spread of observed plasma concentration data (e.g., a 
standard deviation for each mean concentration point), the prediction was assumed to be 
valid. 
2.3.4 Data analysis 
Unless otherwise stated, all simulations of plasma concentration-time profiles were 
presented as arithmetic mean and 5-95th percentiles.  In circumstances where reported 
concentration-time profiles did not provide corresponding tabulated summary data, the 
observed data points were retrieved using the WebPlotDigitizer v3.10 
(http://arohatgi.info/WebPlotDigitizer/) (229) and superimposed onto simulated profiles for 
visual predictive checks. Statistical analysis was used to determine statistical difference 
between different sets of data where necessary. 
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2.4 Results 
2.4.1 Base model development  
Model parameters obtained from published sources were used for initial simulation of 
single doses of 80 mg artemether and 480 mg lumefantrine while keeping all unknown 
parameters as default values or values predicted based on physicochemical properties of each 
drug compound. The plasma concentration-time profiles of both drugs using these parameters 
(listed in Table 2.3) did not recover the observed plasma concentration time points on the 
published clinical concentration time profiles as reported in two single dose studies reported 
by Lefevre et al (2013) (Figure 2.5 A-B)(230, 231).  
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Figure 2.5: Simulation of single dose artemether (A) and lumefantrine (B) with base 
model  
Simulation of (A) artemether and (B) lumefantrine concentration time profiles following a 
single oral dose of 80 mg and 480 mg respectively using the base model. For all simulations, 
a standard population size of 100 subjects was used. The solid line represents population 
mean predictions and the dash lines represent 5th and 95th percentiles of prediction. Mean 
observed plasma concentrations are represented by the solid circles (Lefevre et al, 2002) and 
diamonds. (Lefevre et al 2013). Error bars represent standard deviations.  
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2.4.2 Step 1: Optimisation and predictive performance for artemether-
lumefantrine models for adults 
Following optimisation of Peff values obtained from the predicted PSA and HBD 
parameters,  3.67 x 10-4 cm/s and 0.97 x 10-4 cm/s were obtained for AL respectively. 
Similarly, following parameterisation of the Kp scalar, the simulated distribution phase 
of the plasma concentration-time profile for artemether and lumefantrine were adequately 
recovered (Table 2.4; Figure 2.6). The ISEF for scaling rhCYP in vitro kinetic data to 
human liver tissue clearance was parameterised from an initial value of 1 (Table 2.3) for 
the enzymatic pathways involved in artemether metabolism (CYP3A4 and CYP2B6) to 
2.42 and 1.70 (Table 2.4) respectively. For lumefantrine, the retrograde calculation 
resulted in an estimated intrinsic clearance of 2.61 µL/min/pmol (Table 2.4) from 
published oral clearance data (172). 
The model consistently captured the observed clinical data points for single and 
multiple dose studies (Figures 2.6 and 2.7) as illustrated in the predicted plasma 
concentration-time profiles relative to the observed clinical profile. In Figure 2.6, single 
dose observed clinical concentration-time points were within the 5th and 95th percentiles 
of the simulated concentration time profile after optimisation of the necessary model 
parameters. In Figure 2.7, the model did not only recover the clinical data points for the 
multi-dose study, it also reflected the inter-individual variabilities observed in clinical 
studies.  
The optimised model parameters (Table 2.4) predicted population plasma 
concentration profiles for both artemether and lumefantrine that recovered the observed 
mean plasma concentration profiles.  The model predicted Cmax values were within 2-fold 
of the reported Cmax for each clinical study for both artemether (139.1 ± 116.2 ng/mL; 
Table 2.5; Figure 2.6A) and lumefantrine (single dose: 6.31 ± 3.72 µg/mL; six doses: 9.56 
µg/mL; range: 5.67-16.78 µg/mL; Table 2.5; Figure 2.6B and 2.7). The 24 h, 48 h, 72 h 
and day 7 lumefantrine concentrations were also predicted to within 2-fold of those 
reported by Ashley et al (2007) (221).  Similarly, the model predicted AUClast for 
artemether  and lumefantrine were within 2-fold of the reported AUClast.  
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Table 2.4: Final optimised model parameter values and predicted PBPK values for 
use in the simulation of artemether, lumefantrine.  
  
 
 
 
 
 
 
 
a Simcyp® mechanistic prediction; b Parameter estimated; c Simcyp® retrograde 
calculation from population estimates of CLpo followed by parameter estimation (final 
optimised value: 0.85 µL/min/pmol for CYP3A4); d Unless otherwise detailed data was 
obtained from Gaohua et al (2015) (232).  MW: Molecular weight; Peff: human effective 
permeability; B/P: blood-to-plasma ratio; CLint: in vitro intrinsic clearance; Vss: Steady state 
volume of distribution; ISEF: Intersystem extrapolation factor for scaling CYP in vitro 
kinetic data.   
Parameters Artemether Lumefantrine 
Compound type Monoprotic base Diprotic base 
Molecular weight (g/mol) 298.4(209) 528.94(209) 
Log P  3.53(210) 8.70(211) 
Fu 0.05(212) 0.003 (212) 
pKa 1 3.9(209) 14.1(209) 
pKa 2 - 9.80(209) 
B/P 0.55a 0.80(213) 
Vss (L/kg) 1.77a 0.70a 
Peff (10
-4 cm/s)  3.67b 0.97b 
Kp scalar 0.21b 0.10b 
Solubility (mg/mL) 0.012(214) 0.002(215) 
CLpo (L/min) - 0.25
(172) 
CLint3A4 (µL/min/pmol) 1.47
(216) 2.61b,c 
CLint2B6 (µL/min/pmol) 9.31
(216) - 
ISEF CYP3A4 2.424b - 
ISEF CYP2B6 1.697b - 
Absorption model  ADAM ADAM 
Distribution model Full Full 
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Figure 2.6: Simulation of single dose artemether (A) and lumefantrine (B) using the 
optimised model 
Simulation of (A) artemether and (B) lumefantrine concentration time profiles following 
a single oral dose of 80 mg and 480 mg respectively using the optimised model.  For all 
simulations, a standard population size of 100 subjects was used. The solid line represents 
population mean prediction and the dash lines represent 5th and 95th percentiles of 
prediction. Mean observed plasma concentrations are represented by the solid circle 
(Lefevre et al, 2002) and diamonds (Lefevre et al 2013). Error bars represent standard 
deviations 
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Figure 2.7: The simulated plasma concentration-time profile of multiple dose lumefantrine with the optimised model 
Simulation of lumefantrine concentration time profile following a 480 mg six-dose three-day regimen using the final optimised model.  A 
standard population size of 100 subjects was used. The solid line represents population means prediction and the dash lines represent 5th and 
95th percentiles of prediction. Individual observed data obtained from Ashley et al 2007 (221) points are represented by open solid circle.
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Table 2.5:  Summary of predicted and observed pharmacokinetic parameters of artemether and lumefantrine in healthy adults 
 
Data represent mean ± SD or mean (range). a Concentrations measured at 24, 48 and 72 hours immediately pre-dose are labelled by the 
subscript time (hour) nominals, with all concentrations units expressed as µg/ml. Cd7 indicates the 7
th day concentration. 
  Prediction 
Lefevre et al 
2013(230) 
Lefevre et al 
2002(220) 
Ashley et al 
2007(221) 
Artemether 
Dose (mg) 80 80 80  
Population size (n) 100 58 16  
Cmax (ng/ml) 139 ± 116 113 ± 69.5 104 ± 40  
AUClast (ng/ml.h) 521 ± 254 408 ± 209 302 ± 135  
      
 Dose (mg) 480 480 480  
Lumefantrine Population size (n) 100 58 16  
Cmax (µg/ml) 6.31 ± 3.72 8.92 ± 3.18 7.91 ± 3.49  
AUClast (µg/ml.h) 251 ± 112 236 ± 93 195 ± 119  
      
 Dose (mg) 6-dose regimen   6-dose regimen 
Lumefantrinea Population size (n) 100   17 
 Cmax (µg/ml) 9.6 (5.7-16.8)   6.9 (3.7-13.2) 
 C24h (pre-dose) 3.4 (2.0-9.3)   2.5 (0.7-9.8) 
 C48h (pre-dose) 5.8 (1.5-13.1)   3.8 (1.9-6.8) 
 C72h (pre-dose) 5.8 (1.1-12.7)   3.9 (2.2-9.6) 
 Cd7 0.32 (0.11-0.78)   0.35 (0.20-0.87) 
 AUC0-∞ (µg/ml.h) 387 (98-1157)   432 (308-991) 
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2.4.3 Step 2: Simulation of the AL DDIs following exposure to ketoconazole 
and rifampicin  
2.4.3.1 Simulation of AL DDI with concomitant administration of ketoconazole 
The artemether and lumefantrine compound files were further assessed for their 
ability to recapitulate the literature reported extent of DDIs on plasma concentration 
profiles in adults. 
Predictions for inhibition-based DDIs with artemether and ketoconazole resulted in 
predicted plasma-concentration profiles for the simulated population within the observed 
range reported by Lefevre et al (2002) (231) (Figure 2.8).  The predicted Cmax ratio was 
2.49 ± 0.51 compared with a reported ratio of 2.24 and predicted AUCr was 2.96 ± 0.80 
compared to a reported ratio of 2.51 (Table 2.6).   
Predictions for inhibition-based DDIs with lumefantrine and ketoconazole, resulted 
in plasma-concentration profiles for the simulated population within the observed range 
reported by Lefevre et al (2002) (231) (Figure 2.9).  The predicted Cmax ratio was 1.16 ± 
0.89 compared with a reported ratio of 1.26 and predicted AUCr was 2.10 ± 0.54 
compared to a reported ratio of 1.65 (Table 2.6). The Cmax estimated under interaction and 
no interaction conditions were slightly under predicted, this might be due to the wide 
inter-individual variation in the absorption of lumefantrine. Lumefantrine is highly 
lipophilic and its absorption may be erratic. Its erratic absorption may be influenced by 
concomitant intake of lumfantrine with food (230). 
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Figure 2.8: The simulated plasma concentration-time profile of artemether in the absence and presence of ketoconazole 
Artemether was dosed as a single 80 mg oral dose in the absence (A) and presence (B) of ketoconazole, dosed as a single 400 mg oral dose over a 24-
hour period under fed-conditions. Open circles represent observed mean data points (231) 
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Figure 2.9: The simulated plasma concentration-time profile of lumefantrine in the absence and presence of ketoconazole 
Lumefantrine was dosed as a single 80 mg oral dose in the absence (A) and presence (B) of ketoconazole, dosed as a single 400 mg oral dose over a 
24-hour period under fed-conditions. Open circles represent observed mean data points (231). 
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Table 2.6: Summary of predicted and observed pharmacokinetic parameters of artemether and lumefantrine in the absence and 
presence of ketoconazole in healthy adults 
 
 
a Artemether: AUC(0-∞); lumefantrine: AUC(0-last); Data represent mean ± SD. 
 
 -Ketoconazole +Ketoconazole Ratio 
 
 Cmax  (ng/mL) AUC
a (ng/mL.h) Cmax (ng/mL) AUC
a
 (ng/mL.h) Cmax AUC 
Artemether 
Predicted 71.2 ± 62.7 316.2 ± 96.05 171.39 ± 115.21 911.24 ± 324.60 2.49 ± 0.51 2.96 ± 0.80 
Observed 104 ± 40 302 ± 135 225 ± 77 718 ± 279 2.24 2.51 
Lumefantrine Predicted 5476 ± 2168 118211 ± 57079 6305 ± 2432 235041 ± 97260 1.16 ± 0.89 2.10 ± 0.5 
Observed 7910 ± 3490 195000 ± 119000 10100 ± 4740 312000 ± 181000 1.26 1.65 
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2.4.3.2 Prediction of AL DDI with concomitant administration of rifampicin.  
For induction based DDI studies, only one clinical study was identified where the 
impact of rifampicin mediated DDIs on the pharmacokinetics of both artemether and 
lumefantrine in the same subjects was reported (180). This study was a small clinical 
study involving six subjects and a narrow age and weight range, therefore, a virtual 
clinical trial of 10 trials consisting of 10 subjects per trial within the weight and age 
boundaries reported by Lamorde et al (2013) was simulated (180).  As there was no direct 
way to specify a weight boundary, the trials containing at least 6 subjects within the 
correct weight boundaries were selected for study and subsequent analysis. 
Predictions for induction-based DDIs with artemether and rifampicin were 
validated against a single study reporting one concentration time point of artemether at 
12-hours (C12h) post final dose (180) in six subjects who were administered AL in the 
absence and presence of FDC treatment for tuberculosis which included rifampicin (180). 
In order to account for the net DDI effect of CYP3A4 interaction (that is the CYP3A4 
interactions due to the APIs within the FDC), the simulation was conducted in the 
presence of isoniazid as this has an inhibitory effect on CYP3A4 using a previously 
validated model for isoniazid (222). The predicted C12h was 3.56 ± 3.13 ng/mL (Figure 
2.10) which reduced to 0.77 ± 1.14 ng/mL (Figure 2.11) in the presence of rifampicin, 
and was within 2-fold of the reported C12h of 0.5 ± 1 ng/mL. 
Predictions for induction-based DDIs with lumefantrine and rifampicin were 
validated against a single study reporting one concentration time point of lumefantrine on 
the 8th day after initiating lumefantrine dosing (Cd8) (7.3 days post first dose).  Using this 
approach, the predicted Cd8, 59.83 ± 24.86 ng/mL, was within 2-fold of the observed 
reported Cd8 of 107.75 ± 19.58 ng/mL (180) (Figure 2.12). 
 
   
1
1
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: The simulated plasma concentration-time profile of artemether in the absence of rifampicin  
Artemether was dosed as 6 doses (80 mg per dose) over 3 days (on days 8–10) in the absence of an interaction with a rifampicin based anti-
TB medication. The solid line represents the population mean prediction with shaded regions representing the 5th and 95th percentiles of 
prediction
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Figure 2.11: The simulated plasma concentration-time profile of artemether in the presence of rifampicin  
Artemether was dosed as 6 doses (80 mg per dose) over 3 days (on days 8–10) of a 14-day trial with rifampicin dosed at 10 mg/kg once daily 
during the duration of the trial. Isoniazid was also dosed at 10 mg/kg and used as a secondary perpetrator considering its inclusion in anti-
TB therapy. (A) represents the entire simulation period, (B) represents the last 14 hours of study and the open circle represents the observed 
mean 12-hour post final dose concentration ± SD. The solid line represents the population mean prediction with shaded regions representing 
the 5th and 95th percentiles of prediction.
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Figure 2.12: Simulated plasma concentration-time profile of lumefantrine in the absence (grey shaded area) and presence (red shaded 
area) of rifampicin  
Lumefantrine was dosed as 6 doses (480 mg per dose) over 3 days (on days 8–10) of a 14-day trial with rifampicin dosed at a dose of 
10 mg/kg once daily and isoniazid (secondary perpetrator) administered at a dose of 5 mg/kg during the duration of the trial. Solid circles 
represent the observed mean day 8 concentration (7.3 h after final dose) ± SD (180). The solid line represents the population mean prediction 
with shaded regions representing the 5th and 95th percentiles of prediction (grey: no interaction; red: interaction). The dashed line represents 
minimum effective parasite clearance plasma concentration for lumefantrine (280 ng/mL).
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2.4.4 Step 3: Predictive performance of model for artemether and 
lumefantrine in children  
2.4.4.1 Step 3a: Predictive performance of model for artemether 
The majority of clinical studies assessing AL pharmacokinetics in children often 
focus on lumefantrine. Existing artemether clinical studies are sparse and include either 
sampling around the expected Cmax (1-2 hours) (233, 234) or limited large population 
based sampling approaches (235), with dosing based on the body weight stratification. 
Therefore, the simulations and interpretation of the results were carried out as close as 
possible to the reported clinical studies.  
The model predicted mean artemether plasma concentration for the lower doses 
(221µg/mL ± 105µg/mL) and higher doses (294 ± 97 µg/mL) were within 2-fold of the 
literature reported plasma concentrations for both lower (150 ± 206 µg/mL) and higher 
doses (196 ± 204 µg/mL) (Figure 2.13A) (233).  Similarly when using a single lower dose 
and stratifying further for weight into 5 < 10 kg and 10 to < 15 kg, the reported 
concentrations for the lower and higher weight banding, 295 ± 214 µg/mL and 137 ± 111 
µg/mL, were within the 5th and 95th percentiles of the mean predicted profiles (Figure 
2.13B), with a predicted mean concentration (mean of 1 and 2 hour time points) of 226 ± 
187µg/mL for the lower weight boundary and 239 ± 187 µg/mL for the higher weight 
boundary (234) (Figure 2.13B). 
To confirm a successful model prediction of the distribution and elimination phases 
of artemether pharmacokinetics, Figure 2.14 illustrates that the model adequately 
predicted the concentration-time profiles for artemether dosing at the lowest (5-14 kg) 
and highest (25-34 kg) doses, where observed sampling points were obtained from a 
population study reported by Hietala et al (2010) (235).  The predicted profile for each 
dosing band fell within the range reported by Hietala et al (2010) (235). However, due to 
the well documented variability in the absorption phase of artemether, the predicted 
concentrations during the absorption phases (0-4 hours) were slightly over-predicted. 
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Figure 2.13: The simulated plasma concentration-time profile of artemether in paediatrics. 
Six doses of artemether were administered at 0, 8, 24, 36, 48 and 60 h based on patient weight (20 mg: 5–15 kg or 40 mg: 15-25 kg). Shaded 
regions between 1 and 2 h indicate observed sampling times (1–2 h). Red circles, black squares, and black diamonds are observed clinical 
data from subjects receiving the weight-based doses. (A): Observed data from Djimde et al (2012) and (B): Observed data from Bassat et al 
(2011) (233, 234). The red and black solid lines indicate mean profiles for the corresponding weight-based doses while the 5th and 95th 
percentiles are illustrated by the corresponding coloured dash lines. 
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Figure 2.14: The simulated plasma concentration-time profile of artemether in paediatrics. 
Six doses of artemether were administered at 0, 8, 24, 36, 48 and 60 h based on patient weight. The black line represents simulated lower 
doses (5–14 kg) and the red line represents the simulated highest dose (25–34 kg). Observed data points are represented by solid black circles 
(180) with red and black solid lines indicating mean profiles with 5th and 95th percentiles illustrated by coloured dashed lines.
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2.4.4.2 Step 3b: Predictive performance for lumefantrine  
Lumefantrine is often studied, in preference to artemether, in clinical trials due its 
longer half-life (231) (160), and a range of clinical studies are available to validate the 
PBPK-based model development where 7-day post-dosing concentration (~280 ng/mL 
(172)) is used as a marker of achieving a successful ‘target’ concentration to obtain 
parasite clearance. To validate the lumefantrine compound we first assessed the predictive 
performance against two studies that reportedmean plasma concentrations through the 
study duration period. Based on a study by Borrman et al (2010) (49) where mean ± SD 
plasma concentration data was available for 30, 54, 66, 84 and 168 hours post first dose, 
the CLint,3A4 was optimised to 0.71 and Kp scalar optimised to 0.05 (Vss: 0.53 L/kg). Using 
this revised lumefantrine compound file, the 4 concentration time-points reported by 
Borrmann et al (2010) over the 3 doses stratification used in their study was recovered 
(Figure 2.15).   
This optimised compound file was then applied to all subsequent simulations, and 
was confirmed with a second study reported by Piola et al (2005) (173) where the 
pharmacokinetics of lumefantrine in 5-14 year olds were simulated with appropriate 
weight-based dosing, and where observed mean ± SD plasma concentration data was 
available for day 3 and day 7 (Figure 2.16).  Day 3 predicted concentrations were 7958 ± 
2381 ng/mL and 8246 ± 5478 ng/mL for the 5-15 kg and 15-25 kg doses, and day 7 
predicted concentrations were 659 ± 289 ng/mL and 719 ± 554 ng/mL for the 5-15 kg 
and 15-25 kg doses. The observed day 3 (7050 ± 3560 ng/mL) and day 7 (376 ± 217 
ng/mL) mean plasma concentrations were within 2-fold of the predicted mean 
concentrations, in addition to being within the 5th and 95th percentiles of the mean 
lumefantrine predicted plasma concentration for the two weight-based doses (Figure 
2.16).  The optimised compound file was further utilised to assess the predictive 
performance for median day 3 and day 7 (predominantly) concentrations (Table 2.7) and 
was able to capture day 3 and day 7 concentrations to within 2-fold of those reported in 
clinical studies. In the observed studies, the reported lumefantrine concentrations were 
not segregated based on the doses taken by the children and the studies only reported 
median and range concentrations for all the paediatric subjects regardless of the doses 
they were administered. In this study however, day 7 concentrations were recorded 
separately based on the doses the patients were administered. 
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Figure 2.15: The simulated plasma concentration-time profile of lumefantrine in children. 
Blue, green and black solid lines indicate 1 (5–14.9 kg), 2 (15–24.9 kg) or 3 (25–34.9 kg) tablet dosing regimens respectively. Upper and 
lower dashed lines represent the 95th percentile for the 360 mg (3 tablets) dose and 5th percentile for the 120 mg (1 tablet) dose, respectively. 
Red circles represent mean population observed concentrations reported in (49). 
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Figure 2.16: The simulated plasma concentration-time profile of lumefantrine in children. 
Blue and green solid lines indicate increasing doses of lumefantrine (1 tablet: 5–14.9 kg); 2 tablets 15–24.9 kg). Upper and lower dashed 
lines represent the 95th percentile for the 240 mg dose and 5th percentile for the 120 mg dose, respectively. Red circles represented mean 
population observed concentration reported in (173). 
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Table 2.7: Summary of simulated and observed median day 3 or day 7 lumefantrine concentrations in children 
 
a  Simulated day 7 median concentrations were predicted following dosing based on body-weight stratification as a result of the lack of clear; 
age-weight dosing strategies detailed in the observed studies. Doses were given at the regimens stated in the studies simulated; b Observed 
study demographics required a single tablet dosing of AL based on weight; c Dosed as 12mg/kg.  
Study Notes 
Observed Simulated 
Median Concentration [Range] (ng/mL) 
Day 3 Day 7 Day 3 Day 7a 
Mayxay et al (2004) (236) n=77; 95% CI reported 
- 520 [390–650] - 
1 tablet: 374 [0.1-2341] 
2 tablets: 392 [0.1-4719] 
3 tablets:   411 [0.3-4853] 
Schramm et al (2013) (237) n=139; IQR reported; 
ACRP results - 356 [211-547] - 1 tablets 
b: 369 [37-885] 
Ngasala et al (2011) (238) n=177; Range reported 
- 205 [0-1887] - 
1 tablet: 392 [0.12-6785] 
2 tablets: 408 [0.13-7511] 
Borrmann et al (2011) (239) n=15; Range reported 
from 2005-2006 study - 536 [178-3270] - 369
c [0.1-5028] 
Checchi et al (2006) (240) n=70; Range reported in 
supervised group in under 
5 years 
7050 [1876-
14985] 
367 [0.12-768] 4877 [1678-25285] 
1 tablet: 389 [0.1-7544] 
2 tablets: 348 [0.3-8641] 
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2.4.5 Step 4: Simulating the impact of rifampicin-mediated CYP3A4 
induction on artemether and lumefantrine pharmacokinetics in 
children  
The presence of tuberculosis is thought to occur in at least 37.5 % of subjects 
infected with malaria (179), and given the potential for TB treatments to attenuate CYP-
mediated drug metabolism (rifampicin being a CYP3A4 inducer and isoniazid a CYP3A4 
inhibitor), the potential risk in paediatric patients is important to assess considering the 
ontogeny CYP3A4 expression during the first 5 years of life (202-204).  Simulations to 
predict the potential impact of TB treatment on subjects who are on anti-malarial 
treatment were assessed to quantify the change in AL plasma concentrations in the 
absence and presence of dosing with rifampicin (and isoniazid) for subjects of 2-5 years 
of age with weight-based dosing (1 tablet: 5-14.9 kg and 2 tablets 15-24.5 kg) where 
rifampicin (and isoniazid) was dosed daily for 7 days prior to the initiation of AL. 
2.4.5.1 Artemether 
A DDI initiated with a combination of rifampicin and isoniazid significantly 
reduced the Cmax for both one and two tablet regimens by approximately 80 %, with a 
calculated Cmax ratio of 0.21 (Figure 2.17) (Table 2.8). Similarly, a significant reduction 
in the AUC following the DDI resulted in an AUCr of 0.22 (Table 2.8) (Figure 2.17).  No 
differences in the overall impact of the DDI between the two dosing groups was reported 
suggesting the magnitude of the DDI is similar across the 2-5 years’ age range. 
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Figure 2.17: The simulated mean plasma concentration-time profile of artemether in paediatrics in the absence and presence of a DDI 
Artemether plasma concentrations following a regular six-dose over three days regimen with 1 tablet (5–14.9 kg) or 2 tablets (15–24.5 kg) 
per dose to children (2–5 years) in a 14-day trial with rifampicin. Solid lines represent clinical trials with artemether alone. Dashed lines 
represented artemether dosing with rifampicin (10 mg/kg). One tablet doses are indicated in black and two tablet doses in blue. Isoniazid was 
also dosed at 10 mg/kg and used as a secondary perpetrator considering its inclusion in anti-TB therapy.   
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Table 2.8:  Summary of predicted artemether pharmacokinetics in the absence and presence of a DDI in children aged 2-5 year. 
 
 
Cmax data is from the final dose; AUC calculated from final dose to end of study period. “One”: subject dosed one (20/120 mg AL) tablet; 
“two”; subject dosed two (40/240 mg AL) tablets. 
 No Rifampicin Rifampicin Ratio 
 
Cmax (ng/mL) AUC (ng/mL.h) Cmax (ng/mL) AUC (ng/mL.h) Cmax AUC 
One 89.1± 78.9 564 ± 317 18.5 ± 31 121 ± 143 0.21 0.22 
Two 210 ± 179 1127 ± 633 39.1 ± 136 243 ± 290 0.18 0.21 
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2.4.5.2 Lumefantrine  
In the absence of a DDI (i.e. malaria only patients), the predicted mean day 7 
concentration was above the minimum therapeutic target of 280 ng/mL (Figure 2.18) for 
both the single tablet per dose (5-14.9 kg) and two tablets per dose (15-24.9 kg) strategies, 
300.49 ng/mL (range: 0.1-4442 ng/mL) and 614.37 ng/mL (range: 0.14-6485 ng/mL) 
respectively (Table 2.9). 
However, in TB co-infected patients receiving lumefantrine and rifampicin, the 
predicted day 7 concentration fell significantly below the therapeutic target of 280 ng/mL 
for both the single and two tablet regimens, with a calculated AUCr of 0.41 and AUCr 
0.40 respectively (data not shown) and no subjects presented with a simulated day 7 
concentration of > 280 ng/mL (Table 2.9).   The potential risk for failure of AMT is 
therefore of significant concern in TB co-infected paediatric patients, particularly those 
falling into the lower body-weight stratification who would typically be younger in age 
and therefore more prone to treatment failure. 
 
  
  
1
2
6
 
 
 
 
 
 
 
 
 
Figure 2.18: The simulated mean plasma concentration-time profile of lumefantrine in paediatrics in the absence and presence of a 
DDI for a standard 3-day regimen 
Lumefantrine plasma concentrations following dosing with 1 tablet (5–14.9 kg) or 2 tablets (15–24.5 kg) to children (2–5 years). Solid lines 
represent clinical trials with lumefantrine alone. Dashed lines represent lumefantrine dosing with rifampicin (10 mg/kg). Isoniazid was also 
dosed at 10 mg/kg and used as a secondary perpetrator considering its inclusion in anti-TB therapy. 
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2.4.6 Dose optimisation 
Given that orally administrated AL often shows absorption saturation kinetics, to 
overcome the risk of significant treatment failure increasing the dose of AL administered 
in each FDC would not be appropriate.  We assessed the impact of increasing the duration 
of treatment from 3 days to 5 or 7 days on the potential impact on day 7 lumefantrine 
concentrations (Figure 2.19-2.20).   
Increasing the duration of treatment to 5 days had a minimal impact on day 7 mean 
concentrations, with a modest increase for the single tablet to 63.63 ng/mL leading to a 
11.1 % (n=5/46) increase in the subjects with day 7 target > 280 ng (Table 2.9) (Figure 
2.19).  Similarly, for the two-tablet treatment an increase in the mean day 7 concentration 
was simulated at 76.9 ng/mL which resulted in an overall increase in subjects with a target 
concentration > 280 ng of 11.3 % (n=6/53) (Table 2.9) (Figure 2.20).  However, for a 7-
day treatment 63 % (one tablet) and 74.5 % (two tablets) of subjects demonstrated a day 
7 concentration in excess of 280 ng/mL (Table 2.9) (Figure 2.20). 
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Figure 2.19: The simulated mean plasma concentration-time profile of one tablet of 
lumefantrine in paediatrics in the presence of a DDI for an adapted 5 (A) and 7-day 
(B) regimen.  
Lumefantrine plasma concentrations following dosing with one tablet (5–
14.9 kg) to children (2–5 years) in the presence of rifampicin (10 mg/kg) when dosed for 
5 days (upper panels) or 7 days (lower panels). Solid lines represent mean and dashed line 
represent upper and lower ranges of predicted concentrations with shaded regions 
representing the range of predicted concentrations. Isoniazid was also dosed at 10 mg/kg 
and used as a secondary DDI perpetrator. 
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Figure 2.20: The simulated mean plasma concentration-time profile of two tablets of 
lumefantrine in paediatrics in the presence of a DDI for an adapted 5 (A) and 7-day 
(B) regimen. 
Lumefantrine plasma concentrations following dosing with two tablets (15–
24.5 kg) to children (2–5 years) in the presence of rifampicin (10 mg/kg) when dosed for 
5 days (upper panels) or 7 days (lower panels). Solid lines represent mean and dashed 
lines represent upper and lower ranges of predicted concentrations with shaded regions 
representing the range of predictions concentrations. Isoniazid was also dosed at 
10 mg/kg and used as a secondary DDI perpetrator.
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Table 2.9:Summary of predicted mean day 7 lumefantrine concentrations during a 3, 5 and 7-day treatment schedule in children 
a Percentage (number) of subjects with Cd7  ≥ 280ng/mL; 3 days: 1 tablet (n=53), 2 tablets (n=45); 5 days: 1 tablet (n=46), 2 tablets (n=53); 
7 days: 1 tablet (n=46), 2 tablets (n=47). NI: no interaction; I: interaction. Cd7: mean day 7 concentration.
Dosing 
Mean Cd7 (Range) (ng/mL) Lumefantrine ≥ 280ng/mLa 
Regimen Regimen 
3 day 5 day 7 day 3 day 5 day 7 day 
1 tablet/NI 300.(0.1-4442) 1451 (15.2-8367) 7509 (79.7-12438) 47.8 (n=22) 86.7 (n=39) 95.6 (n=44) 
1 tablet/I 18.1 (0.01-88.9) 63.6 (0.01-578) 329 (0.12-4385) 0 11.1 (n=5) 63 (n=29) 
2 tablets/NI 614 (0.14-6485) 1516 (14.9-9656) 9748 (28.5-14375) 46.6 (n=21) 60.3 (n=32) 85 (n=40) 
2 tablets/I 42.7 (0.01-154) 76.9 (0.02-1087) 704 (0.08-7895) 0 11.3 (n=6) 74.5 (n=35) 
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2.5 Discussion 
Children are more vulnerable to the effects and complications of malaria infections 
than adults (153). The need for optimising the dosing strategy of antimalarials in children 
especially in the case where there is the risk of clinically significant DDI is very important 
because they are often excluded from clinical trials for ethical reasons. In the highly likely 
case when children are coinfected with malaria and tuberculosis, there are currently no 
clear guidelines on how to treat malaria infection in a child using anti-tuberculosis (anti-
TB) therapy. Antimalarial drugs like AL, which are available in resource limited countries 
to treat malaria, significantly interact with the standard anti-tuberculosis regimens, in fact, 
the administration of AL and the standard rifampicin based anti-TB cocktail is 
contraindicated in adults (180).  
The ultimate goal of this study was to address the potential risk associated with 
DDIs related to tuberculosis therapy in children between 2-5 years of age. This age group 
accommodates the lowest dosing range (age based) for use of both AL and rifampicin.  
Our modelling strategy included a 4-step approach commencing with the prediction of 
AL pharmacokinetics in adult population groups with the developed and validated 
compound files (Step 1 and 2) before scaling the model to paediatric subjects and 
validating with published non-DDI clinical studies (Step 3). Finally, potential AL DDI 
risks in co-infected malaria-tuberculosis children receiving a rifampicin based anti-TB 
regimen were simulated which was then followed by proposing dosing optimisation 
strategies (Step 4).   
2.5.1 Model development 
The development of a PBPK model which is able to predict clinically observed 
pharmacokinetic parameters of APIs is key in PBPK modelling and hinges on the concept 
of in vitro to in vivo extrapolation (IVIVE) approaches whereby mechanistic in vitro 
parameters are used in a bottom-to-top fashion to predict in vivo pharmacokinetic 
parameters of drugs (138). Since PBPK modelling is mainly dependent on mechanistic 
data, the challenge of unavailability of certain in vitro data poses a significant challenge 
on the ability to successfully develop the models. For example, in this study, the effective 
permeability (Peff) values of AL, an important parameter to mechanistically predict their 
absorption rate constants (ka) might have been estimated from the apparent permeability 
(Papp) value obtain in in vitro cell-based models like Caco-2, but due to unavailability of 
 132 
  
published Papp values for AL, the molecular descriptors of AL, that is, the polar surface 
area (PSA) value and the hydrogen bond donor of the drug were used to predict the Peff 
value for both compounds using equation 43. The resultant predicted Peff values did not 
adequately recover the absorption profile of the observed clinical data of AL as seen in 
Figures 2.5A-B but following the optimisation of the predicted Peff parameter, there was 
an improvement in the simulation of the absorption phases of AL in both single and 
multiple dose simulations (Figures 2. 6A-B, 2.7). As an example, the optimised Peff value 
for lumefantrine (Table 2.2) resulted in estimation of ka as 0.43 h
-1 at a 30% coefficient 
of variation. This was similar to the ka values reported in Salman et al (2011) and 
Tchaparian et al (2016) as 0.46 h-1 and 0.45 h-1 respectively (241, 242). While the fa values 
of lumefantrine are scarcely reported, a study reported an estimate of fa ≈ 1 (243); again 
this value is close to predicted lumefantrine fa (0.73) in this current study.  
2.5.2 Simulation of AL pharmacokinetics in adults in the presence and 
absence of DDIs 
In adults, successful AL model development (Step 1) was achieved through 
comparison to 3 key clinical studies quantifying both artemether and lumefantrine in each 
study and all predictions were within 2-fold of the reported Cmax and AUC from clinical 
studies (Table 2.5).  The large variability in the absorption phase of artemether and 
lumefantrine (Figure 2.6B, 2.7) was evident in the observed clinical data and the slight 
model over prediction may be as a result of the lower limit of detection for artemether in 
the studies reported by Lefevre et al (2002, 2013) (220, 230) compared to that reported 
by Bindschedler et al (2002)(244). 
Following successful model development, the ability of each compound file to 
mechanistically predict a DDI was then assessed through the use of two inbuilt Simcyp® 
inhibitors, namely ketoconazole (CYP3A4 inhibitor) and rifampicin (CYP3A4 inducer) 
(Step 2).   For CYP3A4 inhibition, the model was able to recapitulate the extent of DDIs 
with reported plasma concentrations within the predicted 5th-95th percentiles for the 
simulation for artemether and lumefantrine (Figure 2.8-2.9 and Table 2.6).  
For the induction-based interactions of CYP3A4 with AL, very few reports have 
characterised rifampicin mediated DDIs and we utilised a study which reported AL 
concentration within the same subjects (180).  Under these circumstances, the model 
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predicted 12-hour post final dose concentration (artemether) and day 8 concentration 
(lumefantrine) was similar (within 2-fold) to that reported by Lamorde et al (2013) 
(Figure 2.10-2.12) (180).  Steps 1 and 2 demonstrate the ability of the developed AL 
models to replicate pharmacokinetic parameters reported from a range of non-DDI and 
DDI studies, confirming successful model development. 
2.5.3 Simulation of AL pharmacokinetics in presence and absence of DDI in 
children.  
2.5.3.1 DDI with AL in paediatrics in developing countries 
Although standard regimens for malaria treatment have shown positive treatment 
benefits with a reduction in mortality rates (2), in many developing countries with a high 
burden of communicable disease such as HIV/AIDS and tuberculosis, the risk potential 
of DDIs with co-infected malaria patients is high (179).  Such DDI issues are more 
apparent in children where the recruitment and inclusion of such onto antimalarial clinical 
trials is limited.  Pragmatically assessing the risk of DDIs in paediatrics is difficult due to 
CYP-ontogeny observed in key drug metabolic pathways associated the AL metabolism, 
mainly CYP3A4, during the first 5 years of life (202-204), where maturation of CYP3A4 
expression may lead to both altered plasma concentrations of CYP3A4-subtrates (such as 
AL) whilst also dynamically altering the magnitude of any CYP3A4-induction process.  
Rifampicin is a known potent CYP3A4 inducer, and therefore has the potential to lead to 
AL treatment failure if the antimalarial metabolic pathway favours CYP3A4-mediated 
transformation. 
2.5.3.2 The usefulness of PBPK modelling approach in studying the 
pharmacokinetics of drugs in children 
The study of pharmacokinetics in paediatric population groups is often neglected for 
many therapeutic agents because of complexities in ethical/legal and recruitment 
strategies coupled with the requirement for limited sample collection and often diverse 
population-based data analysis.   
Although allometric scaling remains a useful tool for first predictions of primary 
pharmacokinetic parameters such as Vss or clearance (245, 246) it can often fail in the 
prediction of clearance (247-250), when assessing dosing-optimisation strategies in 
paediatrics (251) and in situations where body weight may be significantly variable based 
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on geographical locations (252).  Further, allometry often does not address the impact of 
maturation at early ages of childhood and can often over-predict clearance during the 
maturation of metabolic elimination pathways (253).  However, PBPK modelling can be 
used to support population modelling approaches such that deviations in covariate models 
can be built into the model based on the mechanistic knowledge of the physiological or 
biochemical variation in parameters in the population under study allowing the rational 
extrapolation of a drug pharmacokinetics across age groups.  In light of these facts, PBPK 
is now gaining regulatory acceptance (108, 141, 254-256) as one approach to assess 
pharmacokinetics in paediatric patients (257) and in complex scenarios such as DDIs 
(258, 259). 
2.5.4 AL pharmacokinetics and interaction with rifampicin in children 
To consider the potential impact of a DDI on AL pharmacokinetics in 2-5-year olds, 
it was important to demonstrate the capability of the developed model to predict AL 
pharmacokinetics in children.  To this end, step 3 focussed on validation of artemether 
and lumefantrine in children.  Artemether model predictions in children were able to 
capture the differences in weight-based dosing strategies on the outcome pharmacokinetic 
profiles, both in ‘single’ point concentrations centred around the Cmax (Figure 2.13-14) 
and population-based sampling over a dosing period (Figure 2.11). Lumefantrine model 
predictions required an optimisation step and following this optimisation procedure, 
observed time-point data for 30, 54, 66, 84 and 168 hours (49) and the day 3 and day 7 
points (173) were within 2-fold of the simulated profiles and within the 5th and 95th 
percentiles of the mean predicted profiles (Figure 2.15-16).  Lumefantrine model 
predictions were finally further validated using median concentration data at day 3 or day 
7 (Table 2.7), which were found to be well predicted and within 2-fold of the reported 
concentrations.  The approach described in Step 3 resulted in appropriate model 
predictions based on existing published literature detailing either a single-time point or 
multiple-time point concentration data of AL in children. 
Having established a working model for AL pharmacokinetics in adults and 
children, along with a working model for quantifying AL DDIs in adults, we addressed 
the major focus of this study, the prediction of potential AL based DDIs in children 
between the ages of 2-5 years of age.  As expected, the impact of rifampicin on the 
pharmacokinetics of artemether was significant, reducing both the final dose Cmax for both 
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one and two tablet regimens by approximately 80 % (Cmax ratio: 0.18-0.21) (Table 2.8) 
along with an AUCr of 0.21-0.22 for both dosing regimens.   
2.5.5 Importance of DDIs of lumefantrine and rifampicin based anti-TB 
treatment in children  
To infer a clinical consequence of this is difficult, given the shorter half-life of artemether 
compared to lumefantrine.  AL is a very efficacious therapy in uncomplicated malaria 
patients with the recommend 6-dose treatment showing efficacy of 97.6% on day 28 and 
96.0% on day 42 (260), however the efficacy of treatment reduces with patients receiving 
lower doses (an 8% decrease in patients for every 1 mg/kg decrease in dose received).  
However, the overall determinant of AL clinical efficacy is AUC of lumefantrine (208), 
with lumefantrine day 7 concentration  of ~280 ng/mL being the primary marker for 
successful therapy under dosing with 3-day dosing regimen. 
The DDI has a detrimental effect on lumefantrine Cd7, significantly reducing this below 
the target concentration for both one and two dose treatment (Figure 2.19-2.20).  
Although data on such interactions in paediatric is lacking, Lamorde et al (2013) (180) 
have demonstrated a similar effect in adults with a significant decrease (3-10 fold) in 
lumefantrine concentrations during TB treatment (180).  Artemether and lumefantrine 
have been reported to show saturation in absorption pharmacokinetics and it would be 
expected that dose increases would have a limited impact on the resultant 
pharmacokinetics of lumefantrine (221) (261).  Therefore, to overcome the DDI-based 
decrease in Cd7, an increase in the dose administered would not be viable for increasing 
Cd7.  We then simulated the impact of an increase in dosing duration to determine how 
this would influence the plasma concentration of AL, and whether an increase in Cd7 
would be evident.  
2.5.6 Optimisation of dosing regimen of AL in the presence of rifampicin 
based DDI in children 
Whilst a 3-day treatment is viable for patient compliance, the day 7 concentration s 
in malaria-TB co-infected children receiving AL and rifampicin based anti-TB regimen 
were significantly lower than the target concentration.  An increase in dosing duration 
was investigated to assess the impact on the predicted target concentration.  Whilst a 5-
day course resulted in some modest increase in the percentage of subjects with a Cd7 > 
 136 
  
280ng/mL (~11% increase), this increase was far greater for a 7-day treatment regimen 
with ~63-75% of subjects demonstrating Cd7 > 280ng/mL across both dosing bandings 
(Table 2.9).  A recent population pharmacokinetic study by Hoglung et al (2015) (262) 
assessed the potential for DDI with malaria-HIV co-infected adult patients.  In 
prospective simulations they demonstrated a similar beneficial effect of an increase in 
dosing duration to counteract the induction effect of antiretroviral on malaria (AL) 
treatment regimens.  
Whilst the impact of this will require prospective clinical analysis, it is suggested 
that an increase in the dosing duration for children who are co-infected with malaria and 
TB and receiving AL and rifampicin based anti-TB drugs from a standard 3 days AL 
regimen to a 7-day regimen might result in full malaria parasite clearance.  Our results 
have demonstrated that children aged 2-5 years of age are susceptible to significant DDI 
when being co-treated with TB chemotherapy, which directly impacts upon the potential 
for AL therapy failure.   
2.5.7 The effect of unbound fraction of lumefantrine on the day 7 
concentrations 
Malaria patients are susceptible to reduced albumin and α1-acidic glycoprotein, 
which can directly impact upon the extent of plasma protein binding and therefore 
exposure of AL to metabolic extraction as reports demonstrate a decrease of ≥ 30 % of 
serum albumin, (≤ 35 g/L) in malaria patients (263-265).  For highly protein bound drugs, 
such as lumefantrine, any change in the extent of protein binding (e.g. reduced binding 
due to reduced serum protein) will inevitably alter the unbound drug concentration but 
not the fraction of unbound drug. This effect will be observed as a change in total drug 
concentration and potentially enhance or reduce both drug tissue distribution along with 
metabolic clearance.   
The potential impact of such a change was assessed in 2-5 year olds (1 tablet per 
dose over the 7 day optimised regimen) (Figure 2.21) and demonstrated that a modest 
increase in fu,plasma from 0.003 to 0.005, results in all subjects possessing a Cd7 of just 
below the target < 280 ng/mL subjects (when considering the range of simulated values).  
Furthermore a 10-fold increase in fu,plasma (0.003 to 0.03) yields Cd7 which would be 
irreconcilable by dosing adjustments. 
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Figure 2.21: The impact of alterations in lumefantrine plasma unbound fraction on 
simulated Cd7 in paediatrics in the presence of a rifampicin-mediated DDI for a 7-day 
regimen (one table/dose)  
Day 7 lumefantrine plasma concentrations (Cd7) were simulated for 56 subjects 
within a weight range of 5–15 kg (1 tablet/dose) in the presence of rifampicin (10 mg/kg). 
The solid line represents the 280 ng/mL lumefantrine ‘target’ concentration. Dashed lines 
represent the simulated range (upper and lower) and Cd7 target concentration when 
fu,plasma = 0.003. Dotted lines represent the simulated range (upper and lower) 
concentrations when fu,plasma = 0.005. Isoniazid was also dosed at 10 mg/kg and used as a 
secondary perpetrator in light of its inclusion in anti-TB therapy.  
2.5.8 Study challenges 
The impact of non-adherence to designed treatment regimens would render the 
impact of the induction effect variable and unpredictable (266). However, given the 
erratic absorption of lumefantrine (and artemether) (267), the extension of a dosing 
regimen from 3 to 5 days would not alter the peak concentrations significantly (Figure 
2.17-2.20) and would be within this erratic absorption range. Furthermore, it should be 
noted that simulations were performed in healthy subjects in our simulations, and 
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therefore we have assumed that any physiological changes associated with malaria are 
negligible and do not impact upon the extent of the DDI in our simulation trials.   
In children, changes in body weight (malnutrition) can potentially impact upon 
pharmacokinetics of antimalarials (268), our dosing range for the age selection (5-15kg 
and 15-25kg) is broad enough to simulate the impact on potential underweight children 
who are within the simulated age range (2-5 years). Interesting, a clinical trial is on-going 
(269) to assess the impact of an increased treatment frequency to 5 days for AL, the 
outcomes of which may support the requirement for an increase in dosing frequency for 
patients subjected to induction-based DDIs.
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2.6 Conclusion 
The WHO have highlighted the increased risks of mortality children face with 
malaria infection (2, 3) and coupled with the complications of co-infection with 
tuberculosis, children are at significant risk of potential drug-drug interactions in many 
areas of sub-Sahara Africa and this DDI may impact upon parasite clearance.  Whilst 
clinical studies exploring this risk of DDI in co-infected paediatric population groups are 
sparse, mechanistic population-based PBPK modelling provides a potential approach to 
assess this risk-potential.  The pharmacokinetics of artemether and lumefantrine has been 
simulated for two-body weights in children ages 2-5 years old, who would be a greater 
risk of mortality associated with both malaria and tuberculosis.  We demonstrated that an 
extension of the current recommended dosing range for AL, from 3 to 7 days, would 
counteract the potential rifampicin-mediated induction on lumefantrine (and artemether) 
metabolic clearance and yields a significantly greater proportion of subjects attaining a 
target lumefantrine concentration thereby preventing recrudescence and potential 
mortality.
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pharmacokinetics of piperaquine 
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3.1 Introduction  
3.1.1 Malaria incidence in pregnancy 
In 2009, it was reported that 25 million pregnant women were at risk of malaria 
infection in a WHO report and that malaria was the cause of death in 10,000 pregnant 
women and 200,000 neonates yearly (270).  More recently, maternal death due to malaria 
was reported to account for up to 25% of maternal deaths due to all causes in malaria 
endemic regions (271).   
3.1.2 Consequences of malaria in pregnancy 
The problem of malaria-induced maternal morbidity and mortality in endemic areas 
for the disease is far reaching, particularly with respect to the unborn child. Malaria 
infection in pregnancy triples the maternal risk of suffering from severe diseases 
compared with non-pregnant women and puts pregnant women at a 50 % higher chance 
of dying from severe malaria (270, 272). In high transmission areas, women pregnant for 
the first time, adolescents, and those infected with human immunodeficiency virus (HIV) 
are said to be at an even greater risk of being infected with disease. The effect of malaria 
in pregnancy depends on immunity of the pregnant woman against malaria and malaria 
infection can result in debilitating complications such as maternal anaemia, miscarriage, 
foetal growth retardation, preterm delivery, illness and low foetal birth weight and foetal 
and/or maternal death (270, 273).  
3.1.3 Treatment of malaria in pregnancy  
The treatment of malaria during pregnancy possesses major challenges to 
healthcare systems. This is because antimalarial treatments (AMT) which yield 
satisfactory safety and efficacy profiles are often found to be unsafe during the early 
stages of pregnancy (274). The WHO’s current recommendations for AMT 
chemoprophylaxis are based on intermittent preventive treatment with sulfadoxine-
pyrimethamine (IPTp-SP) (165). This recommendation was based on a review (275) of 
seven trials which assessed the use of monthly SP administration for malaria prevention 
in pregnant women across six African countries.  The result of the review demonstrated 
that there was a significant reduction in both low birth weights and placental and maternal 
parasitaemia following administration of no less than two doses of SP monthly during 
pregnancy (275). 
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However, with the spread of SP resistance, new interventions have been sought.  In 
high transmission settings where there may be widespread resistance to SP-IPTp, 
dihydroarteminisin-piperaquine (DHA-PQ) has been demonstrated to result in a lower 
malaria burden (276).   
In practice, other non-pharmacological methods previously discussed, and the use 
of other ACTs have been used for prevention of the disease. Adequate treatment of 
uncomplicated malaria is also encouraged during pregnancy to avoid complications. 
3.1.3.1 Dihydroartemisinin/piperaquine  
The effectiveness of DHA-PQ in the treatment of malaria during the second and 
third trimesters of pregnancy has been robustly demonstrated. In more than 2000 pregnant 
women in Thailand and Indonesia in either the second and third trimesters of their 
pregnancy, the administration of DHA-PQ resulted in successful antimalarial treatment 
and safety outcomes. The safety of DHA-PQ in pregnancy has been demonstrated in 
many studies. In 2015, a randomised controlled superiority trial showed that in addition 
to the observed efficacy of DHA-PQ for preventing malaria in pregnancy, DHA-PQ 
resulted in fewer detrimental maternal and infant side effects compared with SP-IPTp 
(277). Also, another study revealed that compared to quinine, DHA-PQ used for the 
treatment of multi-resistant malaria in the second and third trimester of pregnancy 
resulted in less perinatal mortality, though in the first trimester, quinine appeared to be 
safer (278). 
In high malaria transmission settings with the possibility of widespread resistance 
to SP-IPTp, dihydroarteminisin-piperaquine (DHA-PQ) has been shown to result in 
reduced malarial burden (276). This is evident in a study which showed that the 
administration of DHA-PQ gave significantly higher protection against placental malaria, 
significantly lowered maternal parasitaemia and reduced prevalence of composite adverse 
birth consequences when compared to the use of SP in pregnant women (276).  
3.1.3.2 Efficacy indicator of dihyrdoartemisinin and piperaquine (DHA/PQ) in the 
treatment of malaria 
In antimalarial therapy with DHA-PQ, study endpoints to determine the efficacy of 
drugs may be primary endpoints or secondary endpoints. Primary endpoints include 
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measuring outcomes such as: early treatment failure which may be manifested as poor 
treatment prognosis between the start and day 3 of treatment, late clinical failure 
measured as fever and parasitaemia between the 4th  and 42nd day of commencing therapy, 
late parasitological failure observed as any recurrence of parasitaemia between the 4th and 
42nd day but without fever, while adequate clinical and parasitological response indicates 
there is not parasitaemia or fever for 42 days after starting therapy. For the secondary 
outcomes, several outcomes are considered, which include but are not limited to 
haemoglobin level changes, occurrence of gametocytes and the correlation of day 7 
concentrations of piperaquine and primary outcome measures above (279). Some studies 
have demonstrated that a significant determination of treatment failure following the use 
of DHA-PQ in patients with malaria is a piperaquine day 7 concentration level lower than 
30 ng/ml and day 7 concentrations below this level are said to be associated with recurrent 
infection. Hence a day 7 plasma concentration of piperaquine is a good surrogate for 
clinical efficacy of DHA-PQ (279, 280).   
3.1.4 HIV and malaria co-infection in pregnancy 
Infectious diseases such as HIV are prevalent in malaria endemic regions (281, 
282). Pregnant women with HIV and malaria coinfection are more vulnerable to all the 
complications of malaria in pregnancy such as anaemia, placental parasitaemia and low 
foetal birth weights (283). It has also been reported that there is higher incidence of 
anaemia and low foetal birth weights in malaria and HIV coinfected pregnant women than 
in pregnant women with either of the infections alone. As malaria may increase HIV viral 
load, there is higher risk of mother to child HIV transmission in pregnant women who 
carry both infections (284).  
The implication of malaria and HIV co-infection in pregnant women suggests that 
some DDIs between drugs used to treat both infections are likely because of the potential 
for many antiretroviral (ART) drugs to elicit (DDIs) on common cytochrome P450 
isozymes (CYP P450), e.g. 3A4 (285-287). Hence, the potential for a DDI to occur is a 
significant cause for concern when treating this population. The reduced systemic 
concentration of DHA-PQ, due to co-administration with efavirenz in HIV infected 
pregnant women, has been demonstrated in a recent study which showed that in Ugandan 
pregnant women, AUC0-8hr and AUC0-21d  of piperaquine was 50% and 40% lower 
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respectively when DHA-PQ was co-administered with efavirenz compared to when 
DHA-PQ was taken alone (288).  
In Mali, the effect of co-administration of nevirapine on the pharmacokinetics of 
quinine was studied in seven pregnant women (289). In this study, it was reported that 
nevirapine, a CYP3A4 inducer, might have been responsible for the lower plasma 
concentration of quinine and higher concentration of its metabolites in the six of the 
pregnant women who were co-administered these drugs compared with the one patient 
who did not have this combination of drugs. The overall effect of the DDI observed in 
the pregnant women was such that the systemic concentration of quinine was lower than 
the therapeutic range in half of the subjects involved in the DDI study (289). Very few 
DDI studies are likely to be granted approval in pregnant women for ethical reasons, but 
a systemic review of data involving DDI between ARV drugs and AMT further 
accentuated the likelihood of a range of such DDIs (290).  
3.1.5 PBPK modelling in pregnancy 
During pregnancy, many physiological changes occur in the body of the pregnant 
woman which potentially alter the pharmacokinetics of drugs (291).  Studies have 
revealed the impact of pregnancy on the efficacy of different drugs. Colbers et al (2015) 
demonstrated that the exposure to darunavir was reduced during pregnancy in an open 
label, non-randomised study involving HIV infected pregnant women (292). Similarly, 
Olagunju et al (2015) showed that in the 44 pregnant and postpartum women recruited 
for their study, there was a reduction in the overall efavirenz exposure in pregnant women 
compared to the postpartum women (293). Kreitchmann et al (2013) showed that an 
increase in Atazanavir/ritonavir dose to 400/100 mg in second and third trimester of 
pregnancy was able to counteract the impact of reduced systemic exposure to atazanavir 
apparent with a 300/100mg dose (294). The impact of ineffective or unsafe drug 
concentrations during pregnancy is not only on the mother but also on the unborn foetus, 
for example in the case of prevention of mother to child HIV transmission during ARV 
therapy (291), therefore, the alteration of ADME during pregnancy may be directly 
caused by pregnancy induced physiological changes.  
 145 
  
3.1.5.1 Physiological changes affecting pharmacokinetic processes during 
pregnancy  
3.1.5.1.1 Plasma/ blood volume 
Pregnancy induced changes to the cardiovascular system result in an increase of 
plasma volume throughout pregnancy. Increase in cardiac output during pregnancy starts 
at as early as gestational week 6, stabilises at around 16 weeks but continues to increase 
gradually until the end of pregnancy resulting in up to 50 % higher maternal blood 
volumes in pregnant women when compared to non-pregnant women.  These 
blood/plasma volume changes have obvious pharmacokinetic implications. The volume 
of distribution of hydrophilic drugs increases with an increase in plasma/blood volumes 
potentially requiring an increase in the loading dose of such a drug so that the therapeutic 
concentration can be achieved during pregnancy because an increase in volume of 
distribution of the drug into extracellular space due to overall increase in total body water 
may lead to a decrease in plasma concentration. Similarly, during pregnancy, there is a 4 
kg increase in body fat and this may potentially increase the volume of distribution of 
lipophilic drugs (295, 296). 
3.1.5.1.2 Protein binding  
The concentration of the major plasma proteins involved in drug binding, human 
serum albumin (HSA) and alpha 1- acidic glycoprotein (AGP) have been reported to 
decrease during pregnancy. Abduljali et al (2015) reported that at around the third 
trimester, HSA concentration is decreased by 31 % while AAG is reduced by 19 %, the 
consequence of which is an increase in amount of free drug available for both distribution 
and clearance leading to overall systemic drug exposure reduction as a result of pregnancy 
(291, 297). 
3.1.5.1.3 Hepatic enzyme activity 
It is known that hepatic enzyme activities may increase or decrease during 
pregnancy. The mechanism behind the changes is thought to be due to an increase in the 
levels of some hormones, such as progesterone, oestradiol and growth hormones during 
pregnancy (298). The extent of changes in hepatic enzyme activities due to pregnancy has 
been demonstrated in the Fotoupolous et al (2009) study where they showed clearance of 
lamotrigine was increase by 197, 236 and 248 % at first, second and third trimesters of 
pregnancy (299). During pregnancy, the metabolic enzymatic activities of CYP 
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isoenzymes 3A4, 2C9, 2D6 and the uridine diphosphate glucuronosyltransferase (UGT) 
isoenzymes UGT 1A1 and 1A4 has been shown to increase, implying that metabolism of 
drugs that are substrates of these enzymes will be increased and consequently resulting in 
lower drug concentrations of these substrates in pregnant subjects. Conversely, the 
metabolic activities of CYP isoenzymes 1A2 and 2C19 are decreased during pregnancy 
implying a reduced metabolism of drug substrates of these and a resultant increase in 
systemic exposure of the drug in pregnant subjects (300). 
3.1.6 Physiological consideration of antimalarial therapies in pregnancy 
In the section, the impact body weight and blood biochemistry might have in the 
AMT will be discussed. Firstly, the body weight used in this context to infer body 
composition can affect mainly the volume of distribution of a drugs as highly lipophilic 
drug will have altered volume of distribution in obese subjects compared to subjects with 
normal weights (301). Secondly, as discussed, pregnancy can alter the blood 
biochemistry, for example, serum albumin concentration which is said to also affect the 
distribution of drugs that are highly bound to it. This effect is further confounded in 
disease states such as malaria whereby HSA levels are reduced as a result of the infection 
(302, 303). Also, the haematocrit levels which is the percentage of red blood cell in whole 
blood volume is particularly important in studying drugs that might have high affinity to 
red blood cells. This is because changes in the haematocrit level can alter the distribution 
of drugs into the plasma for a drug that is highly bound to red blood cells (304).  
Physiological and biochemical parameters may vary across ethnic groups and in 
disease states. For instance, the age-weight distributions in malaria endemic regions have 
been shown to differ greatly from average global weight-for-age distributions (283). Also, 
Goselle et al (2007) and Silamut et al (1999)  (264, 305) studied the effect of malaria 
parasitaemia has on the levels of plasma proteins. Goselle et al  (2007) revealed that in 
Nigerian subjects, serum albumin level is reduced in subjects with malaria compared to 
those without malaria, while Silamut et al (1999) showed that in Thai patients who had 
malaria, there was increase in AAG levels but they returned to almost half of what they 
were in the infected state after the patients had recovered from the infection. Newton et 
al (2013) reported that the haematocrit levels of nearly a thousand subjects in Thailand 
and found that the average level was 37 (range 6–56) % in a population of 60 % male – 
compared to normal haematocrit levels of 37-48% in men and 42-52% in women (306). 
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In pregnant women, changes to body physiology that may or may not significantly 
affect the pharmacokinetics of drugs. The effect of pregnancy on the PK of drugs is 
difficult to assess clinically due to ethical constraints, more so, in pregnancy several 
physiological and biochemical changes are happening simultaneously, and it might be 
difficult to determine which in particular is implicated in the alteration of the 
pharmacokinetics of a drug. Therefore, the use of the mechanistic approaches in PBPK 
modelling may proffer a holistic understanding of what physiological or biochemical 
factors or parameters might influence the pharmacokinetics of drugs during pregnancy.  
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3.1.7 The importance of PBPK modelling in pregnancy antimalarial drug 
research 
Antimalarial clinical research aimed at addressing PK issues associated with 
antimalarial therapy like DDIs is not only ethically difficult but also very expensive. 
When studying the pharmacokinetics of antimalarial drugs in pregnancy, the effect of 
each physiological changes described earlier in a clinical setting may be difficult to 
ascertain. But PBPK modelling utilises virtual patients in whom there has been an 
extensive and robust validation of their capability to imitate real pharmacokinetic 
scenarios, therefore, studying how individual physiological variables may impact drug in 
such a manner that other cofounding factors are controlled, is feasible. Also, PBPK 
modelling has been successfully applied in many studies to describe the pharmacokinetics 
of drugs in pregnancy (134, 307, 308) hence there is an increasing confidence in the use 
of PBPK modelling to assess safety and efficacy of drugs in pregnancy, with a clear 
application of this technique to antimalarial agents during gestation. 
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3.2 Aims and objective 
3.2.1 Aim  
The aim of this study was to investigate the impact of changes in PQ plasma 
concentrations in the absence and presence of ARV-mediated DDIs in pregnant 
population groups from three malaria-endemic geographical regions (Thailand, Papua 
New Guinea and Sudan), such that changes in maternal physiology, biochemical and 
haematology were incorporated into the design of the population group.  
3.2.2 Objectives 
1. To develop and validate a PBPK model for PQ in non-pregnant and 
pregnant women 
2. To simulated PQ concentration time profiles in adapted virtual pregnant 
women and non-pregnant population groups.  
3. To simulate and validate ARV mediated DDI with efavirenz and ritonavir 
in pregnant and non-pregnant women 
4. To determine the impact of human albumin levels on the PQ day 7 
concentrations 
5. To study the impact of gestational weeks on the pharmacokinetics of PQ.  
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3.3 Methods 
All population based PBPK modelling was conducted using the virtual clinical trials 
simulator Simcyp® (Simcyp Ltd, a Certara company, Sheffield, UK, Version 16) using 
either a pre-validated in built “Healthy Volunteer” population group, a “Pregnancy” 
group, or an adapted “Pregnancy” population group. The adaptation of population group 
was done based on age for weight relationships and blood biochemistry peculiar to the 
population groups of interest. In all cases, population variability was accounted for by the 
inclusion of a variability metric (% coefficient variability) having been established from 
public health data bases such as the US National health and Nutrition Examination Survey 
(https://www.cdc.gov/nchs/nhanes/). 
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3.3.1 Study design 
A four-stage stepwise approach was employed for model development. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Diagrammatic representation of the work flow process of model development for the simulation of piperaquine 
pharmacokinetics in non-pregnant and pregnant women.
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3.3.1.1 Step 1: Base model development and validation 
Piperaquine physicochemical properties were obtained from the literature to create 
a drug compound file which was used to develop a model with the aim to recover the 
absorption, distribution and the elimination phases of the concentration time profiles 
observed from clinical studies and to simulate its maximum concentration (Cmax), area 
under the curve (AUC) and day 7 concentration under different dosing schedules.  Where 
some model parameters were not available in published studies, these were either 
predicted from the molecular descriptors of piperaquine or calculated from a clinical in 
vivo parameter when available using the Simcyp® retrograde calculator (see section 
2.3.1.1). Some model parameters were optimised using the Weighted Least Square 
(WLS) approach and the Nelder-Mead minimisation method on Simcyp® to produce 
parameters with better certainty, and which best recovered published clinical drug 
profiles. The parameters used to develop the base model are illustrated in Table 3.1 
The piperaquine model was developed and validated from two studies of PQ dosed 
in fasted Caucasian healthy volunteers (309, 310).  Given the high lipophilicity and 
expected wide-spread tissue distribution of PQ, a full PBPK model was employed for all 
model simulations.  As a result of a lack of published in vitro Caco-2 permeability 
measurements, molecular descriptors (hydrogen bond acceptors: HBA; polar surface 
area: PSA) were used to estimate the absorption rate constant (ka) (see equation 43 and 
equation 44). 
𝐾𝑎 =   
2 × 𝑃𝑒𝑓𝑓
𝑅
                                ( 44 ) 
where Peff  is the effective gut wall permeability and R the intestinal radius 
The ka and fraction of dose absorbed (fa) were then used to simulate the absorption 
phase using a first-order absorption model. This resulted in an initial estimate of 4.6 h-1 
and 0.99 for ka and fa respectively, however this was unable to capture an appropriate tmax 
for piperaquine (~6 hours) (309, 310). A single dose study in healthy volunteers has 
reported ka of 0.93 h
-1 (311), and was better able to capture an appropriate tmax.  These 
parameters were further estimated using a Weighted Least square fitting algorithm and a 
Nelder mead minimisation method to single dose fasted profiles reported by Sim et al 
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(2005) (310), yielding a final parameter estimate of 0.45 h-1 for ka and 0.5 for fa. Visual 
predictive checks identified that the absorption kinetics were still inadequately predicted, 
therefore, to account for the wide variability in PQ concentration around the expected tmax 
in reported clinical studies, the CV of ka and fa were set at 50 %.  This was better able to 
capture the range of data points within the 5th – 95th percentiles in our predictions.  For 
all simulation, we assumed that the PQP:PQ was 57.5 % and hence all dosing regimens 
reporting PQP were appropriately scaled to reflect the PQ base (100, 310). 
To recover the general shape of the distribution and elimination phases of the 
plasma-concentration time profiles, the volume of distribution (Vss) was estimated from 
published clinical data through empirically fixing the global tissue-partition coefficient 
Kp scaler to yield a Vss of 823 L/kg, the mean of 4 reported Vss from clinical studies (310, 
312-314).  
The availability of in vitro metabolic clearance data is limited for piperaquine with 
CYP3A4 identified as the major metabolic pathway and CYP2B6 playing a minor role 
(315).  It was therefore assumed that the major pathway would be CYP3A4 and an 
intrinsic clearance (CLint) was estimated using the retrograde calculation (see section 
2.3.1.1 ) with a fixed CLoral of 69.3 mL/min, the mean of 3 reported CL/F (and assuming 
F~1) (310, 313, 314), with CYP3A4 as the major isozyme and allocated 99 % of the total 
clearance (8.18 µL/min/pmol) with CYP2B6 allocated 1 % (0.37 µL/min/pmol) (315). 
Final estimates of CLint and Kp, for single dose healthy Caucasian subjects, were obtained 
from optimisation using datasets from Ahmed et al (2008) (309), yielding CLint3A4: 3.08 
µL/min/pmol, CLint2B6: 0.13 µL/min/pmol and Kp scalar: 13 (Vss: 820.5 L/kg). 
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Table 3.1: Input base model parameters values and predicted PBPK values used in  
the simulation of piperaquine.  
 
  
 
 
 
 
 
a Vss values was predicted on Simcyp® based on a default Kp scalar value of 1. b ka and 
fa were estimated from molecular descriptor – PSA 38.7 and HBD of 0 (PubChem). c CLpo 
was obtained by finding the average of three reported CL/F assuming F~1 (310, 313, 
314).d CLintCYP was based on a retrograde calculation, described in Step 1, with fa fixed at 
0.5 and FG assumed = 1.  Assumption that fmcyp of 0.99 and 0.01 for CYP3A4A and 
CYP2B6 respectively was made. fu: unbound fraction; B/P: blood-to-plasma ratio; Vss: 
steady state volume of distribution; ka: absorption rate constant; fa: fraction dose 
absorbed; CLpo: oral clearance; CLint: in vitro intrinsic clearance. 
3.3.1.2 Adaptation of age-weight relationships and blood biochemistry parameters 
in non-Caucasian females  
The ‘Healthy Volunteer’ (HV) population group within Simcyp® was adapted to 
address the differences in patient demographics (primarily body weight) and biochemistry 
(haematocrit/plasma proteins) between healthy-subjects and malaria-subjects. A custom 
age-body weight relationship was developed for studies based on the publication of 
growth references for malaria-endemic countries (283).  Median age-weight reference 
charts were used to establish polynomial mathematical relationships for age and weight 
using TableCurve 2D (Systat Software, San Jose, CA, USA), which were applied within 
Parameters Piperaquine 
Compound type Diprotic base 
Molecular weight (g/mol) 535.51(316) 
Log P  6.2 (317) 
Fu 0.014 (318) 
pKa 1 8.6 (317) 
pKa 2 6.5 (317) 
B/P 0.90 (318) 
Vss (L/kg) 63.2a 
ka (h
-1)  4.6b 
Fa 0.99
b 
Kp scalar 1 
CLpo (mL/min) 69.3
c 
CLint3A4 (µL/min/pmol)  8.18
d 
CLint2B6 (µL/min/pmol)
  0.37d 
Absorption model  First-Order 
Distribution model Full 
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the population ‘demographics’ section of Simcyp® to create user-defined age-weight 
relationships and, unless otherwise specified within clinical studies, were applied to an 
age range of 18-30 year olds for non-pregnant and pregnant female subjects only. 
In malaria population groups, it has been reported that a reduction in HSA is 
commonly detected (319), often coupled with a 3-4 fold increase in AAG (320).  To create 
a Malaria-type population group, we identified haematocrit, HSA and AAG levels in the 
3 population groups (Table 3.2) and revised these within our Simcyp® population group. 
3.3.1.3 Step 2: Simulation and validation of PQ in non-pregnant malaria 
population groups  
To assess the predictive performance of the model in non-Caucasian non-
complicated malaria population groups, four studies where PQ was dosed to non-pregnant 
females in Thailand (281, 313), Papua New Guinea (282) and Sudan (321) were used. 
Tarning et al 2008 (322) was excluded from this study due to the difficulty in obtaining 
individual data points for the study duration. Using the adapted subject population groups, 
each of the studies mentioned were simulated such that the demographic patient data in 
the actual clinical studies were maintained when possible during the simulation. Ten 
virtual trials involving 10 virtual subjects were implemented during the simulation.  
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Table 3.2: Malaria population versus healthy Caucasian blood biochemistry 
 
 
 
a Default values within Simcyp® North European Caucasian and Healthy Volunteer population groups.  M: male; F: female. b Assumed to 
be equivalent to Thai patients.c Calculated from haemoglobin (11.8 g/dL)reported in Benjanmin et al, 2015(282) and assuming the following 
relationship: haematocrit = 5.62 + 2.60 * haemoglobin reported in Senn et al. 2010 (327). d Value was assumed to be equivalent to Thai 
patient based on a similar range reported in children in Rosale et al, 2000 (328). We assumed the ‘worst-case’ scenario and selected the 
lowest HSA value. d Assumed to be equivalent to that of the Sudanese population group.
Biochemistry Caucasian a Sudan Thai PNG Uganda 
Haematocrit (%) M: 43  F: 38 M: 38.6 F: 40 (323) 37 (306) 35.78 c 31.8 (324) 
AAG (g/L) M: 0.811  F: 0.791 1.55 b 1.55 (325) 1.55 b 1.55d 
HSA (g/L) M: 34-50 F: 38-49 45.3 (326) 33.7 (306) 33.7 d 45.3d 
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3.3.1.4 Step 3: Simulation and validation of PQ model in pregnant malaria 
population groups 
The predictive performance of the model in non-Caucasian pregnant women with 
uncomplicated malaria population groups was assessed using four studies where PQ was 
dosed to pregnant females in Thailand (281, 313), Papua New Guinea (282) and Sudan 
(321). The corresponding adapted population groups were used during each simulation 
and the simulation involved 10 virtual subjects in 10 virtual trials and the demographic 
characteristics of the actual clinical study was maintained wherever possible during the 
simulation. 
3.3.1.5 Step 4: ‘What-If’ scenarios  
3.3.1.5.1 Efavirenz/Ritonavir-mediated drug-drug interactions 
To assess ‘What-If’ scenarios (Figure 3.1), case studies were included, in order to 
demonstrate the impact of possible drug-drug interactions (DDIs) mediated by efavirenz 
(EFV) or ritonavir (RTV); the former was selected due to the potential for CYP3A4 
induction and the latter for its CYP3A4 inhibitory effects. A recently published clinical 
study (329) that demonstrated a DDI between EFV and PQ in pregnancy was used to 
validate the ability of the PBPK model to predict DDIs, however, as there was no clinical 
data available for DDIs in between PQ and RTV in pregnancy, a successful simulation of 
DDI between PQ and EFV was assumed to mean successful simulation of PQ and RTV. 
It should be noted that this age-weight relationship was based on non-HIV co-infected 
subjects and therefore may not fully represent the age-weight distributions for co-infected 
subjects, however the  simulated weight range for this population group, 43.9 kg to 78.3 
kg (median: 56.2 kg), was within the range reported by Kajubi et al (2017) for subjects 
around gestational week 28 (329).  Hematocrit was fixed at 37.9 % in non-pregnant 
females and 31.7% in pregnant females (324) with AAG/HSA assumed to be equivalent 
to that of the Sudanese population group (Table 3.2). Model predictions for HIV-
uninfected non-pregnant (malaria) females and HIV uninfected pregnant (malaria) 
females in an adapted Ugandan female population were validated with the corresponding 
observed data as reported by Kajubi et al (2017) (329).  
3.3.1.5.2 Human serum albumin study 
Human serum albumin (HSA) concentrations were set at 20 g/L and 50 g/L within 
population groups, to mimic the reduction in serum albumin reported at different stages 
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of malaria infection, with 20 g/L representing severe malaria (330). The Simcyp® 
‘Pregnancy’ population includes a description for alterations in HSA during pregnancy 
and the baseline initial HSA concentration was fixed at the aforementioned 
concentrations. 
3.3.1.5.3 Gestational week 
The impact of gestation week on PQ pharmacokinetics during EFV/RTV-mediated 
DDI was assessed at weeks 10, 20 and 30 for all population groups.   
3.3.2 Predictive performance 
Although no uniform criterion has been accepted for defining an ‘optimal’ 
predictive performance range, a prediction to within 2-fold of the observed data is 
generally accepted in this context (227) and was employed as our criterion for Cmax and 
AUC comparisons to those clinically reported.  For EFV/RTV DDI simulation, as the 
clinical efficacy of PQ is determined by its day-7 concentration (post-first dose) of 30 
ng/mL (280), the impact of a DDI on PQ pharmacokinetics was assessed by direct 
analysis of the day-7 concentration. 
3.3.3 Data analysis 
Unless otherwise stated, all simulations of plasma concentration-time profiles were 
presented as arithmetic mean and 5 - 95th percentiles.  Reported concentration-time 
profiles from clinical studies were digitally retrieved using the WebPlotDigitizer v3.10 
(http://arohatgi.info/WebPlotDigitizer/) (229) and superimposed onto simulated profiles 
for visual predictive checks.   Where applicable, statistical analysis was conducted using 
paired t-tests or one-way ANOVA with a p < 0.05 indicating statistical significance. 
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3.4 Results  
3.4.1 Step 1a: Base model development  
The base model developed using drug physicochemical data obtained from 
published studies (Table 3.3) resulted in a concentration time profile which did not 
adequately recover the clinically reported concentration time profiles (Figure 3.2). The 
initial model development for healthy volunteer (HV) (Caucasian) subjects focussed on 
addressing model validation to recover appropriate absorption kinetics coupled with an 
appropriate prediction of steady state volume of distribution (Vss) and CYP3A4 and 
CYP2C8-mediated metabolic clearance.   
 
Figure 3.2:  The simulated plasma fasted single-dose concentration-time profile of 
500mg piperaquine in healthy-volunteers using the base model  
Simulation of PQ plasma concentration-time profiles following a single oral dose of 500 
mg PQP to 100 healthy volunteers using the base model. Observed data were obtained 
from Ahmed et al (2008) (309). Insert graphs illustrate plasma concentration profiles in 
the first 24-hours post-dosing. Open circles are observed mean points. Solid lines 
represent population mean prediction with dashed lines representing the 5th and 95th 
percentiles of prediction.
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Table 3.3: Parameter values for the optimised model and predicted PBPK values used 
in the simulation of piperaquine.  
a An appropriate Kp scalar was identified during base-model development (Step 1) and 
further empirically optimised using multi-dose studies described in Step 2.  Final Vss 
estimates are within the range reported for PQ (322, 331, 332). b CLpo was obtained by 
finding the average of three reported CL/F assuming F~1 (310, 313, 314).c CLintCYP was 
based on a retrograde calculation, described in Step 1, with fa fixed at 0.5 and FG assumed 
= 1.  Final estimates were obtained through parameter estimation assuming an fmcyp of 
0.99 and 0.01 for CYP3A4A and CYP2B6 respectively, using multi-dose studies 
described in Step 2. fu: unbound fraction; B/P: blood-to-plasma ratio; Vss: steady state 
volume of distribution; ka: absorption rate constant; fa: fraction dose absorbed; CLpo: oral 
clearance; CLint: in vitro intrinsic clearance. 
Parameters Piperaquine Notes 
Compound type Diprotic base  
Molecular weight (g/mol) 535.51(316)  
Log P  6.2 (317)  
Fu 0.014 (318)  
pKa 1 8.6 (317)  
pKa 2 6.5 (317)  
B/P 0.90 (318)  
Vss (L/kg) 947a Final optimised 
ka (h
-1)  0.50 50 % CV 
Fa 0.45 50 % CV 
Kp scalar 15 Final optimised 
CLpo (L/min) 69.3
b  
CLint3A4 (µL/min/pmol) 
f 3.08c Final optimised 
CLint2B6 (µL/min/pmol)
 f 0.13c Final optimised 
Absorption model  First-Order  
Distribution model Full  
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3.4.2 Step 1b: Optimised model for piperaquine in healthy volunteers 
(Caucasian) 
The resultant model was found to be appropriate to capture Cmax and tmax and 
resulted in a broadly consistent simulated Cmax (21.5 ng/mL ± 9.2 ng/mL), tmax (5.3 hours) 
and AUC (AUC0-24: 384.2 ng h/mL ± 145.9 ng h/mL; AUC0-last: 3207.3 ng h/mL ± 1121 
ng h/mL) when compared to Ahmed et al (309) (Cmax: 41.6 ng/mL ± 29.5 µg/L; tmax: 4.0 
hours; AUC0-24: 393 ng h/mL ± 149 ng h/mL; AUC0-last: 2312 ng h/mL ± 790 ng h/mL) 
(Figure 3.2) and Sim et al (310) (Cmax [range]: 21.0 µg/L [14-31.4 µg/L]; tmax: 6.8 hours 
[2.1-11.5 hours]; AUC0-last: 2818 µg h/L [1566-5070 µg h/L]) for a 500 mg PQP dose 
(Figure 3.3).   
For a higher 1500 mg PQP dose, PK parameters consistent with those reported in 
Ahmed et al (309) were predicted. In this study, Cmax (76.1 ng/mL ± 69 ng/mL), tmax (5.1 
hours) and AUC (AUC0-24: 1243 ng h/mL ± 193.8 ng h/mL; AUC0-last: 9065 ng h/mL ± 
1299 ng h/mL) were simulated when compared to Ahmed et al (309) (Cmax: 147 ng/mL ± 
110 µg/L; tmax: 2.5 hours; AUC0-24: 1418 ng h/mL ± 775 ng h/mL; AUC0-t: 6399 ng h/mL 
± 2067 ng h/mL) (Figure 3.4). These predictions implied successful model development 
in HV population groups for fasted single dose studies only.   
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Figure 3.3:  The simulated plasma fasted single-dose concentration-time profile of 500mg piperaquine in healthy-volunteers using the optimised 
model  
Simulation of PQ plasma concentration-time profile following a single oral dose of 500 mg PQP (open circles are observed mean points) to healthy 
volunteers (n=6). Observed data was obtained from Ahmed et al (2008) (309). (A) plasma concentration profiles during the simulated study period, (B) 
plasma concentration profiles in the first 24-hours post-dosing. Solid lines represent population mean prediction with dashed lines representing the 5th 
and 95th percentiles of prediction.  
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Figure 3.4:  The simulated plasma fasted single-dose concentration-time profile of 500mg piperaquine in healthy-volunteers using the optimised 
model.  
Simulation of the PQ plasma concentration-time profile following a single oral dose of 500 mg PQP to healthy volunteers (n=8). Observed data is 
represented by open circles and represents the 3 individual subject concentration-time points only that were reported by Sim et al (2005)(310) out of a 
total study size of 8 subject.  (A) plasma concentration profiles during the simulated study period, (B) plasma concentration profiles in the first 24-
hours post-dosing. Errors bars indicate reported range of Cmax (vertical red line) or tmax (horizontal red line) values. 
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Figure 3.5: The simulated plasma fasted single-dose concentration-time profile of 1500mg piperaquine in healthy-volunteers using optimised 
model  
Simulation of the PQ plasma concentration-time profile following a single oral dose of 1500 mg PQP (open squares are observed mean points) to 
healthy volunteers (n=6). Observed data were obtained from Ahmed et al (2008) (309). (A) plasma concentration profiles during the simulated study 
period, (B) plasma concentration profiles in the first 24-hours post-dosing. Solid lines represent population mean prediction with dashed lines 
representing the 5th and 95th percentiles of prediction. Errors bars indicate lower SD at Cmax for observed data. 
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3.4.3 Adaptation of age-weight relationship and blood biochemistry for non-
Caucasian females 
The following equations were used to adapt the age-weight relationships already 
in-built into Simcyp®. See section 3.3.1.2 for details on how the equations were derived. 
3.4.3.1.1 Thai females:  
The equation below was implemented on Simcyp® to derive an age-weight 
relationship was reflective of ideal age-weight relations in the Thai female population 
group 
Body weight = (6.03+0.197*age2+0.0012*age4)/(1+0.00127*age2+0.0000255*age4)  
( 45)  
It should be noted that the growth references charts published by Hayes et al (283), 
cover age range from 0-25 years of age.  Although minimal changes are expected between 
20-60 years of age, this model was applied to 20-50 year olds only, and this gave a mean 
(± SD) body weight of 49.65 ± 7.13 kg which was similar to the ranges reported in clinical 
studies (333), compared to the ‘Healthy Volunteer’ population (66.99 ± 14.41 kg) 
(simulated using a 10x10 trial design).  
3.4.3.1.2 Papua New Guinea females: 
The equation below was implemented on Simcyp® to derive an age-weight 
relationship that was reflective of ideal age-weight relations in the Papua New Guinea 
(PNG) female population group. 
Body weight = 3.53+((age*2.92)+(-0.48*age2)+(0.022*age3))/((1+-0.084*age)+(-
0.0014*age2)+(0.00025*age3))        ( 46 ) 
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For the PNG population group, age-weight data was not collated by Hayes et al 
(2015) (283) for this region, however the closest country (Solomon Islands) gives a 
similar weight range for 18-30 year old females as the range reported by Benjamin et al 
(2015) (282) (54.7 ± 7.2 kg), compared to the ‘Healthy Volunteer’ population group 
(66.67 ± 13.68 kg) for 18-30 year old females. As a result the Solomon Islands was used 
as a surrogate for age-weight distribution, resulting in a final weight range of 58.32 ± 12.2 
kg. 
3.4.3.1.3 Sudanese females: 
The equation below was implemented on Simcyp® to derive an age-weight 
relationship was reflective of ideal age-weight relations in the Sudan female population 
group. 
Body weight = (1.94+2.627*age0.5)+(-1.7086*age)+(0.245*age1.5))/(1+(-
0.658*age0.5)+(0.157*age)+(-0.017*age1.5)+(0.00088*age2))         ( 47 ) 
Age-weight data was not collated by Hayes et al (2015) (283) for Sudan, however 
the age-weight charts for Chad were used as a surrogate as these best matched the median 
body weight (53 kg) reported for the media age (21 years) in the reported study by 
Hoglund et al (2012) (321).  The simulated weight range for this population group 
(matching age-ranges to Hoglund et al  (2012) (321)) was under-predicted and the range 
was better recapitulated following an increase in the % CV assigned to the variability in 
body weight for female to 20 % (53.2 kg ± 14.46 kg). 
3.4.3.1.4 Ugandan females:  
The equation below was implemented on Simcyp® to derive an age-weight 
relationship that was reflective of ideal age-weight relations in the Ugandan female 
population group. 
Body weight = (2.759+(2.3*age) + (-0.344*age2) + (0.014*age3)) / (1+(-0.094*age ) + 
(0.000398*age2 ) + (0.000148*age3)).       ( 48 ) 
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It should be noted that this age-weight relationship was based on non-HIV co-infected 
subjects and therefore may not fully represent the age-weight distributions for co-infected 
subjects, however the  simulated weight range for this population group, 43.9 kg to 78.3 
kg (median: 56.2 kg), was within the range reported by Kajubi et al (2017) for subjects 
around gestational week 28 (329).   
The age-weight relationships between healthy Caucasian and non-Caucasian 
population groups involved in the study was found to be significantly different (Figure 
3.6-3.7).  
 
Figure 3.6: Weight comparisons between 25 years old female population groups 
based on Hayes et al study (283). 
Statistical comparison between weight of 25-year-old adults across three population 
groups. p < 0.01 : significant difference between three non- Caucasian population groups 
compared to healthy Caucasian population as  represented on Simcyp®. Std “HV”: 
Simcyp® health volunteer population. PNG: Papua New Guinea. 
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Figure 3.7: Age-weight relationship between Caucasian and subjects from three of 
population groups. 
Age-weight relationship of three population groups in malaria endemic regions compared 
to Simcyp® age-weight relationships in healthy Caucasian populations. Body weight was 
compared between three non-Caucasian virtual populations groups and healthy Caucasian 
subjects within Simcyp®.  Simulated non-Caucasian subjects had body weight adjusted 
based on the polynomial equations obtained from Hayes et al (2015). Comparison size 
was five hundred subjects between 20 year and 50 years of age.  Black triangles represent 
Healthy Caucasian population, red circle represent Thailand population (A), blue squares 
represent PNG population (B) and green cross represent Sudanese population (C). 
 169 
  
 
 Step 2: Validation of PQ model in non-Caucasian, non-pregnant malaria population 
groups  
To assess the predictive performance in multi-dose studies, three-population groups were 
developed for Thailand, Papua New Guinea and Sudan females based on published 
clinical studies within these groups, under conditions of standard multi-dose regimens (10 
mg/kg PQ base once daily for 3 days). 
For all population groups, the majority of predicted parameters (Table 3.4) fell within 2-
3-fold of the reported metrics (Table 3.5). Simulated concentration time profiles 
adequately recovered the concentration time points reported for the Thailand population 
groups in the Rijken et al (2011) (Figure 3.8 ) (313) and Tarning et al (2012) (281) (Figure 
3.9) studies, the PNG population groups in Benjamin et al (2015) (282) (Figure 3.10) and 
the Sudan population groups in Hoglund et al (2012) (321) (Figure 3.11).  
Notable however, for the Thailand population group, the predicted increase in 
median Cmax following each dose was only moderately correlated with that reported by 
Rijken et al (2011) (313) (Figure 3.8).  However, the clinical end-point marker of 
successful antimalarial therapy (day 7 concentration) (280) were all simulated (Table 3.4) 
to within 2-fold of the reported clinical measures (Table 3.5), in addition to day 14 and 
day 28 concentrations.  
Furthermore, the model predictions were also able to capture the differences in day 
7 concentration across population groups, despite similar dosing strategies, e.g. Thai 
24.74 ng/mL (4.42-64.93 ng/mL) vs. Sudanese 34.0 ng/mL (6.8-86.7 ng/mL) population 
groups.  A one-way ANOVA indicated statistical differences in the median day 7 
concentrations, when comparing all 4 predicted population studies, with the Sudanese 
population group demonstrating a statistically higher median Cmax (p = 0.0415) compared 
to the other population groups. This highlighted the successful creation of sub-population 
groups. 
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Figure 3.8: The simulated plasma fasted multi-dose concentration-time profile of piperaquine in non-pregnant adapted Thailand 
malaria-female subjects.  
Multidose simulations of PQ (10 mg/kg base once daily for 3 days) were conducted on virtual Thailand malaria-non-pregnant female 
population groups as detailed in Rijken et al, (2011) (313), adapted from the ‘Healthy Volunteer’ population group with Simcyp® with 
adaptations to the age-weight relationships and blood biochemistry and matching (where possible) the clinical trial design (subject numbers 
and age range) within Simcyp®. Crosses indicate observed data obtained from reported individual subject plasma concentration-time profile 
lines. The solid lines represent population median predictions with the dashed lines/shaded area representing the 5th and 95th percentiles of 
prediction.  (A) the concentration time profile throughout the study period as reported in referenced study, (B) plasma concentration profiles 
in the first three days post-dosing.  
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Figure 3.9: The simulated plasma fasted multi-dose concentration-time profile of piperaquine in non-pregnant adapted Thailand 
malaria-female subjects.  
Multidose simulations of PQ (10 mg/kg base once daily for 3 days) were conducted on virtual Thailand malaria-non-pregnant female 
population groups as detailed in Tarning et al (2012) (281), adapted from the ‘Healthy Volunteer’ population group with Simcyp® with 
adaptations to the age-weight relationships and blood biochemistry and matching (where possible) the clinical trial design (subject numbers 
and age range) within Simcyp®. Open circles indicate observed data obtained from reported individual subject plasma concentration-time 
profile lines. The solid line represent population median predictions with the dashed lines/shaded area representing the 5th and 95th percentiles 
of prediction.  (A) the concentration time profile reported throughout the study period as reported in referenced study, (B) plasma 
concentration profiles in the first three days post-dosing. 
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Figure 3.10: The simulated plasma fasted multi-dose concentration-time profile of piperaquine in non-pregnant adapted Papua New 
Guinea (PNG) malaria-female subjects.  
Multidose simulations of PQ (10 mg/kg base once daily for 3 days) were conducted on virtual PNG malaria-non-pregnant female population 
groups as detailed in Benjamin et al (2015) (282), adapted from the ‘Healthy Volunteer’ population group with Simcyp® with adaptations 
to the age-weight relationships and blood biochemistry and matching (where possible) the clinical trial design (subject numbers and age 
range) within Simcyp®. Open circles indicate observed data obtained from reported individual subject plasma concentration-time profile 
lines. The solid lines represent population median predictions with the dashed line/shaded area representing the 5th and 95th percentiles of 
prediction.  (A) the concentration time profile reported throughout the study period as reported in referenced study, (B) plasma concentration 
profiles in the first four days post-dosing. 
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Figure 3.11: The simulated plasma fasted multi-dose concentration-time profile of piperaquine in non-pregnant adapted Sudan 
malaria-female subjects.  
Multidose simulations of PQ (10 mg/kg base once daily for 3 days) were conducted on virtual Sudan malaria-non-pregnant female population 
groups as detailed in Hoglund et al (2012) (321), adapted from the ‘Healthy Volunteer’ population group with Simcyp® with adaptations to 
the age-weight relationships and blood biochemistry and matching (where possible) the clinical trial design (subject numbers and age range) 
within Simcyp®. The open circles indicate observed data obtained from reported individual subject plasma concentration-time profile lines. 
The solid lines represent population median predictions with the dashed line/shaded area representing the 5th and 95th percentiles of prediction.  
(A) plasma concentration time profile throughout the study period, (B) plasma concentration profiles in the first three days post-dosing. 
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Table 3.4: Simulated PQ pharmacokinetics in non-Caucasian non-pregnant females 
  
 Thailand PNG Sudan 
 Rijken Tarning Benjamin Hoglund 
 Median (range) Median (range) Median (range) Median (range) 
Cmax 1
st (ng/mL) 66.1 (17.2-182) 64.6 (18.7-189) 87.7 (20.8-216) 92.2 (25.11-262) 
Cmax 2
nd (ng/mL) 85.3 (21.23-242) 88.2 (23.74-252) 116 (25.8-292) 117 (30.71-338) 
Cmax 3
rd (ng/mL) 98.5 (23.9-281) 99.2 (24.2-285) 135 (29.3-343) 135 (34.51-389) 
Tmax 1
st (h) 4.8 (2.9-6.5) 4.8 (2.8-6.1) 4.7 (2.9-6.5) 3.8 (2.2-5.0) 
Tmax 2
st (h) 4.6 (2.6-6.0) 4.6 (2.5-6.3) 4.7 (2.7-6.1) 3.6 (2.2-4.8) 
Tmax 3
st (h) 4.6 (2.6-7.6) 4.6 (2.7-7.2) 4.4 (2.7-6.1) 3.6 (2.2-4.8) 
AUC0-24 (ng/mL.h) 998 (240-2831) 993 (248-2825) 1372(297-3467) 1261 (318-3679) 
AUC24-48 (ng/mL.h) 1409 (324-4075) 1429 (332-4108) 1968 (405-5064) 1790 (436-5254) 
AUC 48-72 (ng/mL.h) 1712 (384-4946) 1762 (381-4995) 2378 (479-6176) 2194 (521-6384) 
AUC 0-∞ (ng/mL.h)   21715 (4463-53646) 35201 (304-74181) 
Day 7 Conc. (ng/mL)  24.7 (4.42-64.9) 25.1 (4.21-65.1) 29.2 (5.31-80.9) 34.0 (6.8-86.7) 
Day 14 Conc. (ng/mL) 17.0 (3.17-41.6) 16.8 (3.22-42.9) 18.8 (3.67-49.9) 24.2 (5.3-54.9) 
Day 28 Conc. (ng/mL) 12.0 (2.34-26.3) 11.6 (2.23-27.3) 11.70 (2.05-26.8) 17.5 (4.02-38.7) 
Half-life (d) 27.3 (21.3-40.9) 28.5 (20.8-39.8) 18.3 (16.1-23.6) 32.1 (21.6-43.3) 
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Table 3.5: Literature reported PQ pharmacokinetics in non-Caucasian non-pregnant females 
    a Half-life is reported as a range or median
 
Thailand PNG Sudan 
Rijken Tarning Benjamin Hoglund 
Median (range) Median (IQR) Median  (range) Median (range) 
Cmax 1
st (ng/mL)  216 (139–276)  102 (40.6-235) 
Cmax 2
nd (ng/mL) 71.6 (10.1–239)    
Cmax 3
rd (ng/mL) 136 (13.6–393)    
Tmax (h) 245 (53.4–798)    
Tmax 1
st (h)  3.04 (2.36–4.13)  1.48 (0.887-4.18) 
Tmax 2
st (h)     
Tmax 3
st (h)     
AUC0-24 (ng/mL.h) 869 (157–2940)    
AUC24-48 (ng/mL.h) 1710 (167–4740)    
AUC 48-72 (ng/mL.h) 2750 (500–8280)    
AUC 0-∞ (ng/mL.h) 24100 (2750–60900) 23400 (17400–35100) 35644 (29546–39541) 38000 (12400–100000) 
Day 7 Conc. (ng/mL)  25.9 (6.80–56.6) 22.7 (17.6–32.8)   
Day 14 Conc. (ng/mL) 16.7 (2.24–59.2)   55.4 (16.6-146) 
Day 28 Conc. (ng/mL) 9.17 (5.14–47.6) 10.3 (8.06–14.9)  15.4 (4.85-38.6) 
Half-life (d)a 8.88-24.9 16.2-19.4 15.9 19.1-25.8 
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3.4.4 Step 3: Validation of PQ model in non-Caucasian, pregnant malaria 
population groups 
The PBPK model was further adapted to evaluate PQ pharmacokinetics in non-
Caucasian pregnant population groups (Figure 3.12-3.15).  For all population groups, the 
majority of predicted parameters (Table 3.6) fell within 2-fold of the reported metrics 
(Table 3.7), with predictions of the median day 7, 14 and 28 concentrations all simulated 
to with 2-fold of the reported clinical measures (Table 3.7).  These predicted point 
markers were not significantly different from those for non-pregnant subjects (p > 0.05) 
(Tables 3.4-3.5). Also, to investigate any difference in the concentration time profile and 
pharmacokinetic parameters of PQ at different stages of pregnancy, the concentration 
time profile at different gestational ages was compared and found to be largely similar 
throughout pregnancy (Figure 3.16).  
A one-way ANOVA indicated statistical differences in the median day 7 
concentrations, when comparing all 4 predicted population studies, with the Sudanese 
population group demonstrating a statistically higher median Cmax (p = 0.0392) compared 
to the other population groups (Table 3.6).  However, when comparing non-pregnant to 
pregnant population groups, no significant difference in the median day 7 concentration 
was identified for each population. Further, predicted half-life in pregnancy population 
groups were significantly different (p < 0.01 for all population groups) from those in non-
pregnant population groups (Table 3.4). This highlighted the successful creation of sub-
population group.
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Figure 3.12: The simulated plasma fasted multi-dose concentration-time profile of piperaquine in adapted Thailand pregnant malaria 
subjects  
Multidose simulations of PQ (10 mg/kg base once daily for 3 days) were conducted on virtual pregnant women from Thailand with 
malaria as detailed in Rijken et al, 2011 (313), adapted from the ‘Healthy Volunteer’ population group with Simcyp® with adaptations to 
the age-weight relationships and blood biochemistry and matching (where possible) the clinical trial design (subject numbers and age range) 
within Simcyp®. (A) the concentration time profile reported throughout the study period (B) plasma concentration profiles in the first three 
days post-dosing. Solid lines (green: non-pregnant [for comparison]; red: pregnant) represent population median predictions with the dashed 
lines/shaded area representing the 5th and 95th percentiles of prediction. Crosses indicate observed data obtained from reported individual 
subject plasma concentration-time profile lines.  
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Figure 3.13: The simulated plasma fasted multi-dose concentration-time profile of piperaquine in pregnant adapted Thailand malaria-
female subjects.  
Multidose simulations of PQ (10 mg/kg base once daily for 3 days) were conducted on virtual pregnant women from Thailand with 
malaria as detailed in Tarning et al., 2012 (281), adapted from the ‘Healthy Volunteer’ population group with Simcyp® with adaptations to 
the age-weight relationships and blood biochemistry and matching (where possible) the clinical trial design (subject numbers and age range) 
within Simcyp®. (A) illustrates the concentration time profile reported throughout the study period study, (B) plasma concentration profiles 
in the first three days post-dosing. Solid lines (green: non-pregnant [for comparison]; red: Open circles indicate observed data obtained from 
reported individual subject plasma concentration-time profile lines. 
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Figure 3.14: The simulated plasma fasted multi-dose concentration-time profile of piperaquine pregnant adapted Papua New Guinea 
(PNG) malaria-female subjects.  
Multidose simulations of PQ (10 mg/kg base once daily for 3 days) were conducted on virtual pregnant women from PNG with malaria 
as detailed in Benjamin et al, 2015 (282), adapted from the ‘Healthy Volunteer’ population group with Simcyp® with adaptations to the age-
weight relationships and blood biochemistry and matching (where possible) the clinical trial design (subject numbers and age range) within 
Simcyp®.   (A) illustrates the concentration time profile reported throughout the study period, (B) plasma concentration profiles in the first 
four days post-dosing. Solid lines (green: non-pregnant [for comparison]; red: Open circles indicate observed data obtained from reported 
individual subject plasma concentration-time profile lines. 
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Figure 3.15: The simulated plasma fasted multi-dose concentration-time profile of piperaquine in pregnant adapted Sudan malaria-
female subjects.  
Multidose simulations of PQ (10 mg/kg base once daily for 3 days) were conducted on virtual Sudan malaria-pregnant female 
population as detailed in Hoglund et al., 2012 (321), adapted from the ‘Healthy Volunteer’ population group with Simcyp® with adaptations 
to the age-weight relationships and blood biochemistry and matching (where possible) the clinical trial design (subject numbers and age 
range) within Simcyp®. (A) illustrates the concentration time profile reported throughout the study period, (B) plasma concentration profiles 
in the first three days post-dosing. Solid lines (green: non-pregnant [for comparison]; red: Open circles indicate observed data obtained from 
reported individual subject plasma concentration-time profile lines. 
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Figure 3.16: Simulated median PQ plasma concentration-time profiles during gestation 
Multi-dose simulations of PQ (10mg/kg base once daily for 3 days) for simulations in a representative population group (Thai) (n=30) across 
gestational weeks 7 to 37. The dashed line represents the day-7 concentration determination point. The Thailand population was chosen as a 
representative of the other population groups as the same pattern of pharmacokinetics is expected for all three population groups.  
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Table 3.6: Simulated piperaquine pharmacokinetics in non-Caucasian pregnant females 
 
 
 Thailand PNG Sudan 
 
Rijken 
Median (range) 
Tarning 
Median (range) 
Benjamin 
Median (range) 
Hoglund 
Median (range) 
Cmax 1
st (ng/mL) 70.4 (33.5-153) 72.4 (31.9-168) 89.5 (38.2-175) 92.9 (41.0-202) 
Cmax 2
nd (ng/mL) 90.5 (46-205) 86.2 (50.6-214) 118 (25.8-238) 117 (55.6-263) 
Cmax 3
rd (ng/mL) 103 (53.9-237) 109 (53.54-264) 137 (62-277) 132 (65.3-303) 
Tmax 1
st (h) 4.8 (2.9-7.7) 4.6 (3.1-7.9) 5.1 (2.9-8.2) 4.3 (2.6-6.9) 
Tmax 2
st (h) 4.6 (2.9-6.9) 4.9 (2.9-7.0) 4.8 (2.9-7.2) 4.1 (2.6-6.5) 
Tmax 3
st (h) 4.6 (2.9-6.9) 4.8 (2.8-7.1) 4.6 (2.9-6.9) 4.1 (2.6-6.2) 
AUC0-24 (ng/mL.h) 1036 (565-2429) 1135 (537-2532) 1399 (681-2850) 1249 (112-2974) 
AUC24-48 (ng/mL.h) 1450 (770-3482) 1424 (779-3599) 2002 (938-4127) 1745 (932-4229) 
AUC 48-72 (ng/mL.h) 1736 (913-4196) 1811 (965-4202) 2408 (1110-4977) 2425 (1114-5108) 
AUC 0-∞ (ng/mL.h)   21633 (8383-42238) 30067 (15267-84201) 
Day 7 Conc. (ng/mL)  25.9 (10.9-52.6) 24.2 (11-53.1) 29.6 (12.2-57.7) 34.0 (15.1-70.6) 
Day 14 Conc. (ng/mL) 19.1 (7.88-39.5) 19.9 (8.24-40.1) 20.2 (7.89-38.8) 26.1 (11.3-56.5) 
Day 28 Conc. (ng/mL) 14.4 (5.63-31.2) 15.1 (5.91-39.9) 13.6 (4.82-27.2) 20.1 (7.94-45.6) 
Half-life (d) 19.4 (18.7-35.4) 19.9 (18.7-35.7) 26.3 (16.7-39.2) 24.7 (14.9-27.2) 
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Table 3.7: Literature reported piperaquine pharmacokinetics in non-Caucasian pregnant females 
a Half-life is reported as a range or median 
 Thailand PNG Sudan 
 Rijken Tarning Benjamin Hoglund 
 Median  (range) Median (IQR) Median  (range) Median (range) 
Cmax 1
st (ng/mL)  291 (194–362)  185 (109–363) 
Cmax 2
nd (ng/mL) 138 (39.3–328)    
Cmax 3
rd (ng/mL) 201 (58.2–455)    
Tmax (h) 309 (138–575)    
Tmax 1
st (h)  3.14 (2.84–3.84)  3.07 (1.65-4.64) 
Tmax 2
st (h)     
Tmax 3
st (h)     
AUC0-24 (ng/mL.h) 1480 (506–3270)    
AUC24-48 (ng/mL.h) 2400 (734–4400)    
AUC 48-72 (ng/mL.h) 3660 (1160–5010)    
AUC 0-∞ (ng/mL.h) 29200 (11600–41800) 27400 (21000–32400) 23721 (21481–27951) 42700 (27100–68700) 
Day 7 Conc. (ng/mL)  31.8 (13.3–80.2) 28.8 (23.6–34.6)  60.7 (40.1-103) 
Day 14 Conc. (ng/mL) 19.5 (7.76–49.3)    
Day 28 Conc. (ng/mL) 10.7 (3.70–31.4) 10.3 (9.18–14.4)  16.1(9.68-26.8) 
Half-life (d)a 4.78-39.9 22-26.1 20.3 20.9-33.3 
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3.4.5 Step 4: ‘What-If’ scenarios 
3.4.5.1 Validation of DDI simulation between piperaquine and efavirenz in 
pregnancy  
To evaluate and validate the impact of ARV on PQ systemic exposure, the only 
known study (to-date) which investigated the impact of ARV (efavirenz) on PQ systemic 
exposure in Ugandan pregnant women (329) was replicated, following creation of a 
Uganda pregnancy-malaria population group where EFV was orally dosed at 600 mg once 
daily. Model predictions for HIV-uninfected non-pregnant (malaria) females (Figure 
3.17A) and  HIV uninfected pregnant (malaria) females (Figure 3.17B) demonstrated the 
successful development of a Uganda population group with model predictions within the 
range reported by Kajubi et al (2017) (329) (Table 3.8), showing a predictions of day 7, 
14 and 21 concentrations to within 2-fold of the reported concentrations.  Concentrations 
for HIV-infected pregnant (malaria) females (Figure 3.17C) were slightly over-predicted 
(Table 3.8) in terminal elimination phases, and this may be a result of physiological 
alternatives during HIV-infection which were not explicitly incorporated into our 
‘Malaria’ population group.  Comparison of all three profiles (Figure 3.17D) showed that 
the HIV-infected pregnant (malaria) subjects had the lowest piperaquine exposure 
relatively. Further, in all simulations the Cmax per dosing day was under-predicted.  As 
simulations were run under fasted-conditions, this under-prediction may be attributed to 
the reported clinical studies not restricting food intake during the study period.  
The predicated day 7, 14 and 21 PQ concentrations were all within 2-fold of that 
reported by Kajubi et al (2017)  (329), with a similar approximate 50 % decrease in the 
predicted mean day 7 concentrations (No EFV: 20.5 ng/mL; EFV: 9.2 ng/mL) (Table 
3.8). Furthermore, our predicted AUC0-21 was within 2-fold of that reported by Kajubi et 
al (2017) (this study: 0.51; Kajubi: 0.62).
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Figure 3.17 : Simulated plasma concentration-time profile of piperaquine in pregnant women in the presence of interaction with 
efavirenz.  
Multi-dose simulations of PQ (960 mg PQP once daily for 3 days) were conducted in (A) HIV-uninfected non-pregnant (malaria) females; 
(B) HIV uninfected pregnant (malaria) females. PQ dosing was started on day 25 of a once daily dosing of efavirenz which was simulated 
over 60 days. Solid lines represent median with shaded areas representing 5th-95th percentile range. Open circles represent observed median 
data points with error bars indicted SD. 
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Figure 3.17 (cont.): Simulated plasma concentration-time profile of piperaquine in pregnant women in the presence of interaction with 
efavirenz.  
Multi-dose simulations of PQ (960 mg PQP once daily for 3 days) were conducted in (C) HIV-infected pregnant (malaria) females treated 
with EFV from day 1 to day 60; (D) Comparison of median plasma concentration-time profiles for the three simulated groups. PQ dosing 
was started on day 25 of a once daily dosing of efavirenz for which was simulated over 60 days. Solid lines represent median with shaded 
areas representing 5th-95th percentile range. Open circles represent observed median data point with error bars indicted SD.  
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Table 3.8:  Predicted and observed day 7, 14 and 21 piperaquine concentrations in the absence and presence of a EFV-mediated DDI 
 
 
Data represents median (range). EFV: efavirenz. 
 During Pregnancy Non-Pregnant 
 HIV-uninfected (no EFV) HIV-infected (EFV) HIV-uninfected (no EFV) 
Observed Cd7 (ng/mL) 30.5 (25.9-36) 15.1 (13-17.6) 39 (32.3-47.2) 
Predicted Cd7 (ng/mL) 20.5 (9.1-54.3) 9.2 (3.1-33.4) 23.7 (9.9-51.2) 
Observed Cd14 (ng/mL) 15 (12.4-18.1) 6.67 (5.44-8.19) 22.6 (18.7-27.3) 
Predicted Cd14 (ng/mL) 11.9 (8.2-16.3) 5.2 (1.25-22.1) 16.5 (7.1-44.9) 
Observed Cd21 (ng/mL) 11.8 (5.7-39) 3.75 (2.77-5.08) 14.5 (12.2-17.1) 
Predicted Cd21 (ng/mL) 10.1 (4.2-32.5) 3.47 (1-15.8) 14.2 (6.2-41.2) 
 188 
  
3.4.5.2 The impact of change in HSA on the extent of ART-DDIs 
In all population groups (absence and presence of a DDI), simulations were 
conducted in 100 virtual subjects. An increase in HSA from 20 g/L to 50 g/L significantly 
increased the median day 7 (total) plasma concentration of PQ (Figure 3.18-3.20).  This 
was associated with a significant increase in the number of subjects with a day 7 
concentration > 30 ng/mL in the absence of an ART (Thailand: 8 to 45, p = 0.007 (Figure 
3.18); PNG: 11 to 53, p = 0.00009 (Figure 3.19); Sudan: 9 to 49, p = 0.0006) (Figure 
3.20), and in the presence of EFV (Thailand: 7 to 48, p = 0.006 (Figure 3.18); PNG: 4 to 
24, p = 0.0003 (Figure 3.19); Sudan: 1 to 16, p = 0.0005 (Figure 3.20)) or RTV (Thailand: 
41 to 80, p = 0.0009 (Figure 3.18); PNG: 49 to 85, p = 0.0008 (Figure 3.19); Sudan: 47 
to 80, p = 0.00003(Figure 3.20)). 
Additionally, the presence of EFV or RTV significantly reduced or increased, 
respectively, the day 7 PQ concentration across all population groups, however the overall 
impact of the HSA were broadly similar under different DDI conditions (Figure 3.18-20).  
This resulted in a similar number of subjects attaining a day 7 concentration ≥ 30 ng/mL 
except for the Sudanese population with a EFV-mediated DDI, where a statistically 
significant difference in the median day 7 concentration across the three population 
groups was identified (one-way ANOVA, p = 0.0023)
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Figure 3.18: The impact of changes in human serum albumin concentrations on the 
piperaquine median day 7 concentration in the absence and presence of an EFZ or 
RTV-mediated DDI 
Multi-dose simulations of PQP (10 mg/kg base once daily for 3 days) were conducted 
100 pregnant women from Thailand with malaria. The human serum albumin 
concentration was fixed at 20 g/L or 50 g/L.  EFV (600 mg once daily) (red bars) or RTV 
(100 mg twice daily) (green bars) were orally dosed throughout the simulation time period 
(30 days) with piperaquine dosed on days 10, 11 and 12. Dashed lines indicate the 30 
ng/mL clinical efficacy cut-off. Numbers above the box and whisker are median values 
and the number (n) of subjects with a predicted concentration of over 30 ng/mL is 
indicated. Vertical drop-lines indicated statistical comparisons between 20g/L or 50 g/L 
simulations. Asterisks above the maximum bar indicate statistical significance when 
compared to black (no DDI) simulations. ** p ≤ 0.01; *** p ≤ 0.001.  
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Figure 3.19: The impact of changes in human serum albumin concentrations on the 
piperaquine median day 7 concentration in the absence and presence of an EFZ or 
RTV-mediated DDI 
Multi-dose simulations of PQP (10 mg/kg base once daily for 3 days) were conducted in 
100 pregnant women from PNG with malaria. The human serum albumin concentration 
was fixed at 20 g/L or 50 g/L.  EFV (600 mg once daily) (red bars) or RTV (100 mg twice 
daily) (green bars) were orally dosed throughout the simulation time period (30 days) 
with piperaquine dosed on days 10, 11 and 12. Dashed lines indicate the 30 ng/mL clinical 
efficacy cut-off. Numbers above the box and whisker are median values and the number 
(n) of subjects with a predicted concentration of over 30 ng/mL is indicated. Vertical 
drop-lines indicated statistical comparisons between 20g/L or 50 g/L simulations. 
Asterisks above the maximum bar indicate statistical significance when compared to 
black (no DDI) simulations. *** p ≤ 0.001; **** p ≤ 0.0001. 
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Figure 3.20: The impact of changes in human serum albumin concentrations on the 
piperaquine median day 7 concentration in the absence and presence of an EFZ or 
RTV-mediated DDI 
Multi-dose simulations of PQP (10 mg/kg base once daily for 3 days) were conducted on 
100 Sudan pregnant female with malaria. The human serum albumin concentration was 
fixed at 20 g/L or 50 g/L.  EFV (600 mg once daily) (red bars) or RTV (100 mg twice 
daily) (green bars) were orally dosed throughout the simulation time period (30 days) 
with piperaquine dosed on days 10, 11 and 12. Dashed lines indicate the 30 ng/mL clinical 
efficacy cut-off. Numbers above the box and whisker are median values and the number 
(n) of subjects with a predicted concentration of over 30 ng/mL is indicated. Vertical 
drop-lines indicated statistical comparisons between 20g/L or 50 g/L simulation. 
Asterisks above the maximum bar indicate statistical significance when compared to 
black (no DDI) simulations. *** p ≤ 0.001; **** p ≤ 0.0001. 
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3.4.5.3 The impact of gestation on the extent of an ART-mediated DDI 
In the absence of ART-mediated DDIs, the median predicted day 7 concentration 
was broadly consistent across all gestational weeks investigated (Thailand: 20.2-21.2 
ng/mL; PNG: 22.5-23.5 ng/mL); Sudan: 25.1-26.2 ng/mL) and demonstrated no 
significant difference across gestational weeks within the same population group (Figure 
3.21-3.23). 
In the presence of EFV, a significant decrease in PQ day 7 concentrations (p < 
0.0001) was simulated across all gestational weeks within each population group 
(Thailand: 9.8-11.3 ng/mL; PNG: 13.2-21.5 ng/mL; Sudan: 15.4-18.3 ng/mL), except for 
gestational week 40 with the PNG population group (Figure 3.21-23).  In the presence of 
RTV, a significant increase in PQ concentrations (p < 0.0001) was simulated across all 
gestational weeks within each population group (Thailand: 34.2-37.9 ng/mL; PNG: 40.7-
42.2 ng/mL; Sudan: 41.3-46.1 ng/mL).  Furthermore, a trend in increasing median day 7 
concentration with increasing gestational week was observed for all population groups, 
although this was not statistically significant (Figure 3.21-3.23).
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Figure 3.21: The impact of changes in gestational week on median day 7 PQ 
concentration in the absence and presence of a DDI mediated by EFZ (induction) or 
RTV (inhibition).  
Multidose simulations of PQP (10 mg/kg base once daily for 3 days) were conducted on 
100 Thailand pregnant female with malaria (over gestational weeks (GW) 10, 20, 30 and 
40. Interaction perpetrators – EFV (600 mg once daily) or RTV (100 mg twice daily) 
were co-administered) were orally dosed throughout the simulation time period (30 days) 
with PQ dosed on days 10, 11 and 12. Box and whisker plots represent minimal, 25th 
percentile, median, 75th percentile and maximum values.  Dashed lines indicate the 30 
ng/mL clinical efficacy cut-off. Numbers above the box and whisker are median values 
and the number (n) of subjects with a predicted concentration of over 30 ng/mL is 
indicated. Horizontal drop-lines indicate statistical comparisons between each GW in the 
absence and presence of the ART. **** p ≤ 0.0001. 
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Figure 3.22: The impact of changes in gestational week on median day 7 PQ 
concentration in the absence and presence of a DDI mediated by EFZ (induction) or 
RTV (inhibition).  
Multidose simulations of PQP (10 mg/kg base once daily for 3 days) were conducted on 
100 PNG pregnant female with malaria (over gestational weeks (GW) 10, 20, 30 and 40. 
Interaction perpetrators – EFV (600 mg once daily) or RTV (100 mg twice daily) were 
co-administered) were orally dosed throughout the simulation time period (30 days) with 
PQ dosed on days 10, 11 and 12. Box and whisker plots represent minimal, 25th percentile, 
median, 75th percentile and maximum values.  Dashed lines indicate the 30 ng/mL clinical 
efficacy cut-off. Numbers above the box and whisker are median values and the number 
(n) of subjects with a predicted concentration of over 30 ng/mL is indicated. Horizontal 
drop-lines indicate statistical comparisons between each GW in the absence and presence 
of the ART. **** p ≤ 0.0001. 
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Figure 3.23: The impact of changes in gestational week on median day 7 PQ 
concentration in the absence and presence of a DDI mediated by EFZ (induction) or 
RTV (inhibition).  
Multidose simulations of PQP (10 mg/kg base once daily for 3 days) were conducted on 
100 Sudan pregnant female with malaria (over gestational weeks (GW) 10, 20, 30 and 
40. Interaction perpetrators – EFV (600 mg once daily) or RTV (100 mg twice daily) 
were co-administered) were orally dosed throughout the simulation time period (30 days) 
with PQ dosed on days 10, 11 and 12. Box and whisker plots represent minimal, 25th 
percentile, median, 75th percentile and maximum values.  Dashed lines indicate the 30 
ng/mL clinical efficacy cut-off. Numbers above the box and whisker are median values 
and the number (n) of subjects with a predicted concentration of over 30 ng/mL is 
indicated. Horizontal drop-lines indicate statistical comparisons between each GW in the 
absence and presence of the ART. **** p ≤ 0.0001. 
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3.4.5.4 The changes in clearances and AUCs in the presence and absence of 
interaction across gestational weeks.  
Using the Thailand population as a representative population group, the possibility 
of changes in oral/hepatic clearance and AUC during gestation was simulated. There was 
a statistical difference (p<0.0001) between the oral clearance estimates in the presence 
and absence of an interaction (Figure 3.24), similarly, there was a statistical difference 
(p<0.0001) between the hepatic clearance estimates in the presence and absence of an 
interaction (Figure 3.24). However, when clearance and AUC comparisons in the 
presence or absence of interaction was made to identify any difference across the 
gestational weeks, there was no statistical difference.  Further, the AUC from the last dose 
to the end of simulation in the absence of interaction was similar throughout pregnancy 
as there was no significant difference between the estimated parameters.  As expected, 
the AUC ratio between aforementioned AUC estimates the in the absence and presence 
of interaction with EFV and RTV was below 1 and above 1 respectively but was largely 
consistent throughout gestational weeks (Figure 3.25).  The impact of HSA on the hepatic 
clearance during pregnancy is summarised in Table 3.9   which showed that hepatic 
clearance was consistently higher in patients with severe malaria compared with healthy 
patients in the presence or absence of DDIs.
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Figure 3.24: Variation in intrinsic hepatic and oral clearance parameters in the 
absence and presence of ART-mediated DDIs 
Comparison of the oral clearance (A) and hepatic intrinsic clearance (B) of piperaquine 
in pregnant representative Thailand subjects administered piperaquine alone and in 
combination with efavirenz or ritonavir. GW: gestational weeks. The simulation was done 
in twenty five subjects per GW. 
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Figure 3.25: Variation in AUC (A) and AUCratio (B) in the absence and presence of 
ART-mediated DDIs 
The AUC between the last dose of piperaquine administered and the specified gestation 
weeks (A), and AUC ratios (B) of piperaquine alone and in the presence of interaction 
with efavirenz or ritonavir in pregnant representative Thailand subjects. GW: gestational 
weeks. The simulation was done in twenty-five subjects per GW. 
 
  
  
1
9
9
 
 
 
 
 
Table 3.9: Impact of changes in human serum albumin on hepatic clearance in the absence and presence of a efavirenz or ritonavir 
mediated drug-drug interaction for a representative population group (Thailand non-pregnant). 
 
 
a Pre-defined fixed mean human serum albumin (HSA) concentration. 
b Simcyp® simulated population median HSA concentration 
Data represented as median ± standard deviation 
Healthy: Healthy Volunteer population group; CLH: hepatic clearance; fuplasma: unbound fraction in plasma; HSA: human serum albumin. 
  
  
No DDI Efavirenz Ritonavir 
Healthy 20 g/L a 50 g/L a Healthy 20 g/L 50 g/L Healthy 20 g/L 50 g/L 
CLh (L/h) 8.4 ± 4.5 16.2 ± 6.9 7.1 ± 3.8 33.9 ± 10.9 46.9 ± 10.3 29.9 ± 9.4 2.6 ± 1.3 5.1 ± 2.4 1.9 ± 0.9 
fuplasma 
0.0139 ± 
0.0014 
0.0368 ± 
0.0037 
0.0135 ± 
0.0013 
0.0138 ± 
0.0016 
0.0375 ± 
0.0032 
0.0136 ± 
0.0014 
0.0137 ± 
0.0016 
0.0381 ± 
0.0031 
0.0138 ± 
0.0014 
HSA (g/L) b 45.3 ± 4.5 16.7 ± 1.7 46.8 ± 4.7 45.7 ± 4.7 16.6 ± 1.7 47 ± 4.6 45.2 ± 4.6 16.9 ± 1.7 47.2 ± 4.6 
 200 
  
3.5 Discussion  
The treatment of malaria in special populations, such as pregnant women and young 
children, is complicated by the ‘moving-target’ nature of such population groups and their 
associated reduced immune function with which to resist the individual impact and spread 
of malaria.  Attempting to address the problem of antimalaria treatments in malaria 
endemic areas requires careful consideration of the disease pathophysiology in those 
population groups which may in turn impact upon the efficacy endpoint of the 
antimalarial treatment.  With the aid of PBPK modelling techniques, these factors can be 
investigated separately to suggest the effect specific impacts can make on antimalarial 
therapy clinically.  Hence, the applied 4-stage workflow model (Figure 3.1) was aimed at 
developing and validating a PBPK model to assess the pharmacokinetics of PQ during 
pregnancy, as well as under conditions of altered serum albumin (mimicking severe 
malaria), and during potential DDIs; these were mediated by common ARTs available for 
use in pregnant women (efavirenz and ritonavir). 
3.5.1 Model development 
Despite the advantages of PBPK/mechanistic modelling, the application of 
modelling approaches to the prediction of plasma concentration profiles has largely been 
based around systems-parameters derived from Caucasian healthy subjects.  The base 
model development in step 1 followed this similar approach, but only to identify and 
optimise parameters for single dose PQ studies.  A common feature of many antimalarials 
is the large variability in absorption kinetic processes, represented by a highly variable 
Cmax, and it was important to capture this, where possible (49, 310, 314, 334). To this end, 
in the absence of appropriate in vitro Caco-2 derived passive permeability (Papp) measures 
for PQ, we applied a first-order absorption model with final estimates of 0.50 for fa and 
0.45 h-1 for ka which were able to recover the Cmax and tmax compared to the single-dose 
studies (Figure 3.3-3.5). However, to capture the range of reported values (e.g. Cmax: 14-
31.5 µg/L and tmax:  2.1-11.7 h) a 50 % CV was applied.  It should be noted that an 
inclusion of a transit absorption model, such as the Simcyp® ADAM module, may 
improve predictions (281) but the lack of appropriate in vitro permeability measures 
makes this less attractive over a first order model.  The development of the base model 
was successful for single dose studies.   
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Malaria is endemic in developing countries and this is reflected by the availability 
of reported clinical studies we identified where PQ was administrated to pregnant and 
non-pregnant women from studies conducted with subjects from Thailand (281, 313), 
Sudan (321) and Papua New Guinea (282). Application of the ‘Healthy-Volunteer’ 
population group to simulate PQ pharmacokinetics would not be appropriate given the 
difference in adult age across these geographic regions (335) and therefore custom age-
weight relationships (283) were generated for each population group to develop non-
pregnant and pregnant populations from these regions, which incorporated alterations in 
blood parameters (haematocrit, human serum albumin and alpha-1-acidic glycoprotein) 
(Table 3.2).  Changes in haematological biochemistry are also common in malaria and it 
plays a major role in pathogenesis (336-338). From a pharmacokinetic perspective, such 
changes are likely impact upon the blood:plasma ratio, but more importantly the unbound 
fraction, a key driver for the prediction of clearance, Vss and the DDIs. 
The development of appropriate systems-based population groups, specific to the 
study design is important and highlighted by the stark differences in body weights 
compared to the ‘Healthy Volunteer’ population.  Using the customised age-weight 
relationships for malaria population body weight for Thai (49.7 ± 7.1 kg), PNG (58.3 ± 
12.2 kg) and Sudan (53.2 kg ± 14.5 kg) were generally consistent and significant 
difference (p < 0.01) from a standard ‘Healthy Volunteer’ population group giving an 
average weight of 66.7 ± 13.1 kg (Figure 3.6). Also, Figure 3.7 illustrates the distribution 
of age-weight relationships between healthy Caucasians and the three non-Caucasian 
population groups. As dosing for many AMT is based on body weight, this may have a 
direct effect on the dose administered and the resultant determination of endpoint 
concentrations (339, 340), particularly considering dosing in many developing countries 
is based on age as a surrogate for body weight, in situations where weight facilities are 
unavailable. 
Further, the inclusion of potential alterations in biochemistry- based changes during 
pregnancy or because of a disease state are important if they are thought to directly impact 
upon the resultant pharmacokinetics of AMT.  Haematological alterations are common in 
malaria and a marker of the severity of malaria is often determined from changes in serum 
albumin. Equally, albumin binding is a direct driver for the free fraction of drugs, and any 
alterations in this may directly impact upon drug distribution and metabolic pathways.  
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Indeed, the stark difference in HSA in Sudanese (45.5 g/L) and Thai (33.7 g/L) 
individuals illustrates this difference across population groups (Table 3.2). 
3.5.2 Model simulations and validation. 
For the three population groups developed, model predictions of key 
pharmacokinetic metrics were within 2-fold of those reported and illustrate the successful 
prediction of PQ in non-pregnant (Table 3.4-3.5) (Figure 3.8-3.11) and pregnant women 
(Table 3.6-3.7; Figure 3.12-3.15).  Notably, no significant differences in key 
pharmacokinetic parameters, including day 7 concentrations, were observed between 
non-pregnant or pregnant population groups, suggesting the systemic exposure of PQ is 
relatively unchanged between the two groups and concurs with other reports of 
unchanged PQ pharmacokinetics in non-pregnant and pregnant populations (281, 313, 
341).  However, model predictions were less successful at predicting the interindividual 
variability in the range of Cmax for population groups for each dosing period (Figure 3.8-
3.15).   This may be partially due to  poor control of food intake during the trial study, 
e.g. Tarning et al (2012) (281),   but may also be a feature of the sparse collection points 
around the expected Cmax for each dosing day compared to the much richer collection 
over the longer elimination phases (281).  Further, the larger predicted Cmax for each 
dosing period could be a result of the splanchnic blood flow (as a result of increased 
cardiac output) seen in pregnancy (342), and which is altered using ‘Pregnancy’ 
population groups in Simcyp®, and hence represents a slight increase in the 
bioavailability of PQ (281). 
3.5.3 Drug-drug interaction predictability of the model 
During pregnancy, the activity of CYP3A4 is also known to increase (343), directly 
impacting upon the metabolic clearance of any CYP3A4 substrates.  In our simulations, 
increasing gestational week had a noticeable impact of the terminal elimination of the PQ 
(Figure 3.15A), as quantified by a decrease in the terminal elimination half-life of PQ 
during pregnancy populations (Table 3.6) compared to non-pregnancy populations (Table 
3.4). 
Having established a working PBPK for PQ in pregnant females, the importance of 
the risk of DDIs was next assessed.  The only existing study assessing the risk of DDI 
with PQ and antiretroviral (efavirenz) was recently published by Kajubi et al (329), and 
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demonstrated a 40% reduction in AUC0-21d along with a 50 % reduction in day-7 
concentrations, highlighting the potential risk EFV-mediated DDIs pose, and our model 
was able to recapitulate these changes (Figure 3.17A-D).  As EFV is known to induce 
CYP3A4, the reduction in AUC and day-7 concentration is likely to be a result of this 
effect (344). Further, this effect would be augmented by the induction of CYP3A4 itself 
during pregnancy, as noted for other drugs (295, 342), and therefore would likely reduce 
day-7 concentrations below the clinical efficacy end-point of 30 ng/mL (280).  Indeed, 
our model simulation demonstrated the impact of this in non-pregnant, pregnant and 
pregnant +EFV populations, demonstrating the additive effect of EFV-mediated DDI and 
pregnancy-related induction of CYP3A4 expression (Figure 3.17A-D). 
3.5.4 The impact of blood biochemistry on the PQ pharmacokinetics when 
co-administered with DDI perpetrators during pregnancy. 
Although pregnancy has been associated with a reduction in haematological 
parameters, e.g. human serum albumin (decrease by 1% at week 8 and 12% at week 32 
(345)), the impact of such changes on the pharmacokinetics of highly bound drugs is not 
well characterised in malaria infected subjects.  Further, as demonstrated by the 
development of specific populations, the overall haematological levels are often reduced 
in such populations.  It has also been speculated that P. falciparum plays a major role in 
proteolysis of albumin (346, 347).  Further, previous reports have demonstrated alteration 
in fuplasma for quinine (348) and halofantrine (349) during the progression of malaria.  In 
attempting to assess the impact of potential changes in human serum, albumin on the 
overall extent of ARV-mediated DDIs (via assessing change in PQ day 7 concentration), 
we set the HSA concentration to 20 g/L (severe malaria) and 50 g/L (healthy subjects).  
In all cases (absence and presence of an ARV) and in all population groups, the change 
from 20 g/L to 50 g/L had a direct impact on day 7 concentrations, leading to a statistically 
significant increase (Figure 3.18-3.20).  For all population groups developed, the 
reduction in HSA to 20 g/L, generally resulted in a statistically significant increase in PQ 
fuplasma (p < 0.001) which subsequently propagated to an increase in the hepatic clearance 
(p < 0.001), when compared to compared to healthy volunteer population groups.  This 
trend was also demonstrated under conditions of efavirenz/ritonavir exposure when 
compared to non-DDI studies (see Table 3.9 for representative illustration in the Thailand 
non-pregnant population).  The impact of this combined reduction in baseline HSA 
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concentration in malaria population coupled with the pregnancy-related reduction in HSA 
is important considering as it can directly impact upon the elimination of the drug. 
As expected, the impacts of EFV and RTV on day 7 concentrations were in-line 
with their function as CYP3A4 inducer (EFV) and inhibitors (RTV) resulting in a direct 
effect on day-7 concentration (Figure 3.21-3.23).  A reduction in AMT concentrations as 
a result of induction will lead to parasite recrudescence, as has been demonstrated for 
lumefantrine (350, 351), dihydroartemisinin (180) and piperaquine (329).  Further, 
piperaquine is known to prolong QTc in a concentrations dependant manner (352), and 
increased concentrations following inhibition of metabolic clearance may potentially lead 
to QTc prolongation, as demonstrated with an adapted 2-day treatment with DHA-PQ 
(353). 
3.5.5 The impact of gestational weeks on the pharmacokinetic of PQ when 
co-administered with DDI perpetrators during pregnancy. 
Physiological changes during gestation can result in significant changes in plasma 
volume, CYP expression and cardiac output (295, 342), it would therefore be expected 
that significant changes in the pharmacokinetics would occur during pregnancy.  We 
explored the impact of gestation on the predicted day-7 concentrations in the three 
pregnancy population groups. 
In all three populations, the baseline median day 7 concentration was consistent 
across all population groups and with increasing GW, approximately 20-26 ng/mL, with 
no significant differences when GW increased (Figure 3.21-3.23).  Given the long half-
life of PQ, the impact of gestation on day 7 concentrations may not be significantly 
noticeable.  However, CYP3A4 activity is thought to increase during pregnancy, reaching 
a peak at approximately week 20-24 (354-356).  When considering the Thai population 
as an example, at baseline, GW20 corresponded with the lowest median day-7 
concentration and highest hepatic CLint (week 17-27) (Figure 3.24B).  However, the 
impact of this may be negligible given the long half-life and large volume of distribution 
of PQ (282, 313, 324, 341).                                                       
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3.5.6 The impact of pregnancy on the AUC and clearance of PQ in the 
presence of interaction 
When ARVs were concomitantly dosed with PQ, statistically significant decreases 
(efavirenz) or increases (ritonavir) in PQ median day-7 concentrations were predicted, in-
line with the role of EFV and RTV as inducer/inhibitors of CYP3A4 expression.  
Surprisingly, there were no significant difference across GW for either ARV, suggesting 
the magnitude of the DDI would be similar, irrespective of the gestation period of the 
mother.  Further, when considering the Thai population as an example, although each 
ARV resulted in a significant change in the hepatic CLint in the absence of ARV and 
presence of ARV, no significant differences across gestational weeks were simulated 
(Figure 3.24B).  Similarly, although each ARV resulted in a significant change in the oral 
CL in the absence of ARV and presence of ARV, no significant differences across 
gestational weeks were simulated (Figure 3.24A).  The resultant AUCratio (last dose-to-
end) in the presence of EFV was consistent across GW 7 to 27 but increased to 0.72 at 
GW 37  (Figure 3.25A-B). Similarly, inhibition results in an AUCratio across GW 7 to 27 
which decreased to 1.64 at GW 37 (Figure 3.25A-B).   
3.5.7 Population variation impact on the PQ pharmacokinetics in pregnant 
women.   
The median day 7 concentration in the absence and presence of an ARV-mediated 
DDI was consistently higher in the Sudanese population compared to Thai and PNG 
populations, and this can be attributed to the lower body-weight corrected doses 
administered to Thai subjects (Table 3.9) coupled with the higher HSA concentrations in 
Sudanese populations (Table 3.9).  Thus, although the impact of ARV on PQ 
pharmacokinetics in pregnancy may lead to treatment failure or an increase in the adverse 
effects, the overall effect and magnitude of the DDI during pregnancy is largely minimal, 
with little change in day-7 concentrations. 
It should be noted that in the population groups developed, only the age-weight 
relationships and haematological parameters were the changes reflecting changes 
observed predominantly in malaria-infected subjects.  Genetic polymorphisms in 
CYP2B6 are common (357-359) and may impact upon the clearance of EFV and hence 
its ability to elicit a DDI, and CYP2B6 population-based polymorphic changes were not 
incorporated into our customised population groups. Further, changes in the abundance 
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of CYP-isozymes across population groups have also not been incorporated and this may 
enable better predictions of the terminal elimination phases for PQ across population 
groups (360).  It should also be noted that only one previous study reported PQ metabolic 
pathways (315) and our assumption of the fraction metabolised by CYP3A4 and CYP2B6 
of 0.99 and 0.01, alongside parameter estimated CLint, may be optimised at a later date 
with in vitro metabolic clearance data to enhance the application of the model, when such 
data becomes available. 
3.5.8 Study challenges 
The complexity of diseases states which can present differently depending upon the 
disease progress, as is common with malaria and HIV (361), would dictate that the 
developed population groups should address these different stages of disease progression.   
Finally, the studies used for validation utilised two DHA-PQ combination formulation 
regimens, Eurartesim® (Sigma-Tau, Rome, Italy) or Artekin® (Holleykin Pharmaceutical 
Co., Guangzhou, China). However only Eurartesim® has gained Good Manufacturing 
Practice compliance, having being developed without the Medicines for Malaria Venture 
(MMV) (362).  Therefore, batch-to-batch variability in the manufacture of the Artekin® 
fixed-dose combination tablet, may lead to variability in disintegration/dissolution 
process resulting in altered absorption kinetics and this should be considered in the 
context of further validation of the absorption kinetics of the model development. Finally, 
estimates of PQ in vitro Caco-2 permeability are currently lacking and therefore this 
precludes the application of the Simcyp® Advanced Dissolution, Absorption and 
Metabolism (ADAM) model, to appropriately model the biopharmaceutic processes in 
greater mechanistic detail. The modelling of the absorption phase of PQ pharmacokinetics 
may therefore be improved when such information becomes available. In the ADAM 
model, more complex processes occurring during the absorption of drug molecules from 
the gut are accounted for. This might involve the simulation of the absorption of drugs 
from immediate release and modified or controlled release dosage forms or the simulation 
of the metabolic and transporter DDIs in the small intestine. The ADAM model therefore 
enables credible simulation of gut absorption, transport, metabolism and interaction 
(115). 
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3.6 Conclusion  
The present PBPK model provides the ability to mechanistically predict the 
pharmacokinetics of PQ in non-pregnant and pregnant women, whilst also considering 
possible population differences in malaria-HIV co-infected subjects.  The present model 
demonstrated that PQ pharmacokinetics in pregnancy was relatively unchanged, 
compared to non-pregnant women and that the impact of ART-mediated DDIs can 
significantly alter the PQ pharmacokinetics, the magnitude of which was generally 
consistent across GW.  Further adaptions of the model presented are warranted and would 
require further detailed collation of relevant physiological and biochemical alterations 
common to HIV/malaria patients and which would further enhance the clinical 
application of the proposed model.
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PBPK optimisation of chloroquine 
dosing for the treatment of Zika 
Virus disease during pregnancy 
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4.1 Introduction 
First isolated in an infected Ugandan monkey in 1947 (363) Zika virus (ZIKV), is 
a single stranded RNA Flavivirus transmitted to its host via bites from various Aedes 
species mosquito and is similar to the dengue virus (364). An epidemic of the disease 
broke out in Yap Island in 2007 and was later known to have been reported in French 
Polynesia between 2013 and 2014 and was followed by a spread to the parts of the 
Americas around 2015 (363, 365) . With cases reported in recent times in several 
countries across the world, the spread of ZIKV disease may now be referred to as a 
pandemic (363). In 2014, cases of Zika virus infection were found in countries from 
Africa, Asia, the Americas and the Pacific (365), while currently the Pan American Health 
Organisation (PAHO) and the World Health Organisation (WHO) report that aside from 
the states within the USA where there are cases  autochthonous cases of ZIKV disease, 
48 other Central and South American countries have now become affected by the 
transmission of the disease. There have been a total of 3720 cases of congenital syndrome 
associated with the infection  (48). During the epidemic in Brazil in 2015, there were 
about 440,000-1,300,000 estimated cases as at December 2015 (366). Due to the non-
specific and asymptomatic nature of the infection, a detailed worldwide prevalence has 
proved difficult to report, however, the Centers for Disease Control and Prevention 
(CDC)  also report that excluding congenital disease cases, between January 2015 and 
May 2018, there had been 5700 symptomatic cases of ZIKV disease in the USA and 
37,229 cases in US territories (367). ZIKV has an incubation period thought to be between 
three and 12 days. A key symptom of the disease is a maculopapular rash in the face, 
palm, sole and trunk which is expected to be seen within seven days of infection and 
infection may last for weeks. Other symptoms of the disease include fever, joint pain, 
conjunctivitis and retroocular headache and usually resolve in one week (368-370). 
4.1.1 Health implications of Zika virus disease 
Though ZIKV may be a mild infection owing to the fact that in about 80 % of cases, 
the disease results in no hospitalisation or deaths, an acute inflammatory 
polyradiculoneuropathy known as Guillian-Barre syndrome, is a complication and can 
consequently cause weakness and reduced reflexes in victims (368, 370). Another rather 
disturbing fact about the infection is its ability to cross the placenta and bring about 
congenital anomalies such as microcephaly and other ophthalmologic abnormalities in 
the foetus. In Brazil, an unusual spike in the incidence of microcephaly by early 2016 was 
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reported involving 270 confirmed cases of microcephaly in the foetus and this was 
thought to be attributed to the outbreak Zika virus at around mid-2015 (371, 372).  
Twenty seven out of 35 infants born with microcephaly involved in a Brazilian 
study exhibited severe microcephaly. Findings in the study revealed that all 35 mothers 
in the study had habited to different extents, areas where cases of ZIKV had been existent 
during their pregnancy and all their infants had not tested positive for any other congenital 
infection (366). ZIKV RNA was found to be present in the placenta and foetal tissue as 
well as the amniotic fluid of mothers with new-borns during the outbreak of the disease 
in Brazil (366, 372). Therefore, a major concern for ZIKV virus disease has over time 
drifted toward the foetus as these are more prone to the consequences of the disease.  
4.1.2 Treatment options of Zika virus disease 
Presently, work is underway to develop new vaccines or treatment for ZIKV disease 
as there are currently none. The potential for new and already existing pharmacological 
agents to be used to treat or prevent ZIKV disease is being explored. For instance, 
interferon (IFN) have been studied by various groups for their effectiveness in treating 
ZIKV. Contreras et al (2016), showed via a ZIKV cultivated in vitro cell culture system 
that IFN-a, IFN b and IFNy inhibit viral replication (373), also another group of 
researchers demonstrated that ZIKV growth is inhibited in trophoblastic and non-
trophoblastic cells when the production of IFN-gamma 1 is stimulated (374). 
Nanchangmycin, a polyether originating from the Streptomyces nanchangensis was 
screened and found to inhibit ZIKV replication abilities, however further research is 
required to further validate its clinical efficacy (375).  
Another potential anti-ZIKV agent, Obatoclax, a broad spectrum antiviral agent 
with probable antineoplastic properties, has been shown to prevent the endosomal fusion 
of ZIKV in in vitro systems and may be considered as a prophylactic option for ZIKV 
(376). A natural product, Cavinafungin has also recently been found to possess an 
inhibitory effect against the ZIKV due to its ability to inhibit the endoplasmic reticulum 
signal peptides of the host in in vitro systems (377). Similarly, 25-hydroxycholesterol has 
been discovered to inhibit ZIKV entry into the host in a mouse and rhesus macaque study 
(378). Cial et al (2017) demonstrated that other agents like ribavirin and favipiravir 
reduce ZIKV induced cell death (379). There are tens of other agents which have been 
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studied in in vitro or in in vivo mouse models but the major concern about them are their 
safety in humans and in pregnancy (380).  
4.1.3 Chloroquine as a potential anti-Zika virus agent 
In a study by Delvecchio et al (2016), it was demonstrated that the antimalarial 
agent chloroquine provides protection to the human brain microvascular endothelial and 
neural stem cells in addition to mouse neurospheres by inhibition of the ZIKV (381). 
Chloroquine is potentially an efficacious inhibitor of the ZIKV disease, this potential 
coupled with the fact that its safety profile as an antimalarial and anti-rheumatoid arthritis 
agent is widely documented makes it stands out as a good candidate for repurposing in 
the prevention of ZIKV disease. 
Chloroquine (CQ) was first developed for the treatment of different forms of 
malaria but is currently recommended for the treatment of Plasmodium vivax malaria 
infection due to wide-spread resistance by the common Plasmodium falciparum malaria. 
In addition to it antimalarial benefits, it has been used as a suppressant of autoimmune 
disorders like rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (382).  
CQ is almost totally absorbed following oral administration. A study showed that in the 
fasted condition and in subjects who took the drug orally, 89% of the drug was absorbed 
(383). There is conflicting data about the effect of food on oral absorption. While one 
study suggests that gastrointestinal absorption of CQ is not altered in the presence of food 
(384), another study reports that maximum concentration (Cmax) and exposure (area under 
the curve (AUC)) of CQ were significantly higher following administration of 600 mg of 
CQ to 7 healthy volunteers who had received a standard breakfast (385). A separate study 
suggested that the intake of CQ with local Sudanese beverages decreased the Cmax and 
AUC of CQ phosphate administered to the subjects in the study. The author of this study 
explained that the acidic beverages might have ionised CQ in the gut thereby reducing its 
absorption (386).  
It is worthy of note that oral absorption can show between 30-100% variability among 
subjects and this might be influenced by certain health conditions, for example in cases 
of malnutrition (387-389). CQ is well distributed in the body and its plasma steady state 
volume of distribution (Vss) has been reported to be between 204 and 800 L/kg (390) with 
plasma protein binding of about 60% (391). With a long half-life of about 20-60 days 
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(383), CQ is both renally and hepatically excreted from the body with both routes 
contributing equally to its excretion. An average of 55% is excreted unchanged in the 
urine while CYP 2C8, 3A4 and 2D6 are the main metabolising pathways in the liver 
(392).    
4.1.4 Chloroquine safety during pregnancy 
Though the efficacy of chloroquine for the treatment of malaria is now mainly 
acknowledged for vivax malaria due to development of resistance to the falciparum 
strains, its safety profiles remains satisfactory in pregnant and non-pregnant subjects at 
doses used for malaria, SLE and RA. The use of chloroquine as an oral antimalarial dates 
as far back as 1984 (393), and in 1985, Wolfe et al (1985) demonstrated that there was 
no significant teratogenic consequences of chloroquine used by pregnant women to their 
foetus (394). They showed that among the 169 births from women who had received 300 
mg weekly of chloroquine for malaria during their pregnancy, there was no significant 
difference in birth defects between these women and those who has not received, the 
treatment. Infants born to the majority of pregnant women with RA and SLE who 
received, in their first trimester up to 250 daily doses of CQ for long periods of time prior 
to and during pregnancy or a 500 mg daily dose for up to three days during early 
pregnancy, did not develop adverse conditions due the use of CQ in their mothers (35). 
Another study showed that compared to pregnant women who received quinine treatment 
during pregnancy, there was no significant difference in the mean gestational age; 
stillbirths and rates of abortion in 130 pregnant women who received 25 mg/kg of CQ for 
three days in their first trimester of treatment for vivax malaria during pregnancy (395). 
Similarly, in 634 Thai pregnant women, treatment of malaria vivax with 25 mg/kg CQ 
for three days resulted in no foetal anomalies in infants born to them (396).  
In this current study, a pharmacokinetic modelling approach will be used to estimate 
the level of exposure following current dosage regimens of CQ to the foetus while a 
prospective   approach to assess dosage regimen options that will ensure adequate foetal 
exposure will be explored.
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4.2 Aims and objectives 
4.2.1 Aims 
The aim of this chapter was to use PBPK techniques to optimise the dosing of oral 
chloroquine for the treatment of ZIKV disease in pregnant women. 
4.2.2 Objectives 
1. To develop and validate a PBPK model for CQ in non-pregnant and pregnant 
women. 
2. To determine an effective and safe systemic concentration of CQ for prevention 
of ZIKV. 
3. To propose a dosing schedule of CQ for the treatment of ZIKV disease in 
pregnant women. 
4. To determine the impact of different stages of pregnancy on the attainment of 
safe and therapeutic concentrations of CQ for the treatment of ZIKV disease in 
pregnant women 
5. To determine the appropriate length of administration of CQ to produce the 
required exposure to ensure protection against ZIKV disease in pregnant 
women.  
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4.3 Methods 
The virtual clinical trial simulator Simcyp® (Simcyp® Ltd, a Certara company, 
Sheffield, UK, Version 17) was used to create all the population based PBPK models used 
in this study through the implementation of a pre-validated ‘Healthy Volunteer’ (HV) 
population.  For simulations requiring the use of pregnant subjects, we utilised the 
Simcyp® ‘Pregnancy’ population group (297, 307, 397), which incorporates gestational-
phase dependant physiological changes associated with pregnancy that may alter the 
pharmacokinetics of drugs such as a change in blood volume and organ/tissue blood 
flows; change in enzyme/protein expressions (297, 398-402). 
A 3-stage workflow model was utilised and is detailed in Figure 4.1.  We adopted 
a robust validation approach utilising 16 clinical studies for CQ, a summary of which is 
described in Table 4.1 and Table 4.2.  Further, unless otherwise stated, population sizes 
used in validation steps simulations and those utilised within Steps 3 included a 10x10 
trial design with 100 subjects
   
2
1
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4.3.1 Study design 
Three stages of model development and validation were followed as depicted below 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: A workflow of the processes involved in the development and validation of the  chloroquine model and optimisation of CQ dosing for 
Zika virus disease
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4.3.1.1 Step 1: Development and validation of the base model of CQ in non-
pregnant Caucasian 
CQ physicochemical parameters were obtained from published studies. Where 
some model parameters where not available in published studies, these were either 
predicted from the molecular descriptors of chloroquine or back calculated from a clinical 
in vivo parameter when available using the Simcyp® retrograde calculator (section 
2.3.1.1). In the process of model development and validation of a CQ model the model 
was optimised to adequately recover the general shape of the plasma concentration-time 
profiles and accurately predict pharmacokinetic parameters of CQ in non-pregnant 
populations. Where the initial model did not appropriately recover pharmacokinetic 
phases and parameters as reported in clinical studies, a parameter estimation methodology 
was employed on Simcyp® with the Weighted Least Square (WLS) approach and the 
Nelder-Mead minimisation method. To determine the effect of final optimised parameter 
on the final predicted outcomes, a sensitivity analysis was done.  
Model development utilised a total of 13 clinical studies reporting CQ 
pharmacokinetics across a range of Caucasian and non-Caucasian population groups 
(Table 4.1).  These studies incorporated both single and multiple dose studies for CQ 
model development and validation. All modelling was conducted within the Simcyp® 
Simulator (Version 17).  
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Data represented as: range, median (range) or mean ± SD. *: Caucasian and Black American, N: number of subjects 
Table 4.1: Summary of single and multiple dose studies used in the validation of CQ pharmacokinetics in non-pregnant subjects 
Study N Ethnic group 
Age 
(Years) 
Weight 
(kg) 
Gender 
(M/F) 
Dosing regimen 
Sampling 
matrix 
Mzayek et al 
(2007)(403) 
24 Mixed* 28.7 ± 5.3 75.8 ± 18.6 M, F 600 mg (single oral) Blood 
Gustaffson et al 
(1983)(404) 
11 Caucasian 20 – 36 65 - 91 M 300 mg (single oral) Plasma 
Najmi et al 
(2008)(405) 
10 Pakistani 33.5 66 M 600 mg (single oral) Plasma 
Höglund et al 
(2016)(406) 
75 Thai 17 – 52 NR M, F 
10 and 5 mg/kg at 0 and 6–12 h on 
day 0, and 5 mg/kg each on day 1 
and day 2 
Plasma 
Karunajeewa et al 
(2010)(407) 
30 Papuan 25.5 ± 8.9 51.8 ± 5.5 F 450 mg once daily for 3 days Plasma 
Tanariya et al 
(1995)(408) 
57 Thai 26.4 ± 8.7 56.4 ± 7.1 M, F 
600 mg initially, followed by 300 
mg at hours 6, 24 and 48 hours) 
Blood 
Na-Bangchang et al 
(1994)(409) 
7 Thai 18 – 35 45 – 68 M 
600 mg initially, followed by 300 
mg at hours 6, 24 and 48 hours) 
Blood 
Chukwuani et al 
(2004)(410) 
5 Nigerian 23 – 37 56 – 66 F 600 mg (single oral) Plasma 
Lee et al (2008)(411) 13 Thai 29 (15 - 40) 46 ± 4.9 F 
10, 10, and 5 mg/kg given at 0, 24, 
and 48 hours 
Blood 
Bustos et al 
(2002)(412) 
11 Filipino 35 (13 - 63) 60 (40-63) M, F 
10 and 5 mg/kg at 0 and 6 hours on 
day 0, and 5 mg/kg each on day 1 
and day 2 
Plasma 
Wetsteyn et al 
(1995)(413) 
5 Caucasian 41 64 ± 10 M, F 300 mg weekly for 3 weeks Plasma 
Frisk-Holmberg et al 
(1984)(414) 
5 Caucasian 37 - 42 72 ± 8 M, F 
150 mg (single oral); 300 mg (single 
oral); 600 mg (single oral) given to 
each subject on 3 separate occasions 
Blood 
Walker et al 
(1987)(413)  
8 Nigerian 19 – 55 53 – 66 M, F 600 mg (single oral) Plasma 
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4.3.1.2 Step 2: Development and validation of a CQ model in pregnant subjects 
For simulations involving pregnant women, the non-pregnant CQ model was 
revised to incorporate a full PBPK distribution model, which allows for consideration of 
gestation-phase dependant changes in maternal physiology (398, 399, 401, 402) for 
pharmacokinetic modelling studies (297, 307, 397). To recover the distribution phase 
profile, an appropriate volume of distribution (Vss) was empirically fixed at the mean of 
the range reported in literature studies utilising pregnant subjects (407, 411, 415), 
following by parameter estimation using a Weighted Least Square (WLS) method and the 
Nelder-Mead minimisation approach. This optimised CQ model was subsequently 
validated utilising three clinical studies, details of which can be found in Table 4.2. 
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Table 4.2:  Summary of single and multiple dose studies used in the validation of CQ pharmacokinetics in pregnant subjects 
 
 
Data represented as: range, mean (range) or mean ± SD 
Study 
Number of 
subjects 
Ethnic 
group 
Age 
(Years) 
Weight (kg) 
Gestation 
(Weeks) 
Dosing 
regimen 
Concentration 
matrix 
Karunajeewa et 
al 2010(407) 
30 Papuan 26.0 ± 5.9 54.0 ± 6.4 NR 
450 mg once daily 
for 3 days 
Plasma 
Lee et al 
2008(411) 
12 Thai 25 (15 - 37) 49.5 ± 5.6 20 -32 
10, 10, and 
5 mg/kg  given at 
0, 24, and 48 hours 
Blood 
Fakeye et al, 
2002(415) 
4 Nigerian 30 ± 2.3 60.3 ± 8.9  
10, 10, and 
5 mg/kg  given at 
0, 24, and 48 hours 
Plasma 
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4.3.1.3 Adaptation of the age-weight relationships for non-Caucasian groups  
The age-weight relationships in the non-Caucasian subjects were adapted from 
Caucasian subjects to reflect the difference in weight for age between these population 
groups as it has been reported that there is a significant difference between the weight for 
age in Caucasians and those of non-Caucasians (252) and this might therefore have 
significant impact on the Vss. In this study, the CQ model validation was condcuted with 
clinical data reported from various ethnic groups such as: Americans, Caucasians, 
Filipinos, Nigerians, Pakistani, Papuans and Thais. For the Americans and Caucasians, 
the healthy Caucasian population groups inbuilt into Simcyp® were used while for the 
non-Caucasian groups a representative age-weight relationship peculiar to the non-
Caucasian ethnic group were built from the Hayes et al (2015) study using TableCurve 
2D (Systat Software, San Jose, CA, USA).
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4.3.1.4 Step 3: Identification of a suitable CQ prophylactic dose regimen for ZIKV  
In order to propose a plasma therapeutic window for CQ which could be used to 
identify an optimal dosing regimen against ZIKV, we utilised reported in vitro and in vivo 
concentrations for the inhibition of ZIKV uptake into cells. Delvecchio et al. (2016) 
reported a CQ EC50 for the inhibition of ZIKV uptake within Vero cells, human brain 
microvascular endothelial cells (hBMEC) and human neural stem cells (hNSC) being 
within the range of 9-15 µM (381).  Further, in ZIKV-infected interferon signalling-
deficient AG129 mice, Shiryaev et al (2017) (416), reported that CQ extended their 
lifespan and confirmed that concentrations up to 40 µM were able to reduce ZIKV uptake 
in primary human foetal neural progenitor cells (NPCs) (with 90 % inhibition at 6 µM).  
In other studies, the correlation between brain and plasma concentrations has been 
identified, with a suggested 10-to-30-fold greater brain concentration compared to plasma 
concentrations for CQ (417, 418) and a 4-to-30-fold difference for the CQ analogue 
hydroxychloroquine (390), highlighting the ability of CQ to adequately partition into 
brain tissue. 
Furthermore, in the study reported by Shiryaev et al (2017) (416), doses of 30 
mg/kg were used in their ZIKV-infected interferon signalling-deficient AG129 mice to 
demonstrate uptake inhibition. This dose was similar to that used in arthritic patients 
where 5 mg/kg CQ salt was administered daily for one week which resulted in CQ plasma 
concentrations of 10 µM (419). A total dose of about 30 mg/kg would be achieved in 
humans, which would comparable to doses used in the study by Shiryaev et al (2017) 
(416), suggesting that such plasma concentrations are attainable using similar dosing 
regimens employed for existing therapeutic indications for CQ. 
Therefore, in order to define a therapeutic window for CQ, we assumed that the 
target brain concentration of a maximum of 40 µM was required and to theoretically 
achieve this concentration in the human brain, a plasma concentration of less than an 
average of at least 20-fold of the brain concentration may be required, that is, 
approximately 2 µM.  This was defined as the upper plasma therapeutic window. Given 
that concentrations in excess of 6 µM have been reported to prevent ZIKV uptake in brain 
derived cells, we set the lower plasma therapeutic window at 20-fold less, that is 0.3 µM.  
Therefore a plasma concentration therapeutic range of 0.3 µM to 2 µM was assumed in 
this study.  
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To identify an appropriate dosing regimen to target this therapeutic window, plasma 
concentration-time profiles for CQ were simulated in 100 pregnant subjects (during the 
entire gestational phase of 280 days) using the validated CQ model at doses used for the 
prophylaxis of malaria and RA, i.e. 150 mg-300 mg weekly or 150 mg daily, respectively.  
During this optimisation phase, the dose regimen which was able to maintain trough 
plasma concentrations above the lower limit of the plasma therapeutic window was 
identified as the optimal predicted dosing regimen. 
4.3.2 Predictive performance 
There are currently no universally agreed measures of predictive performance range 
when comparing observed data to predicted data in PBPK pharmacokinetic studies, 
however, a 2- fold prediction of observed data is largely accepted (420-422).  
4.3.3 Visual Predictive Checks 
Model predictions were compared to existing clinical studies using visual predictive 
checking (VPC), an approach described at the 2012 FDA Pediatric Advisory Committee 
(US Food and Drug Administration, 2012) (228). In brief, the predictability of the 
simulations was confirmed by comparing the predicted 5th and 95th percentiles of 
predicted concentration–time profiles with the observed data for any validation data sets.  
When the predicted data points overlapped with those from the observed data sets, which 
should (normally) contain a measure of spread of observed plasma concentration data 
(e.g., a standard deviation for each mean concentration point), the prediction was assumed 
to be valid. 
4.3.4 Data analysis 
Retrospective clinical data used for VPC were extracted using WebPlotDigitizer 
v.3.10 (http://arohatgi.info/WebPlotDigitizer/) (229).  Where applicable, statistical 
analysis was conducted using paired t-tests with a p < 0.05 indicating statistical 
significance.  
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4.4 Results  
4.4.1 Step 1a: Development of base model in non- pregnant subjects 
The validity of the initial base model was  assessed using a 300 mg single dose CQ 
study (383) in order to visualise the segment(s) of the concentration time profile that 
differed from published profiles. The model failed to recover the absorption kinetics of 
CQ and poorly predicted the distribution and elimination kinetics of CQ in a healthy 
Caucasian population (Figure 4.2). 
 
Figure 4.2:  Concentration time profile of single dose CQ using the base model 
Simulation of plasma concentration time profile of CQ following the administration of a 
single oral 300 mg dose using the base model according to the Lars et al study 
(383). Solid line represents the population means prediction and the dash lines 
bordering the shaded portion represent the 5th and 95th percentiles of prediction. 
He mean observed plasma concentration is represented by solid red circles while 
the red solid error bar represents the standard deviation of maximum plasma 
concentration. 
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4.4.2 Step 1b: Optimisation of base model in non- pregnant subjects 
To recover the shape of the absorption phase, a first order absorption model was 
utilised to identify appropriate maximum plasma/blood concentrations (Cmax) and time to 
reach the Cmax (tmax).  Clinically reported absorption rate constants (ka) and fraction 
absorbed (fa) values were selected with ka reported in literature as ranging from 0.27 to 
3.4 h-1 and fa reported as 0.9.  These were empirically fixed (with ka fixed as the mean of 
the reported range), and subsequently optimised by parameter estimation methodology 
implementing a Weighted Least Square (WLS) approach and the Nelder-Mead 
minimisation method to arrive at parameters which appropriately recovered the 
absorption phase (fa: 0.8; ka: 1.2 h
-1) (Table 4.3), and were within the range reported from 
clinical studies (385, 423, 424). 
The volume of distribution at steady-state (Vss) was estimated by a similar 
methodology as that applied for the absorption phase, with Vss reported in clinical studies 
as ranging from 100 L/kg to 1000 L/kg (390, 407, 425), and empirically fixed as the mean 
of this range prior to parameter estimation.  As the reported Vss was large, a minimal 
PBPK model was utilised with the incorporation of a ‘single adjusting compartment’ 
(SAC) to capture the correct distribution phases of the plasma concentration-time profile.  
Final parameter estimates of 125 L/kg for the central compartment (Vss) and 52.9 L/kg for 
the SAC (Vsac) were able to appropriately recover the distribution phase of the profile.  It 
should be noted that this was achieved following the incorporation of a change in the 
mean dispersion parameter applied to the central compartment (i.e. the coefficient of 
variation), which was adjusted from the Simcyp® default of 30 % to a revised 40 %. 
Finally, the rates of metabolite formation, Vmax and Michaelis-Menten constants 
(Km) for CYPs 2D6, 3A4 and 2C8 elimination pathways were obtained from a literature 
reported study (426) using recombinant P450 systems.  However, to achieve satisfactory 
recovery of the elimination phase, the Inter-System Extrapolation Factor (ISEF) for 
scaling recombinant cytochrome (CYP) P450 enzymes from in vitro kinetic parameters 
were estimated for all three metabolism pathways. In addition, CQ elimination has 
contributions from both hepatic and renal pathways, with the latter contribution 
approximately 30-50 % of the total clearance of CQ (404, 427).  Therefore, a renal 
clearance parameter was estimated based on an empirically fixed mean estimate.  
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Parameter sensitivity analysis was subsequently conducted on ISEF for CYP2D6 
and CYP3A4 (the two isozymes requiring significant changes in ISEF).  When conducted 
over a range of 0.2-2, there was minimal sensitivity of CL, Cmax and AUC to changes in 
ISEF (Figure 4.3) confirming appropriate estimates of ISEF for CYP2D6 and CYP3A4.  
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Figure 4.3: Sensitivity analysis of CYP3A4 and CYP2D6 ISEF 
Sensitivity analysis of (A) clearance, (B) first dose Cmax and (C) AUC following 
alterations in CYP3A4 and CYP2D6 ISEF (over a range of 0.2-2) for non-pregnant adults. 
Current optimised model estimates (CYP3A4 ISEF = 0.42 and CYP2D6 = 0.5) and 
default estimates (ISEF = 1) are illustrated. 
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Following the optimisation of the model, the final model predicted Cmax, AUC and 
tmax were within 2-fold of the reported parameters across all thirteen published single and 
multiple dose clinical studies in Caucasian and non-Caucasian subjects (Table 4.4).  
Further, as demonstrated in Figures 4.4-4.7, the model was able to appropriately recover 
the plasma concentration-time profiles.  
Mzayek et al (2007) (403) demonstrated a wide variability in the absorption phase 
of the reported plasma concentration-time profiles (Figure 4.5A), and the optimised 
model developed was able to recover this, with resultant predicted pharmacokinetic 
parameters within 2-fold of those reported (Table 4.4).  Further, for the Walker et al 
(1987) (428) study, the terminal elimination phase was slightly over predicted (Figure 
4.5D), however, the resultant AUC predicted by the model was within 2-fold of that 
reported (Table 4.4).  
The wide inter-individual variation observed on the predicted concentration time 
profiles were perhaps due to the population size used during the virtual clinical trial 
simulations compared to the actual studies which involved few subjects (see Table 4. 1)
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Figure 4.4: Simulated blood or plasma concentration-time profiles of single dose CQ 
in non-pregnant subjects 
Simulated blood or plasma concentrations for CQ following single dose studies in 
healthy Caucasian subjects. (A): Frisk-Holmberg et al – 150mg; (B): Frisk-Holmberg et 
al– 300mg; (C): Frisk-Holmberg et al – 600mg; (D): Gustaffson et al. Solid lines 
represent mean predicted concentration-time profile with dotted lines representing the 
5th and 95th  percentile range. Open red circles represent observed clinical data from 
each study. For the Frisk-Holmberg et al studies, individual observed data were 
reported in the original studies. Where presented, error bars indicate standard deviation. 
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Figure 4.5: Simulated blood or plasma concentration-time profiles of single dose CQ 
in non-pregnant subjects 
Simulated blood or plasma concentrations for CQ following single dose studies in non-
Caucasian subjects except (A) involving Caucasian healthy volunteers. (A): Mzayek et 
al; (B): Chukwuani et al; (C): Najmi et al; (D): Walker et al. Solid lines represent mean 
predicted concentration-time profiles with dotted lines representing the 5th and 95th  
percentile range. Open red circles represent observed clinical data from each study. For 
the Mzayek et al study, red circles indicate data extracted from complete plasma 
concentration profile ‘lines’ for individual subjects rather than discrete time-points. 
Where presented, error bars indicate standard deviation. 
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Figure 4.6: Simulated blood or plasma concentration-time profiles of multiple dose 
CQ in non-pregnant subjects 
Simulated mean blood or plasma concentrations for CQ following multi- dose studies in 
non-Caucasian subjects. (A): Karunjeewaa et al; (B): Lee et al; (C): Hoglund et al. Solid 
lines represent mean predicted concentration-time profiles with dotted lines representing 
the 5th and 95th  percentile range. Open red circles represent observed clinical data from 
each study. Error bars indicate standard deviation in Lee et al while Individual plasma or 
blood concentration data points are represented by open red circles in the Karunajeewa 
and Hoglund studies. Left-hand side panels indicate simulations for the total study 
duration and right-hand side panels illustrate the first three dosing days. 
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Figure 4.7: Simulated blood or plasma concentration-time profiles of multiple dose 
CQ in non-pregnant subjects 
Simulated mean blood or plasma concentrations for CQ following multi- dose studies in 
non-Caucasian subjects (D: healthy Caucasian subjects). (A): Na-Bangchang et al; (B): 
Tanariya et al; (C): Bustos et al; (D); Wetsteyn et al. Solid lines represent mean predicted 
concentration-time profile with dotted lines representing 5th and 95th  percentile range. 
Open red circles represent observed clinical data from each study. Error bars indicate 
standard deviation in the Na-Bangchang; Tanariya; Bustos and Wetsteyn studies. 
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4.4.3 Step 2: Development and validation of an optimised model of CQ in 
pregnant subjects  
Following the optimisation of the CQ model developed for non-pregnant subjects, 
a CQ pregnancy model was developed and the parameter estimates for the final optimised 
pregnancy model are detailed in Table 4.3. 
Simulation and validation of the pregnancy model for CQ was conducted using the 
clinical studies summarised in Table 4.2 while ensuring gestational weeks reported in the 
clinical studies matched (where possible) those in the pregnancy group simulated in the 
current study. Subsequently, the model was able to satisfactorily predict the plasma 
concentration-time profiles of CQ in pregnant women (Figures 4.8) with all 
pharmacokinetic parameters predicted to within 2-fold of those reported in clinical studies 
(Table 4.4). 
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Table 4.3: Model parameter values for base and optimised model of CQ in non-
pregnant and pregnant subjects 
 
 
 
 
 
 
 
 
 
 
aSimcyp® mechanistic prediction; b parameter estimated using a minimal PBPK model 
with a single adjusting compartment (SAC); c an appropriate Kp scalar was empirically 
optimised for a full PBPK model in pregnancy; d parameter estimated using a first order 
absorption kinetic model; e parameter estimated; f parameter estimated for use in 
optimisation of clearance kinetics; g parameter estimated. logP: the logarithm of the n-
octanol:buffer partition coefficient; fu: unbound fraction; B/P: blood-to-plasma ratio; 
Vss: steady state volume of distribution; Vsac: volume of single adjusting compartment; 
Q: blood flow to the single adjusting compartment; ka: absorption rate constant; Kp 
scalar: scalar applied to all predicted tissue partition values fa: fraction dose absorbed; 
ka: absorption rate constant; Vmax: maximum rate of metabolite formation; Km: 
Michaelis-Menten constant; fumic: fraction of unbound drug in the invitro microsomal 
incubation; ISEF: Intersystem extrapolation factor for scaling CYP in vitro kinetic data; 
CLrenal: renal clearance.  
Parameter 
Optimised model 
(non-pregnant) 
Optimised model 
(pregnant) 
Compound type Diprotic base (429) Diprotic base (429) 
Molecular weight (g/mol) 319.9 (316) 319.9 (316) 
log P  4.72 (430) 4.72 (430) 
Fu 0.55 (431) 0.55 (431) 
pKa 1 10.1 (430) 10.1 (430) 
pKa 2 8.38 (430) 8.38 (430) 
Vss (L/kg) 125 (CV: 40 %) b 130b 
Vsac (L/kg) 52.9 b - 
Q (L/h) 5 b - 
Kp scalar - 3.35 c 
Fa 0.8 d 0.8 d 
ka (h
-1) 1.2 d 0.5 d 
Solubility (mg/mL) 0.0175 (316) 0.0175 (316) 
Vmax2D6 (pmol/min/pmol) 2.10 
(426) 2.10 (426) 
Vmax3A4 (pmol/min/pmol) 2.94 
(426) 2.94 (426) 
Vmax2C8 (pmol/min/pmol) 8.33 
(426) 8.33 (426) 
Km2D6 (µM) 19.5 
(426) 19.5 (426) 
Km3A4 (µM) 294 
(426) 294 (426) 
Km2C8 (µM) 111 
(426) 111 (426) 
Fumic 0.13 e 0.13 e 
ISEF CYP2D6 0.5 f 0.8 f 
ISEF CYP3A4 0.42 f 0.7 f 
ISEF CYP2C8 1.1 f 1.6 f 
Clrenal (L/h) 4.6 
g 5.5 g 
Absorption model  first order first order 
Distribution model minimal PBPK full PBPK 
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Table 4.4:  Summary of predicted and observed pharmacokinetic parameters of for CQ 
    Cmax tmax (h) AUC 
    Predicted Observed Predicted Observed Predicted Observed 
C
a
u
ca
si
a
n
 
S
in
g
le
 D
o
se
 Gustafsson  
a,  e 56.8 ± 23.8 76 ± 14 4.9 ± 2.6 3.6 ± 2.0 9315 ± 3951 6111 ± 1315 
Mzayek  b, f * 1.4 (0.3 – 6.1) 1.8 (1.3-5.2) 
4.2 (1.5 – 
7.1) 
3.0 (1.0-
8.0) 
112 (31.5 - 225) 90 (48.9-212 
Frisk (150 mg dose) b,  i 0.11 NR 5.2 ± 2.4 NR 3.14 ± 1.3 2.54 ± 0.55 
Frisk (300 mg dose) b,  i 0.94 NR 5.2 ± 2.4 NR 6.28 ± 2.5 6.19 ± 1.39 
Frisk (600 mg dose) b, i 1.9 ± 7.4 NR 5.2 ± 2.4 NR 12.6 ± 5.1 11.6 ± 2.4 
N
o
n
-
C
a
u
ca
si
a
n
 
S
in
g
le
 D
o
se
 Chukwuani  a, e 177 ± 170 391 ± 91 4.7 ± 2.4 5.6 ± 0.8 7408 ± 4622 10820 ± 2714 
Najmi  c, g,** 172 ± 166 201 ± 15 4.6 ± 2.3 
6.10 ± 
0.66 
12775 ± 5835 10827 ± 1340 
Walker  a, e 159 ± 149 374 ± 56 4.8 ± 2.4 5 ± 3 25865 ± 10608 18609 ± 4254 
N
o
n
-C
a
u
ca
si
a
n
 
M
u
lt
i 
D
o
se
 
Karunajeewa  c, g,** 297 (79.1-769) 376 # - - 
57014 (11218-
112760) 
47892 (43486-53746) 
Na-Bangchang  a,  j.*** 883 (266-2306) 838 (656-1587) - - 167 (35.4-315) 122 (103-182) 
Bustos  a,  k,** 166 (63.47-336) 285 (186-422) - - 2189 (525-4760) 2299 (1149 -39908) 
Lee  a, e,** 836 (244-3006) 
700 (403 - 
1625)## 
- - 
189024 (47160 - 
334210) 
134087 (62940 - 
229695) 
Hoglund  b, I,** 2.7 (2.04) NR 3.8 NR 24.2 (10.3) NR 
Tanariya  a, k,** 994 (666) NR 4.3 NR 7897 (3245) NR 
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C
a
u
ca
si
a
n
 
M
u
lt
i 
D
o
se
 
Wetsteyn  d, l,** 85.6 (56.1) NR 3.6 NR 1429 (590) NR 
 
P
re
g
n
a
n
t Fakeye 
 a, e 124 ± 56.0 204 ± 135 4.6 ± 1.68 2 2114 ± 38.3 NR 
Karunjeewa  d, h,** 145 (53.4-240) 296** - - 
38585               
(14236-65641) 
35750 (31343-39729) 
Lee  a, e,** 482 (167-921) 960 (297-1835) 
3.84 (2.4- 
4.8) 
3 (1.5- 8) 
156 847               
(54768-349488) 
122216 (74145- 
269600) 
 
Units for Cmax are as follows: 
a ng/mL; b µM; c mg/L; d µg/L; Units for AUC are as follows: e ng/mL.h; f µM.h; g mg/L.h; h µg/L.h; i µM.day; 
j µg/mL.h ; k ng/mL.Day; l µg/L.Day. Unless otherwise stated, data represent means ± SD or median (range). * Data represents median 
(range); ** AUC0-∞ (AUC calculated from the start of the study and extrapolated to infinity); *** AUC0-28d: AUC calculated 28 days period 
only; **** AUC0-48d: AUC calculated 48 days period only. # No SD or median was reported; ## Cmax reported for the first dose only 
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Figure 4.8: Simulated plasma concentration-time profiles of multiple dose CQ in 
pregnant subjects 
Simulated mean plasma concentrations for CQ following multidose studies in pregnant 
subjects. (A): Karunjeewa et al; (B): Fakeye et al; (C): Lee et al. Solid lines represent 
mean predicted plasma concentration-time profiles with dotted lines the representing 5th 
and 95th  percentile range. Open red circles represent observed clinical data from each 
study. Error bars indicate standard deviation. Left-hand side panels indicate simulations 
for the total study duration and right-hand side panels illustrate the dosing period only.  
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4.4.4 Adaptation of the age-weight relationships for non-Caucasian groups 
The following mathematical expressions of age-weight distribution showed were 
inputted into Simcyp® in order to adapt its Caucasian age-weight relationships to the 
appropriate population groups 
4.4.4.1 Filipinos and Papuans 
Due to geographical locations, the age-weight relationship for Filipinos and 
Papuans were assumed to be similar and the age weight relationship was shown below: 
Adult males: 
Body weight = (6.0000871 + (1.8363904*age) + (-0.28876641*age2) + 
(0.011482471*age3)) / (1 + (-0.06584622*age) + (-0.0016572488*age2) + 
(0.00016955778*age3))         ( 49 ) 
Adult females: 
Body weight = (6.03 + 0.197*age2 + 0.0012*age4) / (1+0.00127*age2 + 
0.0000255*age4)           ( 50 ) 
4.4.4.2 Nigerians  
Adult males: 
Body weight = (3.1190351 + (2.7547707*age0.5)+(-1.9861521*age) 
+(0.29731577*age1.5))/(1+(-0.63494158*age0.5)+(0.15239313*age)+(-  
0.017751472*age1.5)+(0.0010549434*age2)       ( 51 ) 
 
Adult females:  
Body weight = (3.9015149 + (0.280026178*age0.5) + (-0.92347063*age) + 
(0.16145376*age1.5)) / (1 + (-0.75349793*age0.5) + (0.2157188*age) + (-
0.028738874*age1.5) + (0.0016167479*age2))      ( 52 ) 
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4.4.4.3 Pakistani and Thais 
Due to geographical locations, the age-weight relationship for Pakistani and Thais 
were assumed to be similar and the age weight relationship is shown below: 
Adult males:  
Body weight = 33.46 + (-0.3569*age2) + (0.001522*age4) / (1 + (-0.00755*age2) + 
(2.78x10 - 5*age4) + (-1.07x10-9*age6))       ( 53 ) 
Adult Females: 
Body weight = -920.66 + (-188.63*age) + (22.48*age1.5) + (-0.999*age2) + 
(700.23*age0.5)         ( 54 ) 
4.4.5 Step 3: Identification of a CQ prophylactic dosing regimen for ZIKV 
during pregnancy 
In order to identify a dosing regimen appropriate for maintaining maternal plasma 
(and foetal exposure) levels, such that a sufficient concentration would be achieved to 
prevent foetal ZIKA brain endocytosis, standard CQ dosing regimens commonly used for 
malaria, RA and SLE (150 mg or 300 mg weekly, and 150 mg or 300 mg daily, 
respectively), were simulated during the first trimester.   
For malaria prophylaxis doses, 150 mg and 300 mg weekly, the simulated plasma 
concentration-time profiles did not achieve the lower target therapeutic limit until the end 
of trimester 1 (Figure 4.9) and were not considered for further optimisation. 
For doses used in RA and SLE, with a 150 mg daily dose the mean trough plasma-
concentration did not reach the lower limit of 0.3 µM until 12 days post first dose (Figure 
4.10) when 96 % of subjects achieved a trough concentration in excess of the lower 
therapeutic window (Table 4.5).   At steady-state, a Cmax of 0.9 ± 0.4 µM was achieved.  
For the 300 mg daily dose, the trough plasma-concentration doubled (Table 4.5) (Figure 
4.11), with a shortening of the time taken to reach the target plasma concentration to 5 
days (Table 4.5).  However, the mean steady-state Cmax was 1.8 ± 0.8 µM with 59 % of 
subject demonstrating a peak plasma-concentration in excess of 2 µM (Table 4.5). 
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Figure 4.9: Simulated plasma concentration-time profiles for CQ dosed once weekly during the first trimester.  
Simulated CQ plasma concentration-time profiles during trimester 1 for: (A) a 150 mg weekly dose; (B) a 300 mg weekly dose. Dark green lines 
indicate mean plasma concentration-time profiles; light green shaded area bordered by the dashed lines indicate the area within the 5th and 95th 
percentile of predicted mean plasma concentration-time profiles; light brown shaded areas represent the proposed therapeutic range of CQ for ZIKV 
(0.3-2 µM).  
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Figure 4.10: Simulated plasma concentration-time profiles for CQ dosed at 150 mg daily during the first trimester. 
Simulated CQ plasma concentration-time profiles during trimester 1 for a 150 mg daily dose. (A) indicates simulations for the first trimester and (B) 
illustrate the dosing for thirty days. Dark green lines indicate mean plasma concentration-time profiles; light green shaded area bordered by the dashed 
lines indicate the area within the 5th and 95th percentile of predicted mean plasma concentration-time profiles; light brown shaded area represents the 
proposed therapeutic range of CQ for ZIKV (0.3-2 µM); dashed vertical lines indicates the time at which trough concentrations are maintained above 
the lower therapeutic window. 
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Figure 4.11: Simulated plasma concentration-time profiles for CQ dosed at 300 mg daily during the first trimester.  
Simulated CQ plasma concentration-time profiles during trimester 1 for a 300 mg daily dose. (A) indicate simulations for the first trimester and (B) 
illustrate the dosing for thirty days. Dark green lines indicate mean plasma concentration-time profiles; light green shaded areas bordered by the 
dashed lines indicate the area within the 5th and 95th percentile of predicted mean plasma concentration-time profiles; light brown shaded area 
represents the proposed therapeutic range of CQ for ZIKV (0.3-2 µM); dashed vertical lines indicates the time at which trough concentrations are 
maintained above the lower therapeutic window.
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Dose optimisation was considered to identify an appropriate dosing regimen for 
trimester 1 to (i) achieve rapid attainment of the lower plasma therapeutic window and 
(ii) to maintain this concentration for the longest duration possible.  The dosing regimen 
identified was a loading dose of 600 mg on day 1 followed by 300 mg for 2 days and 
subsequently 150 mg daily during trimester 1 (Figure 4.12). Under this regimen, the time 
taken for trough plasma concentrations to be maintained within the therapeutic window 
shortened by six days (Figure 4.12) (Table 4.5) compared to a 150 mg daily dose (Figure 
4.10) (Table 4.5).  Further, only 1 % of subjects achieved a plasma concentration above 
the upper therapeutic limit of 2 µM (Table 4.5). 
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Table 4.5: Simulated steady-state pharmacokinetic parameters of CQ during pregnancy 
Data represents mean ± standard deviation. a Time taken for mean trough plasma concentrations to be maintained above 0.3 µM; b Percentage 
of subjects with trough plasma concentrations above 0.3 µM at steady-state; c Percentage of subjects with peak plasma concentrations below 
2 µM at steady-state.  AUC was calculated for the final dosing day.  
  
Dose (mg) Cmax (µM) tmax (h) AUC (µM.h) 
Time to lower 
window a (days) 
Percentage of subjects 
with Cmin > 0.3 µM at 
SS b 
Percentage of subjects 
with Cmax < 2 µM at 
SS c 
150 0.9 ± 0.4 2.4 ± 0.5 21.8 ± 9.4 12 96 99 
300 1.8 ± 0.8 2.4 ± 0.5 43.9 ± 18.7 5 99 59 
Optimised 0.9 ± 0.4 2.4 ± 0.5 48.8 ± 30.9 6 96 99 
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Figure 4.12: Simulated plasma concentration-time profiles for CQ dosed at optimised dose during the first trimester.  
Simulated CQ plasma concentration-time profiles during trimester 1 for an optimised CQ dose: a loading dose of 600 mg on day 1 followed 
by 300 mg for 2 days and subsequently 150 mg daily during trimester). (A) indicates simulations for the first trimester and (B) illustrates 
dosing for thirty days. Dark green lines indicate mean plasma concentration-time profiles; light green shaded area bordered by the dashed 
lines indicate the area within the 5th and 95th percentile of predicted mean plasma concentration-time profiles; light brown shaded areas 
represent the proposed therapeutic range of CQ for ZIKV (0.3-2 µM); dashed vertical lines indicates the time at which trough concentrations 
are maintained above the lower therapeutic window. 
 245 
  
Subsequently, the impact of initiating the optimal dosing regimen at the start of 
each trimester on the pharmacokinetics of CQ was assessed. CQ pharmacokinetics were 
simulated for each trimester period. In comparison to the results from trimester 1, dosing 
this optimal regimen during either trimester 2 or 3 resulted in a progressive and 
statistically significant decrease (p < 0.001) in AUC, from 20.9 ± 9.6 µM.h to 11.8 ± 4.8 
µM.h (calculated on the final day of the trimester) (Figure 4.13) with an increase in the 
time to reach target trough plasma concentration from 6 days for trimester 1 to 35 days 
for trimester 3 (Table 4.6) (Figure 4.13).  Further, at trimester 3, only 79 % of subjects 
achieved a trough plasma concentration above the lower therapeutic limit (Table 4.6). 
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Figure 4.13: Simulated plasma concentration-time profiles for optimised CQ dosed during each trimester 
Simulated CQ plasma concentration-time profile utilising the optimised dosing regimen, during each trimester. (A) Simulated profiles for 
the entire duration of each trimester; (B) Simulated profiles for the first 40 days of each trimester. Dark green, red and blue lines indicate 
mean plasma concentration-time profiles during the 1st, 2nd and 3rd trimesters respectively; lighter shaded areas indicate the area within the 
95th and 5th percentile of the predicted mean plasma concentration-time profiles during trimester 1 (upper, light green) and trimester 3 (lower, 
light blue); light brown shaded area represents the proposed plasma therapeutic window of CQ for ZIKV (0.3-2 µM); dashed vertical lines 
indicates the time at which trough concentrations are maintained above the lower therapeutic window. 
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Table 4.6: Steady-state pharmacokinetic parameters of the optimised CQ regimen during pregnancy 
 
Data represents mean ± standard deviation. a Time taken for mean trough plasma concentrations to be maintained above 0.3 µM; b Percentage 
of subjects with trough plasma concentrations above 0.3 µM at steady-state; c Percentage of subjects with peak plasma concentrations below 
2 µM at steady-state.  AUC was calculated for the final dosing day.
Trimester 
Cmax 
(µM) 
tmax 
(h) 
AUC 
(µM.h) 
Time to lower 
window a (days) 
Percentage of 
subjects with Cmin > 
0.3 µM at SS b 
Percentage of 
subjects with Cmax < 
2 µM at SS b 
1 0.92 ± 0.41 2.2 ± 0.5 21.8 ± 9.6 6 96 99 
2 0.75 ± 0.32 2.2 ± 0.5 17 ± 7.2 14 93 100 
3 0.53 ± 0.21 2.6 ± 0.7 11.8 ± 4.8 35 79 100 
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Finally, to identify an appropriate CQ dosing regimen for the entire duration of 
pregnancy, CQ treatment was extended from the end of the first trimester to the end of 
the second trimester. During trimester 1 (days 1 to 84), the predicted mean plasma 
concentration was maintained above the lower therapeutic window (Figure 4.14) with a 
steady-state Cmax of 0.92 ± 0.41 ng/mL (Table 4.7).  Assuming CQ was halted at the end 
of trimester 1, mean plasma concentrations reached the lower therapeutic window on day 
150 with 95 % of subjects possessing a trough plasma concentration above the lower 
therapeutic window (Table 4.7).  When dosing was continued throughout trimester 2 
(Figure 4.15), steady-state plasma concentrations were maintained with a Cmax of 0.92 ± 
0.41 ng/mL (Table 4.7) until the end of trimester 2 (day 168), at which point CQ was 
halted.  Mean plasma concentrations reached the lower therapeutic window on day 279 
with 94 % of subjects possessing a trough plasma concentration above the lower 
therapeutic window and 5 % of subjects possessing a peak plasma concentration below 
the lower therapeutic window (Table 4.7).
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Figure 4.14: Simulated plasma concentration-time profiles for optimised CQ dosed during trimester 1  
Simulated CQ plasma concentration-time profile utilising the optimised dosing regimen during trimester 1.  (A) indicates the entire 
duration of gestation (day 0 to 280) and (B) indicate periods from the end of the trimester to the point at which mean trough plasma 
concentrations fall below the lower therapeutic window. Dosing schedule is Day 1:600 mg; Day 2 and 3: 300 mg and 150 mg to 
end of 1st trimester. Dark green lines indicate mean plasma concentration-time profiles during the study period with transparent 
area bordered by dashed line indicating the area within the 95th and 5th percentile of the predicted mean plasma concentration-time 
profiles; light brown shaded areas represent the therapeutic range of CQ proposed to be effective against ZIKV.  The times at 
which the mean trough plasma concentrations fall below the lower therapeutic window are indicated by the arrows. 
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Figure 4.15: Simulated plasma concentration-time profiles for optimised CQ dosed during trimester 2 
Simulated CQ plasma concentration-time profile utilising the optimised dosing regimen throughout trimester 1 and 2. (A) indicates 
the entire duration of gestation (day 0 to 280) and (B) indicates period from the end of the trimester to the point at which mean 
trough plasma concentrations fall below the lower therapeutic window. Dosing schedule is Day 1:600 mg; Day 2 and 3: 300 mg 
and 150 mg to end of 2nd trimester. Dark blue lines indicate mean plasma concentration-time profiles during the study period with 
light blue area bordered by dashed line indicating the area within the 95th and 5th percentile of the predicted mean plasma 
concentration-time profiles; light brown shaded area represent the therapeutic range of CQ proposed to be effective against ZIKV.  
The time at which the mean trough plasma concentrations fall below the lower therapeutic window is indicated by the arrows. Red 
dashed lines indicate the ‘at term’ phase. 
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Table 4.7: Steady-state pharmacokinetic parameters of the optimised CQ regimen during pregnancy 
 
 
 
 
 
 
 
Data represents mean ± standard deviation from the final dose. * Cmax, tmax and AUC collected on the final dosing day.  
a Time 
taken for mean concentrations to be reach 0.3 µM; b Percentage of subjects with trough plasma concentrations above 0.3 µM; AUC 
was calculated for the final dosing day; c Time taken for mean plasma concentrations to decrease to 0.3 µM; d Percentage of subjects 
with peak plasma concentrations below 0.3 µM. 
  Trimester 
  1 1 and 2 * 
Cmax  (µM) 0.92 ± 0.41 0.92 ± 0.41 
tmax (h) 2.2 ± 0.5 2.2 ± 0.5 
AUC (µM.h)  20.9 ± 9.6 21.0 ± 9.5 
Time to increase to lower window a (Days) 6 6 
Subjects with Cmin above window (%) 
b 67 65 
Time to decrease to lower window c (Days) 150 279 
Subjects with Cmin above window (%) 
b 95 94 
Subjects with Cmax below window (%) 
d 1 5 
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4.5 Discussion 
The Zika virus (ZIKV) is an infectious disease that began spreading at an alarming 
and unprecedented way in the early part of the current decade, and its spread has been 
classified as a pandemic (363).  Perhaps alarmingly (and importantly) a prominent feature 
of ZIKV which gained much publicity was the foetal and neurological consequences on 
infants born to infected mothers, and which primarily exhibited as microcephaly and 
Guillian-Barr syndrome.  Although no current treatment options are available for the 
prevention of the spread of ZIKV, the opportunity for repurposing existing treatments 
towards ZIKV exists for the antimalarial drug chloroquine (CQ).  This study addressed 
the potential to repurpose CQ for use in ZIKV, with a focus on developing potential 
dosing regimens for use in pregnancy.  
4.5.1 Model development and validation 
During model development and validation (Step 1), model performance depends 
largely upon the certainty of model input parameters describing CQ absorption, 
distribution and metabolism and elimination (ADME) (142).  When using literature 
reported pharmacokinetic parameters for absorption (ka), distribution (Vss) and 
elimination (clearance), the model performance was poor. This may be, in part, due to the 
wide variability reported for these parameters, for instance, ka has been reported in 
different studies as 1.8 h-1 (0.27-3.4 h-1) (424); 1.19 h-1 ± 1.44 h-1 (423) and 0.51 h-1 ± 0.11 
h-1 (385) and Vss has been reported as 204-800 L/kg (390); 128 L/kg (112-137 L/kg) (407) 
and 100-1000 L/kg (425).  Further, the reported Vss of CQ depends on whether they were 
estimated based on the plasma concentration or blood concentrations, particularly given 
that CQ has a high blood-to-plasma partitioning ratio of >5:1, therefore the blood Vss is 
likely to differ from that of the plasma Vss by up to 10-fold (432, 433). Therefore, we 
utilised a parameter estimation approach with the application of Weighted Least Square 
(WLS) and the Nelder-Mead minimisation, final optimised parameter value were 
obtained (Table 4.3), and this model was used for subsequently validation purposes.  
The application of this optimised model with retrospective clinical studies 
conducted in Caucasian subjects (403, 414, 434)  resulted in model predictions of 
pharmacokinetic parameters to within 2-fold of these reports (Table 4.4), with VPCs 
confirming appropriate predictions of the plasma concentration-time profiles for each 
study (Figure 4.4, 4.5A, 4.7D). 
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In non-Caucasian subjects, physiological parameters, such as body-weight, vary 
significantly from typical Caucasian subjects and these differences may alter the 
pharmacokinetics of the drugs (283). We have previously demonstrated the impact of this 
in Thai (145, 435), Sudanese and Papua New Guinea (145), Ugandan (436) and 
Malaysians (437) population groups, and these alterations were made to the Simcyp® HV 
population groups as explained above.  Following these revision, in all single and 
multidose simulations involving Caucasians and non-Caucasian subjects, plasma 
concentration-time profiles and resultant pharmacokinetic parameters were well predicted 
(Figure 4.4 – 4.7) and within 2-fold of the reported parameters (Table 4.4) (406-409, 411-
413). 
Having successfully validated a non-pregnant model in Caucasian and non-
Caucasian subjects, the model was extended to pregnant subjects. The non-pregnant 
model was adapted by the inclusion of a full PBPK distribution model, which enables the 
consideration of gestational-age related alterations in maternal physiology.  This is 
important considering that physiological alterations such as blood volume, tissue 
perfusion, plasma protein binding (398, 399, 401, 402) and CYP450 metabolic capacity 
(400) can occur.  One strength of PBPK modelling is in its ability to incorporate these 
changes into predictive modelling approaches (297).  When using this pregnancy model, 
key pharmacokinetic parameters were predicted to within 2-fold of the reported clinical 
parameters (Table 4.4), with plasma concentration-time profiles well recovered for all 
studies (Figure 4.8) (407, 411, 415).  The altered blood volumes, blood flows and albumin 
binding capacity expected in pregnancy led to a reduction in the overall exposure of CQ 
in pregnant subjects compared to non-pregnant subjects (Table 4.4), and a similar 
decrease in exposure (AUC) and associated Cmax has been reported in studies where CQ 
was used in pregnant subjects (407, 411, 415). 
4.5.2 Considerations for CQ dosing for ZIKV disease in pregnancy 
Current dose regimens for CQ use in antimalarial prophylaxis, RA and SLE 
treatment were next examined to determine the ability of these regimens to drive steady 
state concentrations within the proposed therapeutic window for ZIKV disease. With a 
malaria prophylactic weekly CQ dose of 150 mg and 300 mg administered to pregnant 
subjects during the first trimester, the proposed therapeutic range for ZIKV was not 
achieved (Figure 4.9).   However, when CQ doses commonly used for SLE, that is, 150 
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mg daily (Figure 4.10 ) or 300 mg daily (Figure 4.11) was administered, the 150 mg daily 
dose achieved a satisfactory mean steady-state Cmax (Table 4.5) within the proposed 
therapeutic window for ZIKV (Figure 4.10), and attained the lower therapeutic window 
on day 12 (Table 4.5). However, despite the higher daily dose of 300 mg achieving the 
target lower therapeutic limit after 5 days, this regimen was not selected as a result of 
peak plasma concentrations exceeding the upper therapeutic window (Figure 4.11) (Table 
4.5).    
4.5.3 Optimisation of CQ dosing for ZIKV in pregnancy 
Based upon the 150 mg daily dose regimen, an optimal dosing regimen was derived 
to reduce the time taken for trough concentration of CQ to fall within the therapeutic 
range proposed, and consisted of: (i) an initial loading dose of 600 mg on day 1; (ii) 300 
mg daily on day 2 and 3; (iii) 150 mg daily thereafter (Figure 4.12).  This dosing regimen 
attained the target lower limit within 6 days with the majority of subjects, 96 %, 
possessing trough plasma concentrations within the lower therapeutic window (Table 
4.5). In order to improve the clinical plausibility of the optimised dose, the optimised dose 
was adapted from doses used for malaria treatment (600 mg at 0 hour, 6 hours, 24 hours 
and 36 hours) (406, 408, 409, 412) and SLE/RA prophylaxis (long-term 150 mg daily 
dose) (35) because there is sufficient evidence to show at these doses, CQ administration 
is safe for both mother and foetus (35) (394). 
Having identified an optimal dosing regimen, we next assessed its application at 
different trimesters, and when comparing starting in trimester 1 to trimester 3, identified 
a concurrent decrease in Cmax and AUC (Table 4.6) (Figure 4.13A), which resulted in an 
increased in the time take to achieve trough plasma concentrations at the lower limit of 
the therapeutic window (Figure 4.13B) (Table 4.6).  It is important to achieve the Cmin as 
quickly and safely as possible to prevent progression of infection. The physiological 
changes during pregnancy, primarily alterations in the body weight, plasma proteins and 
plasma volume (438-442), will drive this decrease in exposure as gestation progresses. 
Finally, when assessing the optimised dosing regimen for its use throughout 
pregnancy, we first considered dosing through trimester 1 only (Figure 4.14), which 
resulted in mean plasma concentrations decreasing below the lower window at 150 days 
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gestation (Figure 4.14) where 95 % of subjects possessed trough plasma concentrations 
above the lower window (Table 4.7).  
On extension of this optimised dosing regimen throughout trimester 2 (Figure 4.15), 
mean plasma concentrations were maintained within the therapeutic window until day 
279 (40 weeks), which exceeded the start of the ‘at term’ phase, commencing from week 
38 onwards (Figure 4.15), and where 94 % of subjects possessed trough plasma 
concentrations above the lower therapeutic window (Table 4.7).  
In summary, we have identified a possible therapeutic range that would be capable 
of proving sufficient plasma exposure for the duration of the gestational period to 
potentially limit ZIKV uptake into the developing foetus.  However, this study is not 
without limitations.  
4.5.4 Safety of chloroquine dosing at high doses in pregnancy 
In relation to the dosing regimen proposed, chloroquine has been in use for at least 
50 years, having been introduced as an alternative to quinine (443, 444).  Its use in 
pregnancy has therefore been examined by various groups for safety and efficacy with 
little reported concerns.  At doses proposed in this simulation, Klinger et al (2001)(445) 
reported no ophthalmic abnormalities in children born followed the maternal use of CQ 
during a mean duration of 7.2 months of gestation for doses of up to 332 mg daily. In a 
further study by Rukaria-Kaumbutho et al (1996) (446), at doses of 25 mg/kg achieved 
over 3 days administration, no safety concerns were identified in births at term.  Further, 
a review by Nosten et al (2006) (447) identified 755 cases of first trimester exposure to 
chloroquine with no significant abortion risk or foetal risk.  Finally, a study by Wolfe and 
Cordero (1985) (394) examined a cohort of 168 births to women treated with 300 mg CQ 
once weekly for the duration of pregnancy and identified no significant increase in the 
proportion of birth defects when compared to a control group who were not treated with 
CQ.  Therefore, the proposed dosing regimen would provide a level of exposure similar 
to those reported in existing studies of CQ in pregnant women. 
4.5.5 Study limitations 
An obvious limitation to our work is the current inability to accurately predict the 
pharmacokinetics of CQ in the foetus. Only two clinical studies have reported CQ as 
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being able to reach the foetus through sampling cord blood (448, 449), but foetal drug 
levels were not recorded. However, the reported foetal: maternal concentration ratio was 
reported to be near unity, suggesting overall foetal exposure would be similar to that 
within the mother.  Therefore, we assumed that the driving force for overall foetal 
exposure would be the maternal plasma concentration, which was used as a measure of 
the ‘target’ concentration within the foetus also.  It further goes without saying that this 
assumption would therefore need to also consider the gestational-related changes in foetal 
physiology.  However, the placenta plays a vital ADME role in controlling delivery of 
xenobiotics to the foetus, and given the similarity in exposure of CQ between both the 
mother and foetus (448, 449), the Simcyp® pregnancy model incorporated these key 
gestation related changes in anthropometric features of the mother and the foetus 
(implemented as a pooled feto-placental compartment within Simcyp®) (297, 307, 397). 
Recently Abduljalil et al (2018) (450) collated foetal biometry and tissue 
composition data which may drive future studies to better describe and drive, from a 
mechanistic pharmacokinetic viewpoint, the development of a more appropriate and 
detailed foetal PBPK model which could predict overall foetal CQ brain exposure, 
however without CQ foetal tissue sampling data, any validation of such prediction would 
be difficult. 
Our modelling approach utilised a ‘worst-case’ scenario in deriving a possible 
plasma therapeutic window for CQ.  Our upper and lower plasma concentrations, 2 µM 
and 0.3 µM respectively, were based on assuming that a 10-to-30-fold greater brain 
concentration existing when compared to plasma concentrations for CQ (417, 418).  We 
utilised the average of this range, a 20-fold lower plasma concentration compared to 
reported range of inhibitory concentration of 6-40 µM (381, 416).  Whilst not being able 
to directly verify human foetal brain concentrations, our range of predicted peak plasma 
concentrations (0.1-1.88 µM) for the final optimised dosing regimen in pregnant subjects 
spanned this range and would potentially provide an overall peak brain exposure of 18.8 
µM to 56.4 µM.  This is assuming that CQ is capable of partitioning across the blood-
brain barrier (BBB), with reports suggesting the BBB does not provide a permeability 
barrier to CQ (418).  However, it is known that the foetal BBB develops from gestational 
week 8 with tight junction formation by week 18 (451).  Therefore, further 
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characterisation of the role of the foetal BBB is warranted to estimate the likely CQ foetal 
brain exposure. 
4.6 Conclusion 
With the CQ model developed in this study, a CQ dose of 600 mg on day one, 
followed by 2 days treatment of 300 mg daily and thereafter 150 mg daily from day 3 
until the end of trimester 2 would provide a plasma concentration within the range of 0.3-
2 µM, potentially providing protection against ZIKV throughout pregnancy.  Though the 
results from this study are subject to clinical confirmation, it serves as a guide for future 
clinical studies.
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CHAPTER 5       
Conclusion and future work 
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5.1 Conclusions 
This thesis has demonstrated that the PBPK modelling approach is a powerful and 
evolving technique that may be used to understand the pharmacokinetic of antimalarials 
and address antimalaria drug therapy problems in special populations. To avoid the threat 
of DDI induced sub-therapeutic antimalarial concentrations which might lead to 
antimalarial drug resistance or the risk of drug toxicities, and to explore the potential of 
current antimalaria therapies for repurposing in other infectious diseases, this thesis 
demonstrates that PBPK modelling and simulations is a valuable tool and its potential to 
address this drug related therapies challenges is fast evolving. 
In Chapter 2, a PBPK model for AL was successfully developed. The model 
performed well in the prediction of the pharmacokinetics of AL first in adult healthy 
volunteers and then in children. The model also performed well in the prediction of DDIs 
with a CYP inhibitor (ketoconazole) and inducer (rifampicin) in adults. The satisfactory 
performance of the model led to a further prediction of the DDI predictions between AL 
and rifampicin in children to address the AL dosing therapy limitations in children with 
tuberculosis and co-infected with malaria. Dosing optimisation of standard AL was 
suggested if they are to be used concomitantly with  rifampicin in children. A  2/12 mg/kg 
of AL over a period of seven days when a patient is co-administered a rifampicin based 
anti-tuberculosis medication was proposed. Though this result is subject to clinical 
verification, it could serve as a guide to planning a clinical trial involving the DDI 
between AL and rifampicin based anti-TB treatment. 
In Chapter 3, a PBPK model was developed that was used to mechanistically predict 
the pharmacokinetics of PQ in non-pregnant and pregnant women in which the population 
differences in malaria-HIV co-infected subjects was incorporated.  We were able to show 
using the model that PQ pharmacokinetics in pregnancy is consistent and was relatively 
unchanged compared to non-pregnant women and that the impact of ART-mediated DDIs 
can significantly change the PQ pharmacokinetics, the magnitude of which was generally 
consistent across GW. The model required further adaptions to include data which 
detailed the relevant physiological and biochemical alterations common to HIV/malaria 
patients and which would further enhance the clinical application of the proposed model. 
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In Chapter 4, the potential to use PBPK modelling techniques to repurpose 
chloroquine for ZIKV treatment was explored. The CQ model developed in this study 
was developed and robustly validated and with the model, a CQ dose of 600 mg on day 
one, followed by 2 days treatment of 300 mg daily and thereafter 150 mg daily from day 
3 until the end of trimester 2 would provide a plasma concentration within the range of 
0.3-2 µM, potentially providing protection against ZIKV throughout pregnancy.  Though 
the results from this study are subject to clinical confirmation, they serve as a guide for 
future clinical studies.  
The thesis clearly demonstrates that PBPK modelling and simulation can be used 
to   understand the pharmacokinetics of antimalarial agents in special populations. An 
understanding of which is required to improve existing antimalaria drug therapy, 
especially in the case of DDI in children or pregnant women or enhance the processes of 
development of new antimalarial agents in these groups. 
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5.2 Future work 
The usefulness of PBPK in addressing drug related problems that may have been 
identified at early stages or translational phases of drug development in special 
populations demonstrated throughout this work is conspicuous. During this project, some 
aspects of antimalarial therapy which require more elaborate research have been 
identified. Some of such areas are: 
5.2.1 Diseases specific physiological or biochemical changes that may affect 
the pharmacokinetics of antimalarials in special populations 
Alteration in physiological and biochemical characteristics can affect the 
pharmacokinetics of antimalarials as demonstrated in this research. This research did not 
explore the effect of diseases common in malaria endemic areas, such as HIV/AIDS, on 
the body biochemistry or physiology and how this might affect the treatment of malaria 
in infected subjects. Therefore, in the future, the impact of disease specific physiological 
and biochemical changes on the pharmacokinetics of antimalarials in special population 
will be evaluated. 
5.2.2 Modelling the effects of ethnic factors (e.g. polymorphisms) on the 
pharmacokinetic of antimalarials in special populations 
Ethnic variation in the polymorphism of CYP enzymes and transport proteins can 
impact on the pharmacokinetics of certain antimalarials for example amodiaquine. 
Amodiaquine is metabolised by CYP2C8 which exhibits four polymorphic alleles which 
occur at varying frequencies in malaria endemic population groups (452). Since 
amodiaquine might be dosed to subjects across different ethnic groups, the significance 
of an alteration in its pharmacokinetics across ethnic population groups is yet to be 
evaluated. This is therefore another area of potential antimalarial research. 
5.2.3 Development of models capable of predicting the pharmacokinetics of 
antimalarials in the foetus during pregnancy and in breastmilk after 
pregnancy 
There is some suggestion that the foetus might be expose to malarial infection from 
its infected mother. Despite the robust data available on the pharmacokinetics of 
antimalarials in pregnant women, there is not much known about the changes in drug 
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disposition in the foetus. During the write up of this thesis, a few studies have provided 
an insight into the maternal to foetal transfer of drugs using a PBPK model (453, 454) but 
none of these models have been validated for antimalarial drugs, also the limitations of 
these studies lies in their ability to assess the maternal to infant drug transfer through the 
milk. Therefore, a PBPK model capable of predicting the pharmacokinetics of 
antimalarials in the foetus during pregnancy and in the infant during breastfeeding will 
be developed. 
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